**RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020**

*Rajeev Chawla¹, S. V. Madhu², B. M. Makkar³, Sujoy Ghosh⁴, Banshi Saboo⁵, Sanjay Kalra⁶, On behalf of the RSSDI-ESI Consensus Group*

¹North Delhi Diabetes Centre, Rohini, New Delhi, ²Centre for Diabetes, Endocrinology and Metabolism, UCMS-GB Hospital, ³Dr. Makkar’s Diabetes and Obesity Centre, Paschim Vihar, New Delhi, ⁴Department of Endocrinology and Metabolism, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, ⁵DiaCare - A Complete Diabetes Care Centre, Ahmedabad, Gujarat, ⁶Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India

**RSSDI-ESI Consensus Group**

<table>
<thead>
<tr>
<th>Diagnosis of Diabetes</th>
<th>Coordinators: S. R. Aravind, Ganapathi Bantwal</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Members: A. H. Zargar Nihal Thomas, Alok Kanugo</td>
</tr>
<tr>
<td>Prevention (Including Screening and Early Detection)</td>
<td>Coordinators: S. V. Madhu, R. M. Anjana</td>
</tr>
<tr>
<td>Treatment 1: Medical Nutrition Therapy and Lifestyle Modification</td>
<td>Coordinators: A. Ramachandran, Eesh Bhatia, Amitesh Agarwal</td>
</tr>
<tr>
<td>Treatment 3: Injectables</td>
<td>Coordinators: Shashank Joshi, Krishna Seshadri</td>
</tr>
<tr>
<td>Treatment 4: Individualizing Therapy</td>
<td>Members: Vijay Panikar, Sameer Agarwal, V. Sringesh</td>
</tr>
<tr>
<td>Post Prandial Hyperglycaemia</td>
<td>Coordinators: A. K. Das, Sanjay Agarwal</td>
</tr>
<tr>
<td>Acute Metabolic Complications</td>
<td>Members: Ajay Kumar, Sunil Jain, Sujit Jha</td>
</tr>
<tr>
<td>Hypoglycaemia</td>
<td>Coordinators: Banshi Saboo, A. K. Singh</td>
</tr>
<tr>
<td>Chronic Complications 1: Retinopathy, Neuropathy, Diabetic Kidney Disease</td>
<td>Members: Muralidharan, Santosh Singh, Rajesh Khadgawat</td>
</tr>
<tr>
<td>Chronic Complications 2: Diabetic Foot and Peripheral Arterial Disease</td>
<td>Coordinators: Hari Kumar, Kaushik Pandit</td>
</tr>
<tr>
<td></td>
<td>Members: S. K. Sharma, Mathew John, Pradip Mukhopadhyay</td>
</tr>
<tr>
<td></td>
<td>Coordinators: Sushil Jindal, Kamlakar Tripathi, Narsingh Verma</td>
</tr>
<tr>
<td></td>
<td>Coordinators: jubin Jacob, Anil Bhansali</td>
</tr>
<tr>
<td></td>
<td>Members: D. C. Sharma, G. Vijaykumar, Dheeraj Kapoor</td>
</tr>
<tr>
<td></td>
<td>Coordinators: Rajeev Chawla, Rakesh Sahay</td>
</tr>
<tr>
<td></td>
<td>Members: Shalini Jagg, R. K. Lalwani, Hitesh Punyani</td>
</tr>
<tr>
<td></td>
<td>Coordinators: S. K. Singh, Vijay Vishwanathan</td>
</tr>
<tr>
<td></td>
<td>Members: Ashu Rastogi, Ghanshyam Goyal, Ashraf Ganie</td>
</tr>
</tbody>
</table>

*Contd...*
Diabetes and CVD

Coordinators: V. Mohan, Arvind Gupta
Members: Shaileja Kale, Sudhir Bhandari, R. V. Jayakumar

Obesity and Type 2 Diabetes Mellitus

Coordinators: B. M. Makkar, Neeta Deshpande,
Members: C. L Nawal, K. A. V. Subramanian, Rucha Mehta

Infections and Vaccinations

Coordinators: Subhankar Chowdhary, Jayant Panda
Members: Pramod Gandhi, J. K. Sharma, Vinay Dhandhania

Sexual Dysfunction

Coordinators: Samar Banerjee, P. K. Jabbar
Members: Mithun Bhartiya, Urman Dhruv, Premlata Varikavi

Glycaemic Monitoring

Coordinators: Siddhartha Das, A. G. Unnikrishnan
Members: Rajiv Kovil, Alok Sachan, Girish Varma

Technologies

Coordinators: Jothdev, Ambrish Mithal
Members: K. M. Prasanna Kumar, Manoj Chawla, Ameya Joshi

Special Situations

Coordinators: Nikhil Tandon, Padma Menon
Members: Sujoy Ghosh, Nalini Shah, Usha Sriram, Rajesh Rajput

Fasting and diabetes

Coordinators: Sarita Bajaj, Manas Barua
Members: M. K. Garg, Sachin Chhitawar, Hemant Thacker

Education

Coordinators: Vasanth Kumar, Sunil Gupta
Members: Meena Chhabra, Amit Gupta, G. D. Ramchandani

Psychosocial Issues

Coordinators: H. B. Chandalia, Sanjay Kalra
Members: G. R. Sridhar, Rishi Shukla, Salam Ranabir

Complementary and Alternate Therapies

Coordinators: P. V. Rao, Anuj Maheshwari
Members: J. P. Sai, K. R. Narsimha Setty, Saurabh Srivastava

Diagnosis of Diabetes

**Recommended Care**

Prediabetes can be diagnosed with any of the following criteria:
- Impaired fasting glucose (IFG): FPG 100 mg/dL to 125 mg/dL or
- Impaired glucose tolerance (IGT): 2-h plasma glucose (2-h PG) during 75-g OGTT 140 mg/dL to 199 mg/dL or
- HbA1c ≥5.7%–6.4%

Diabetes can be diagnosed with any of the following criteria:
- FPG ≥126 mg/dL or
- FPG ≥126 mg/dL and/or 2-h PG ≥200 mg/dL using 75-g OGTT
- HbA1c≥6.5% ** or
- Random plasma glucose ≥200 mg/dL in the presence of classical diabetes symptoms

Asymptomatic individuals with a single abnormal test should have the test repeated to confirm the diagnosis unless the result is unequivocally abnormal.

**Limited Care**

Diabetes can be diagnosed with any of the following criteria:
- FPG ≥126 mg/dL or
- FPG ≥126 mg/dL and/or 2-h plasma glucose ≥200 mg/dL using 75-g OGTT or
- Random plasma glucose ≥200 mg/dL in the presence of classical diabetes symptoms

Asymptomatic individuals with a single abnormal test should have the test repeated to confirm the diagnosis unless the result is unequivocally abnormal.

**NOTE**

- Estimation of HbA1c should be performed using NGSP standardized method.
- Capillary glucose estimation methods are not recommended for diagnosis.
- Venous plasma is used for estimation of glucose.
- Plasma must be separated soon after collection because the blood glucose levels drop by 5%–8% hourly if whole blood is stored at room temperature.

*FPG is defined as glucose estimated after no caloric intake for at least 8–12 hours.

**Using a method that is National Glycohaemoglobin Standardization Program (NGSP) certified. For more on HbA1c and NGSP, please visit http://www.ngsp.org/index.asp

**BACKGROUND**

The diagnostic criteria of diabetes have been constantly evolving. Both type 1 and type 2 Diabetes mellitus (DM) are diagnosed based on the plasma glucose criteria, either the fasting plasma glucose (FPG) levels or the 2-h plasma post-prandial glucose (2-h PPG) levels during a 75-g oral glucose tolerance test (OGTT), or the newer glycosylated haemoglobin (HbA1c) criteria which reflects the average plasma glucose concentration over the previous 8–12 weeks.[1,2] The International Expert Committee Report recommend a cut-point of ≥6.5% for HbA1c for diagnosing diabetes as an alternative to fasting plasma glucose (FPG ≥7.0 mmol/L).[3] HbA1c testing has some substantial advantages over FPG and OGTT, such as convenience, pre-analytical stability, and less day-to-day fluctuations due to stress and illness.[3] Additionally, HbA1c has been recognized as marker to assess secondary vascular complications due to metabolic derailments in susceptible individuals.[2,4,5] However, given ethnic differences in sensitivity and specificity of HbA1c population-specific cut-offs might be necessary.[6,7] Moreover, measuring HbA1c is expensive as compared to FPG assessments and standardization of measurement techniques and laboratories are poorly practiced across the country.[8] Also, in several countries including India, HbA1c demonstrated inadequate predictive accuracy in the diagnosis of diabetes, there is no consensus on a suitable cut-off point of HbA1c for diagnosis of diabetes in this high-risk population.[9] In lieu of this, the panel expressed concerns on using HbA1c as sole criteria for diagnosis of diabetes particularly in resource constraint settings. Therefore, a combination of HbA1c and FPG would improve the identification of individuals with diabetes mellitus and prediabetes in limited resource settings like India.

**CONSIDERATIONS**

The decision about setting diagnostic thresholds values was based on the cost-effective strategies for diagnosing diabetes that were reviewed in Indian context.

**RATIONALE AND EVIDENCE**

**Glycosylated haemoglobin cut off for diagnosis of diabetes in Indian patients**

- The RSSDI expert panel suggests
  - HbA1c ≥6.5% as optimal level for diagnosis of diabetes in Indian patients
  - HbA1c cannot be used as ‘sole’ measurement for diagnosis of diabetes in Indian settings.

These recommendations are based on the Indian evidences

- A recent study conducted in Singapore residents of Chinese, Malay and Indian race to assess the performance of HbA1c as a screening test in Asian populations suggested that HbA1c is an appropriate alternative to FPG as a first-step screening test, and a combination of HbA1c with a cut-off of ≥6.1% and FPG level ≥100 mg/dL would improve detection in patients with diabetes.[6]

- A study to assess the diagnostic accuracy and optimal HbA1c cutoffs for diabetes and prediabetes among high-risk south Indians suggested that HbA1c ≥6.5% can be defined as a cut-off for diabetes and HbA1c ≥5.9% is optimal for prediabetes diagnosis and value <5.6% excludes prediabetes/diabetes status.[9]

- Data from a community based randomized cross sectional study in urban Chandigarh suggest that HbA1c cut point of 6.5% has optimal specificity of 88%, while cut off point of 7.0% has sensitivity of 92% for diagnosis of diabetes.[10]

- The results of the Chennai Urban Rural Epidemiology Study (CURES) demonstrated 88.0% sensitivity and 87.9% specificity for detection of diabetes when HbA1c cut off point is 6.1% (based on 2-h post load plasma glucose) and 93.3% sensitivity and 92.3% specificity when HbA1c cut off point is 6.4% (when diabetes was defined as FPG ≥7.0 mmol/L).[11]

However, panel emphasized that HbA1c can be used in settings where an appropriate standardized method is available.

**IMPLEMENTATION**

Individuals should be educated on the advantages of early diagnosis and should be encouraged to participate in community screening programs for diagnosis.
## PREVENTION

### RECOMMENDATIONS

#### Recommended Care

**Screening and early detection**
- Each health care service provider should have a program to detect people with undiagnosed diabetes.
  - This decision should be based on the prevalence of undiagnosed diabetes and available support from health care system/service capable of effectively treating newly detected cases of diabetes.
  - Opportunistic screening for undiagnosed diabetes and prediabetes is recommended. It should include:
    - Individuals presenting to health care settings for unrelated illness
    - Family members of diabetes patients
    - Antenatal care
    - Dental care
    - Overweight children and adolescents at onset of puberty
  - Wherever feasible, community screening may be done
- Detection programs should be usually based on a two-step approach:
  - Step 1: Identify high-risk individuals using a risk assessment questionnaire
  - Step 2: Glycaemic measure in high-risk individuals
  - Where a random non-FPG level ≥100 (or random capillary glucose >110mg/dL) to <200 mg/dL is detected, OGTT should be performed.
  - Use of HbA1c as a sole diagnostic test for screening of diabetes/prediabetes is not recommended.
- Universal screening and diagnosis of gestational diabetes mellitus must be done to identify women at very high risk of future diabetes and cardiovascular diseases (CVD).
- People with high blood glucose during screening need further diagnostic testing to confirm diabetes while those with screen-negative for diabetes should be retested as advised by the physicians.
- Paramedical personnel such as nurses or other trained workers should be included in any basic diabetes care team.

**Prediabetes**
- People who are screen-positive for prediabetes (FPG=100-125 mg/dL or 2-h PG in the 75-g OGTT=140-199 mg/dL or HbA1c=5.7%-6.4%) should be monitored for development of diabetes annually.
- Should be simultaneously screened and treated for modifiable risk factors for CVD such as hypertension, dyslipidaemia, smoking, and alcohol consumption.
- Screening strategies should be linked to health care system with capacity to provide advice on lifestyle modifications:
  - May be aligned with ongoing support national programs available at community health centres
  - Patients with IGT, IFG should be referred to these support programs.
- People with prediabetes should modify their lifestyle including:
  - Attempts to lose 5%–10% of body weight if overweight or obese
  - Participate in physical activity (e.g., walking) for at least 1-h daily if overweight or obese. and at least half hour daily if normal weight
  - 6-8 h of sleep daily
- Healthy lifestyle measures including diet and physical activity are equally important for non-obese patients with prediabetes.
- People with prediabetes failing to achieve any benefit on lifestyle modifications after 6 months may be initiated on oral antidiabetic agents (OADs):
  - Metformin: In younger individuals with one or more additional risk factors for diabetes regardless of BMI, if overweight/obese and having IFG + IGT or IFG + HbA1c >5.7%, addition of metformin (500 mg, twice daily) after 6 months of follow-up is recommended.
  - Alternatively, alpha-glucosidase inhibitors (AGIs) such as acarbose or voglibose may be initiated if metformin is not tolerated.
  - Other pharmacological interventions with pioglitazones, orlistat, vitamin D, or bariatric surgery are not recommended.
- People with prediabetes should be educated on:
  - Weight management through optimal diet and physical activity
  - Stress management
  - Avoidance of alcohol and tobacco

#### Limited Care

- The principles for screening are as for recommended care.
- Diagnosis should be based on FPG or capillary plasma glucose if only point-of-care testing is available.
- Using FPG alone for diagnosis has limitations as it is less sensitive than 2-h OGTT in Indians.
  - **Prediabetes**
    - The principles of detection and management of prediabetes are same as for recommended care.
    - Linkages to healthcare system with capacity to provide advice on lifestyle modifications and alignment with on-going support national programs available at community health centres where patients detected with prediabetes can be referred are critical.
**Background**

Chronic hyperglycaemia is associated with significantly higher risk of developing diabetes related micro- and macrovascular complications. Early detection of diabetes/prediabetes through screening increases the likelihood of identifying asymptomatic individuals and provides adequate treatment to reduce the burden of diabetes and its complications. Through a computer simulated model on the data from the Anglo-Danish-Dutch study of intensive treatment in people with screen-detected diabetes in primary care (ADDITION-Europe), Herman et al. have demonstrated that the absolute risk reduction (ARR) and relative risk reduction (RRR) for cardiovascular (CV) outcomes are substantially higher at 5 years with early screening and diagnosis of diabetes when compared to 3 years (ARR: 3.3%; RRR: 29%) or 6 years of delay (ARR: 4.9%; RRR: 38%).[12] Adopting a targeted approach and utilizing low-cost tools with meticulous planning and judicious allocation of resources can make screening cost-effective even in resource-constrained settings like India.[13] Furthermore, in a systematic review and meta-analysis, screening for type 2 DM (T2DM) and prediabetes has been found to be cost-effective when initiated at around 45–50 years of age with repeated testing every 5 years.[14]

Prediabetes is defined as blood glucose concentration higher than normal, but lower than established thresholds for diagnosis of diabetes. People with prediabetes are defined by having IGT (2-h PG in the 75-g OGTT: 140-199 mg/dL) or IFG (FPG: 100-125 mg/dL). It is a state of intermediate hyperglycaemia with increased risk of developing diabetes and associated CV complications and therefore early detection and treatment of IGT and IFG is necessary to prevent the rising epidemic of diabetes and its associated morbidity and mortality. Although, IDF guideline does not deal with screening and management of prediabetes, the ADA recommends screening for prediabetes and T2DM through informal assessment of risk factors or with an assessment tool. [1] To prevent the progression of pre-diabetes to T2DM, ADA recommends an intensive behavioural lifestyle intervention (BILI) programme (eg, medical nutrition therapy (MNT) and physical activity) in susceptible individuals.[15]

Based on the Indian Council of Medical Research-IndiaDIABetes (ICMR-INDIAB) study conducted in 15 states, the overall prevalence of diabetes and prediabetes was 7.3% (95% CI: 7.0, 7.5) and 10.3% (10.0, 10.6), respectively.[16] Another study conducted among residents of urban areas of east Delhi-The Delhi Urban Diabetes Survey (DUDS) demonstrated a strikingly high prevalence of diabetes (18.3%; known, 10.8%; newly detected, 7.5%) and prediabetes (21% [WHO criteria], 39.5% [ADA criteria]).[17] Given the high prevalence rates of prediabetes in our country, the RSSDI panel holds the opinion that including screening and management aspects of prediabetes is logical and will provide an important opportunity for prevention of diabetes in India.

**Considerations**

The decision about conducting a screening program should be based on the following local factors that were reviewed in Indian context: limited resources, lack of quality assurance in labs, high-risk population for diabetes, large unrecognized burden of undiagnosed diabetes, high prevalence of prediabetes, fast conversion rates from population prediabetes to diabetes, large rural–urban divide, largely sedentary population in urban areas, onset of T2DM at least a decade earlier that in western countries, newer technologies for screening, cost of early detection to the individual, capacity for carrying out screening and capacity to treat/manage screen-positive individuals with diabetes and prediabetes.

**Rationale and Evidence**

**Opportunistic screening**

The panel suggests that screening should be opportunistic but not community-based as they are less effective outside health care setting and poorly targeted, i.e., it may fail to identify individuals who are at risk. In a cross-sectional study on 215 participants in a tertiary care hospital in Haryana, opportunistic screening showed that for every seven patients with known diabetes, there are four undiagnosed diabetes patients.[18] In the ICMR-INDIAB study, the ratio of known-to-unknown diabetes was at least 1:1, with rural areas being worse than urban.[16] Opportunistic screening is more cost-effective with better feasibility within the health care system while minimizing the danger of medicalization of a situation. Furthermore, patients diagnosed through this screening have good prognosis over those diagnosed by clinical onset of symptoms.[19]

**Risk assessment questionnaire**

There are two risks cores specific for Indians developed by Madras Diabetes Research Foundation (MDRF) and by Ramachandran et al.[20] [Annexures 1 and 2]. Both risk scores are validated and are being used widely in our country. The MDRF-Indian Diabetes Risk Score (IDRS) tool has been found to be useful for identifying undiagnosed patients with diabetes in India and could make screening programs more cost-effective.[21] It is also used in several national programs for prevention of not only diabetes but also cardiometabolic diseases such as stroke. Also its applicability in identifying prevalence of diabetes-related complications such as CAD, peripheral vascular disease (PVD), and neuropathy among T2DM patients has been found to be successful.[25] Risk scores by Ramachandran et al. is simple with few risk variables listed and can be applied at any worksite by a paramedical personnel and help identification of the high risk group by the presence of a minimum of 3 or more of the risk variables used in the risk score.[23]

**Random plasma glucose level**

- The panel endorse the IDF recommendation on the need to measure FPG and perform OGTT based on random plasma glucose levels which are associated
with the development of diabetes (2-h PG ≥200 mg/dL) or prediabetes (2-h PG ≥140 to <200 mg/dL). According to IDF guidelines, FPG values ≤100 mg/dL are considered normal and FBG ≥100 mg/dL is considered to be at risk of developing diabetes. Further, individuals with FPG between 100-125 mg/dL have IFG, suggesting an increased risk of developing T2DM.

Confirming the FPG levels ≥126 mg/dL by repeating tests on another day, confirm diabetes. In a cross-sectional study on 13,792 non-fasting National Health and Nutrition Examination Surveys (NHANES) in participants without diagnosed diabetes, random blood sugar level of ≥100 mg/dL was strongly associated with undiagnosed diabetes. Prediction of diabetes carried out on the basis of this data showed that random blood glucose ≥100 mg/dL was 81.6% (95% CI: 74.9%, 88.4%) sensitive and 78% (95% CI: 76.6%, 79.5%) specific to detect undiagnosed diabetes, which is better than current screening guidelines. Evidence from community-based opportunistic screening in India suggests that random capillary blood glucose level of ≥110 mg/dL can be used to identify those individuals who should undergo definitive testing for diabetes or prediabetes. In patients with no history of diabetes or prediabetes, random blood glucose screening is effective in promoting additional screening among high-risk age groups and encourages patients to make lifestyle changes.

The panel suggest that although the present criteria of IFG (100-125 mg/dL) may be sensitive and has lesser variability, measuring 2-h PG levels may give more accuracy and confidence in targeting this population for prevention strategies.

**Glycosylated haemoglobin as criteria for screening**

- A meta-analysis of 49 studies involving patients aged ≥18 years reported that HbA1c as a screening test for prediabetes has lesser sensitivity (49%) and specificity (79%). Moreover, the use of ADA recommended HbA1c threshold value of 6.5% for diagnosis of diabetes may result in significant under diagnosis. The predictive value of HbA1c for T2DM depends on various factors such as ethnicity, age, and presence of iron deficiency anaemia (IDA). In a cohort study on individuals from Swedish and Middle-East ancestry, HbA1c ≥48 mmol/mol had a predictive sensitivity of 31% and 25%, respectively, for T2DM. Furthermore, HbA1c values ≥42 and ≥39 mmol/mol as predictors for prediabetes were associated with a sensitivity of 15% and 34% in individuals of Swedish and 17% and 36% in individuals of Middle-East ancestry. Similarly, a systematic review and meta-analysis of 12 studies including 49,238 individuals without T2DM reveal that HbA1c values are higher in Blacks (0.26% (2.8 mmol/mol), p <0.001), Asians (0.24% (2.6 mmol/mol), p <0.001), and Latinos (0.08% (0.9 mmol/mol); p <0.001) when compared to Whites. Moreover, significantly high HbA1c levels are observed in patients with IDA when compared to healthy subjects (5.51±0.696 vs 4.85±0.461%, p <0.001) and HbA1c levels decline significantly after treatment with iron supplements in IDA subjects (5.51±0.696 before treatment vs 5.04±0.603 post-treatment; p <0.001).

- The panel recommends the use of HbA1c as sole criteria for screening of diabetes/prediabetes would be inappropriate in most settings in India, at this time. However, HbA1c may be utilized for screening if it is being done from a laboratory known to be well-equipped with external quality assurance.

- The panel expresses concerns of high prevalence of anaemia and high prevalence of haemoglobinopathies in certain regions/populations particularly from the North East as these can have significant impact when HbA1c is used as diagnostic test for screening.

**Diagnosis of prediabetes**

- The panel endorses the ADA criteria for diagnosis of prediabetes for Indian context

**Pregnancy as a critical target for diabetes prevention strategies**

- Gestational diabetes mellitus (GDM) is a known risk factor for T2DM. Women with GDM have a 7-fold higher risk of developing T2DM and are at a higher risk of developing metabolic syndrome and CVD. Also children of GDM mothers are at higher risk of development of T2DM later in life compared with non-GDM mothers.

- Given the high prevalence of GDM in Indian women, early detection and effective treatment can prevent all adverse outcomes of pregnancy and result in a normal and healthy postpartum course for both mother and baby.

**Children and adolescents: Screening strategies**

- Screening studies in obese adolescents have reported a prevalence of 0.4% up to 1% of type 2 diabetes mellitus in obese children ≥12 years.

- Overweight (BMI >90 percentile) or obese children (BMI >99.5 percentile) with familial history of T2DM, children from a predisposed race/ethnicity such as Asian, American Indian, etc., with associated risk factors such as IR, dyslipidemia, polycystic ovarian syndrome must be screened periodically.

- Consistent with the recommendations for screening in adults, children at substantial risk for the development of T2DM should also be tested. The ADA recommends screening in high risk overweight children and adolescents at onset of puberty. The screening must be performed every 2 years from diagnosis using fasting glucose or OGTT.

**Rescreening**

- The panel emphasize on striking balance between cost of screening and cost of treating complications.
On the basis of expert opinion of the panel, general population should be evaluated for the risk of diabetes by their health care provider on annual basis beginning at age 30.

Yearly or more frequent testing should be considered in individuals if the initial screen test results are in the prediabetes range or present with one or more risk factors that may predispose to development of diabetes.

The panel opine that screening programs should be linked with health care system and ongoing national prevention programs that will facilitate effective and easy identification of people at high-risk of developing diabetes and its complications.

**Paramedical personnel**

Paramedical personnel play a key role as facilitators in imparting basic self-management skills to patients with diabetes and those at risk. They can be actively involved in implementing diet and lifestyle changes, behavioural changes, weight management, pre-pregnancy counselling, and other preventive education.

- Nurses or other trained workers in primary care and hospital outpatient settings can:
  - Help in identification of individuals at risk of diabetes
  - Help in recognition of symptoms of diabetes, hypoglycaemia, and ketosis
  - Help in timely referral of these cases.

- Nurses or nurse educators in secondary and tertiary care settings can:
  - Perform all the above activities
  - Help in prevention and treatment of hypoglycaemia
  - Help in problems with insulin use.

**Evidence**

It has been observed that Indians are more prone to diabetes at a younger age and at a lower BMI compared to their Western counterparts.\[42,43\] The reason for this difference has been attributed to the “Asian Indian phenotype” characterized by low BMI, higher body fat, visceral fat and WC; lower skeletal muscle mass and profoundly higher rates of IR.\[44,45\] The 10-year follow-up data of the CURES that assessed incident rates of dysglycaemia in Asian Indians are now available.\[46\]

In a cross-sectional study on slum dwellers in Bangalore, prevalence of diabetes and prediabetes was identified as 12.33% and 11.57% in people aged ≥35 years.\[47\] Moreover, in case of female gender, increasing age, overweight and obesity, sedentary lifestyle, tobacco consumption, and diet habits were strongly associated with prevalence of diabetes and prediabetes. Similarly, in a cross-sectional study in Tamil Nadu, prevalence of diabetes and prediabetes was identified as 10.1% and 8.5% respectively.\[48\] Risk factors associated with prediabetes in this study were age of 40 years, male gender, BMI >23 kg/m², WHR for men >1 and women >0.8, alcohol intake and systolic blood pressure (SBP) >140 mmHg. Likewise, in a household survey in Punjab, using World Health Organization STEP wise Surveillance (WHO STEPS) questionnaire, prevalence of diabetes and prediabetes were identified as 8.3% and 6.3% respectively.\[49\]

Risk factors that were significantly associated with diabetes were age (45–69 years), marital status, hypertension, obesity and family history of diabetes. A study on 163 north Indian subjects proposed severity of IR and family history of diabetes as determinants of diminished beta-cell function leading to diabetes in MS.\[50\] Predictors of progression to impaired glycaemia were advancing age, family history of diabetes, 2-h PPG, HbA1c, low density lipoprotein (LDL) and HDL, and physical inactivity.

Despite the escalating burden, the current evidence on the prevention of T2DM and its complications in India is scarce. Though the general practitioners in India are well aware of symptoms and complications of T2DM, they are oblivious regarding the use of standard screening tests resulting in significant delay in diagnosis and treatment.\[51\]

Considering significant resource constraints together with awareness levels of patients and physicians, there is a need for prevention strategies that are culturally relevant and cost-effective.\[52\] Following section covers evidence from Indian studies on various strategies that are helpful in detecting and minimizing the risk of development of diabetes and its associated complications.

- Simplified tools for detection of diabetes such as IDRS developed by MDRF and Diabetes Risk Score for Asian Indians devised by Prof. A. Ramachandran are found to be useful for identifying undiagnosed patients with diabetes in India. Use of these tools could make screening programs more cost-effective.\[20,21\]

Studies from different regions of India including Jammu, Kashmir, Chennai, Haryana, Delhi, Jabalpur, and Kerala estimated the utility of MDRF-IDRS in identifying risk for DM and prediabetes in Indian adult population and found statistically significant association between IDRS and DM patients indicating MDRF-IDRS to be efficient tool to screen and diagnose the huge pool of undiagnosed diabetics in India.\[53-58\]

- It is also found by that identifying the presence of multiple risk factors could be used as a simple measure of identifying people at high risk of diabetes.\[59\]

- The panel suggests that individuals with diabetes or at risk of developing diabetes should be advised on lifestyle changes and implementing strategies focusing on diet, exercise and weight loss to prevent the risk of progression and thus complications of diabetes.\[60,61\]

- Several landmark studies have shown that lifestyle intervention could prevent the progression to T2DM.
Recent studies have proven while providing long-term evidence from literature. The evidence identified that lifestyle intervention reduced risk of developing diabetes and its complication and also helps in improving dietary patterns of individuals with prediabetes and diabetes. \(^{52,75}\) Mobile phone messaging was found to be an inexpensive and most effective alternative way to deliver educational and motivational advice and support towards lifestyle modification in high-risk individuals. \(^{23}\) Recent studies have proven the advantages of using mhealth strategies in promotion of prevention of NCDs. The WHO has recommended the use of such strategies for large scale programmes. \(^{76,77}\)

- Interventions predominantly based on counselling and education are found to be effective in preventing/reducing the risk of developing diabetes and its complication and also helps in improving dietary patterns of individuals with prediabetes and diabetes. \(^{52,75}\)

- Dietary interventions such as high-carbohydrate, low-fat diet,\(^{78}\) fibre-rich,\(^{79}\) and protein-rich diet\(^{80,81}\) were found to have definite role in prevention of diabetes. Furthermore, components of whole grains, and fruit and green leafy vegetables such as cereal fibre and magnesium, are consistently associated with lower risk of developing T2DM. \(^{80}\)

- Evidence from the CURES and Prevention Awareness Counselling and Evaluation (PACE) diabetes project suggests that awareness and knowledge regarding diabetes is inadequate among patients in India and implementation of educational programs at massive level can greatly improve the awareness on diabetes and its associated CVD. \(^{82,83}\)

- A prospective, randomized controlled study of Fenugreek conducted in nondiabetic people with prediabetes demonstrated a significant reduction in FPG, PPG and LDL and showed insulinotropic effect. \(^{85}\)

- Currently, the role of yoga and fenugreek in the prevention of diabetes is being evaluated in the Indian prevention of Diabetes Study by RSSDI.

### Implementation

A clear and transparent decision should be made about whether or not to endorse a screening strategy. If the decision is in favour of screening, this should be supported by local protocols and guidelines, and public and health-care professional education campaigns.
TREATMENT 1: MEDICAL NUTRITION THERAPY (MNT) AND LIFESTYLE MODIFICATIONS

Recommended Care

MNT

- The nutrition chart and support should be made in conjunction with a trained nutritionist along with physician/diabetologist.

- Carbohydrates
  - Carbohydrate content should be limited to 50%-60% of total calorie intake.
  - Complex carbohydrates should be preferred over refined products.
  - Low glycaemic index (GI) and low glycaemic load (GL) foods should be preferred.
  - Quantity of rice (GI: 73) should be limited as it has high GI; Brown rice (GI: 68) should be preferred over white rice.
  - Fibre intake: 25-40 gm per day.

- Proteins
  - Protein intake should be maintained at about 15% of total calorie intake.
  - Quantity of protein intake depends on age, sarcopenia and renal dysfunction.
  - Non-vegetarian foods are sources of high quality protein, however intake of red meat should be avoided.

- Fats
  - Fat intake should be limited (<30% of total calorie intake).
  - Oils with high monounsaturated fatty acid (MUFA) and polyunsaturated fatty acid (PUFA) should be used.
  - Use of 2 or more vegetable oils is recommended in rotation.
  - For non-vegetarians, consumption of 100-200 g of fish/week is advised as good source of PUFA and for vegetarians, vegetable oils (soybean/safflower/sunflower), walnuts and flaxseeds are recommended.
  - Avoid consumption of foods high in saturated fat (butter, coconut oil, margarine, ghee).
  - Saturated fatty acids (SFAs) intake should be less than 10% of total calories/day (<7% for individuals having high triglycerides).
  - Use of partially hydrogenated vegetable oils (Vanaspati) as the cooking medium should be avoided.
  - Reheating and refrying of cooking oils should be avoided.

- Food groups and patterns
  - Diet rich in fruits, leafy vegetables, nuts, fibre, whole grains and unsaturated fat is preferred.
  - Food plate should include pulses, legumes, unprocessed vegetables and low fat dairy.
  - Extreme diets including low-carbohydrate ketogenic must be planned and executed following consultation with physician and nutritionist, and for a short period.
  - Overall salt consumption should be <5 g/day (with sodium consumption <2300 mg/day).
  - Avoid or decrease alcohol intake.
  - Smoking cessation should be advised to all. Smoking cessation therapies may be provided under observation for patients who wish to quit in step-wise manner.
  - Sugar sweetened beverages are best avoided.
  - Artificial sweeteners may be consumed in recommended amounts.
  - Meal plans with strategic meal replacements (partial or full meal replacements) may be an option under supervision when feasible.

- Lifestyle modifications
  - Recommended care could be imparted by physician and diabetes educator.
  - Careful instructions should be given for initiating exercise programme. Help of a physical instructor can be taken.
  - Lifestyle advice should be given to all people with T2DM at diagnosis. It should be an effective option for control of diabetes and increasing CV fitness at all ages and stages of diabetes.
  - Lifestyle intervention is a cost-effective approach in prevention of T2DM.
  - Lifestyle interventions should be reviewed yearly or at the time of any treatment or at every visit.
  - Advise people with T2DM that lifestyle modification, by changing patterns of eating and physical activity, can be effective in managing several adverse risk factors related to T2DM.
  - Physical activity should be introduced gradually, based on the patient’s willingness and ability and the intensity of the activity should be individualized to the specific goals.
  - A minimum of 150 min/week of physical activity is recommended for healthy Indians in view of the high predisposition to develop T2DM and CAD
    - ≥30 min of moderate-intensity aerobic activity each day
    - 15-30 min of work-related activity
    - 15 min of muscle-strenthening exercises (at least 3 times/week)
  - While effect of yogic practices is encouraging, it should not replace aerobic exercise.
  - Use of monitoring tools like accelerometers, GPS units, pedometers, mobile based apps or devices to measure the intensity and duration of physical activity may be encouraged.

Behavioural lifestyle intervention (BLI)

- BLI involves patient counselling for strategies such as tailoring goals, self-monitoring and stimulus control.
- BLI approaches have shown to improve adherence to lifestyle changes and achieve more sustained effects.
- Diabetes self-management support is important and could be done with physician or educator with small groups or face-to-face discussions in chat rooms.
**Limited Care**

- Nutritional counselling may be provided by health care providers (HCPs) trained in nutrition therapy, not necessarily by an accredited dietician nutritionist.
- Overall, reduced consumption of simple carbohydrates, sugar and fried foods and higher consumption of complex carbohydrates with high protein intake are recommended.
- Salt intake should be in moderation.
- Encourage increased duration and frequency of physical activity (where needed).
- Mass awareness campaign for healthy diet and lifestyle should be conducted.

**BACKGROUND**

Unhealthy diet and sedentary lifestyle have been identified as fundamental modifiable risk factors in T2DM. Rapid urbanization and rampant availability of westernized, processed foods that contain high amounts of refined carbohydrates, saturated fats and added sugars have dramatically changed the local food environment in India. Along with increasing physical inactivity, these adverse dietary changes have been associated with detrimental influences on the onset and progression of T2DM in India. MNT is a systematic approach to optimize dietary intake in order to achieve metabolic control and maximize favourable treatment outcomes in T2DM. Conceptually, MNT involves counselling and recommendations from a registered dietician (RD) under the regular supervision of the consulting diabetologists.

Current global clinical practice guidelines for T2DM from the ADA, American Association of Clinical Endocrinologists (AACE) and IDF advocate the importance of integrating MNT in the management of T2DM as a first-line therapy and provide consistent recommendations for day-to-day nutritional requirements. MNT is a lifestyle transforming process that is beyond calorie restriction and portion control. Implementation of MNT in India is challenging owing to its cultural and culinary diversity. Consumption of high amounts of carbohydrates including ghee-laden sweets loaded with sugar or jaggery are inherent to the standard Indian diet and have religious significance, thus escalating the challenges of restricting carbohydrate intake. Therefore designing individualized diet plans as a part of MNT in India should consider regional, cultural, economic and agricultural factors as these have a marked influence on the acceptance of MNT by the patient.

**Role of medical nutrition therapy in prevention and management**

Dietary counselling and adherence of healthful, calorie-restricted diet and regular exercise have been associated with lower rates of incident diabetes in Indian men with impaired glucose tolerance. Community health programs and implementation of MNT-based model meals in rural and urban populations from South and North of India have shown favourable changes in dietary patterns and improvements in several parameter including BMI, waist circumference, fasting blood glucose and so on. A stepwise Diabetes Prevention Program lowered the 3-year risk of diabetes by 32% (95% CI: 7, 50) in obese Asian Indian adults with any form of prediabetes. These studies including few others involving Indians with risk factors for diabetes reported benefits of dietary approaches such as high consumption fibre-rich foods, high-protein meal replacements, or replacement of polished white rice with whole grain brown rice and increased intake of fruits and vegetables.

The landmark lifestyle intervention program, Look Ahead examined the effects of calorie-restricted diet and reduce intake of high-GI carbohydrates such as sugar, flavoured beverages and high calorie snacks on glycaemic control and prevention of CV complications. At 11 years, participants benefited from the regimented diet and had an average weight loss of 5% along with substantial improvements in HbA1c levels, blood pressure, lipid profile and overall fitness and well-being. In a year-long prospective randomized study from India, individuals with T2DM, randomized to MNT, achieved significant lowering of HbA1c and all lipid parameters, especially triglyceride levels. This study involved 20 dieters and reported the success of a guided, evidence-based, individualized MNT versus usual diabetes care. Based on these clinically relevant observations in the Indian population, the RSSDI recommends the adoption of dietician-guided MNT as an integral component of diabetes management [Figure 1]. The MNT and lifestyle modifications should be individualized based on diseases profile, age, sociocultural factors, economic status, and presence of sarcopenia and organ dysfunction.

**Rationale and Evidence**

**Carbohydrate monitoring**

Meal planning approaches should include carbohydrate counting, exchanges or experience based estimation and measurement of GI and GL to monitor the amount of carbohydrate in food and understand its physiological effects of high-carbohydrate diets.

**High-carbohydrate, low-fat diets**

Although there is a dichotomy in recommendations with regard to high-or low-carbohydrate diets, historic data from India suggest the metabolic benefits of high-
Recent studies support the implementation of a long-term high-carbohydrate high-fibre diet in promoting weight loss, improving glycaemic control, and lowering CV risk. High carbohydrate diets should comprise large amounts of unrefined carbohydrate and fibre such as legumes, whole grains, unprocessed vegetables, and fruits. High carbohydrate diet regimens in T2DM patients have been associated with favourable weight loss and reductions in plasma glucose, HbA1c and LDL levels with good adherence and sustainability, comparable with low carbohydrate diets. The concern of possible untoward effect of high carbohydrate diet on lipid profile (increase in triglycerides and reductions in HDL) and CV risk can be mitigated by lowering the glycaemic index of diets by incorporating fibre-rich foods. 

Cross-sectional data from the CURES suggests that Indians consume high amounts of refined grains (~47% of total calories), which is associated with significant increases in waist circumference (p<0.0001), systolic blood pressure (p<0.0001), diastolic blood pressure (p=0.03), fasting blood glucose (p=0.007), serum triglyceride (p<0.0001), lower HDL (p<0.0001), and insulin resistance (p<0.001). Further, Indians who consumed refined grains were more predisposed develop metabolic syndrome (odds ratio [OR]: 7.83; 95% confidence interval [CI]: 4.72, 12.99) and insulin resistance versus those consumed lower quantities.

In an assessment of the quality and type of carbohydrates in a subset of patients from the CURES study, consumption of refined grain (OR: 5.31; 95% CI: 2.98, 9.45; p<0.001), total carbohydrate (OR: 4.98; 95% CI: 2.69, 9.19; p<0.001), GL (OR: 4.25; 95% CI: 2.33, 7.77; p<0.001), and GI (OR: 2.51; 95% CI: 1.42, 4.43; p=0.006) positively correlated with the risk of T2DM. In contrast, high intake of dietary fibre showed an inversely correlation with T2DM (OR: 0.31; 95% CI: 0.15, 0.62; p<0.001).

Additional analysis of the data from the CURES study population revealed the detrimental dietary habits among South Indian adults (daily energy intake: carbohydrates [64%], fat [24%], protein [12%]) that escalates the risk of T2DM. It was observed that refined cereals contributed to nearly 46% of total energy intake, followed by visible fats and oils (12.4%), pulses and legumes (7.8%), and intake of micronutrient-rich foods (fruits, vegetables, fish etc.) was inadequate and below the recommended standards of FAO/WHO.

Given that carbohydrates are an inherent part of the staple Indian diet and Indians habitually tend to consume high amounts of carbohydrates, improving the quality of carbohydrates in the diet by replacing high-GI carbohydrates with fibre-rich, low GI counterparts. It was observed that consumption of brown rice significantly reduced 24-h glycaemic response 24-h (p=0.02) and fasting insulin response (p=0.0001) in overweight Asian Indians.

Replacement of white rice with brown rice was found to be feasible and culturally appropriate in Indian overweight adults and correlated with lower risk of T2DM. Fortification of humble Indian dishes with fibre-rich alternatives, for example adding soluble fibre in the form of oats in upma or improving the glycaemic quality of Indian flatbreads (rotis or chapattis) by adding wheat flour with soluble viscous fibres and legume flour have shown favourable outcomes on the lipid profile and postprandial glucose and insulin responses in T2DM patients.

Sugar and sugar-sweetened beverages increase the dietary GL. Overall, the consumption of total sugar (25.0 kg/capita) among Indians exceeds the average global annual per capita consumption (23.7 kg).

Consumption of sweets, sweetened beverages (e.g. lassi, aamras) or addition of sugars in curries, gravies etc. have customary and regional importance in India. It is observed that in urban South India, the added sugars in
hot beverages (tea or coffee) majorly contribute to sugar intake and account for around 3.6% of total GL.\[107\]

**Low-carbohydrate, ketogenic diet**

Low-carbohydrate diets may be particularly beneficial in patients with impaired glucose tolerance, and obesity, however, to balance the macronutrient content, these diets tend to be high in fats and proteins. Therefore, while adopting such diets, fat intake should occur mainly in the form of MUFA with a parallel decrease in saturated fatty acids (SFAs) and *trans* fatty acids (TFAs). As the metabolic pathways of carbohydrates and fats are interlinked, low carbohydrate diets that are high in fats and protein are associated with long-term effects such as ketosis, and adverse lipid, and renal effects.\[118\]

- Evidence suggest that T2DM patients on low carbohydrate diet achieve favourable outcomes due to reduced energy intake and prolonged calorie restriction and not due to low carbohydrate intake. Obese T2DM patients should therefore consider switching to a low-carbohydrate diet designed based on calorie restriction as well as regulated intake of fats to reduce the incidence of T2DM and myocardial infarction.\[119,120\] These diets should be considered for a limited period only.

- In a small study, overweight patients with T2DM were randomized to a very low carbohydrate ketogenic diet and lifestyle modifications such as physical activity, sleep etc. had significantly improved their glycaemic control (p=0.002) and lost more weight (p<0.001) than individuals on a conventional, low-fat diabetes diet program.\[121\]

- In another similarly designed randomized controlled trial, overweight individuals with T2DM or elevated HbA1c levels on very low carbohydrate ketogenic diet for a period of 12 months had significant reductions in HbA1c levels (p=0.007) and body weight (p<0.01) than participants on moderate-carbohydrate, calorie-restricted, low-fat diet.\[122\]

- In a 24-week interventional study, a low-carbohydrate ketogenic diet in patients with T2DM favourably improved body weight, glycaemic and lipid profiles in patients with T2DM as compared with patients on a low carbohydrate diet.\[123\]

**Low glycaemic index of pulses and pulse-incorporated cereal foods**

As compared with other Western or Asian diets, traditional Indian diets comprising dal, roti, rice, and curry provide a wholesome supply of balanced, mixed nutrients. The mix of various pulses and legumes in a standard Indian meal offer variations in the glycaemic and insulinaemic indices that are attributed to the nature of available and non-available (non-starchy polysaccharides) carbohydrates in the foods and alterations in rates of carbohydrate absorption.\[124,125\] Inclusion of grams and pulses in rice or wheat-based starchy high GI diets reduces the glycaemic index and brings satiety along with adequate supply of calories. Meals with mixed sources of cereals, pulses and legumes contribute to regulation of insulin and glycaemic responses.

- Combining acarbose in regular daily diets was associated with significant decline in postprandial blood glucose in T2DM patients, including those who failed prior treatment with OADs.\[126\]

- Similarly, consumption of adai dosa (a type of Indian pancake with 75% pulses and 25% cereals) versus normal diet (75% cereal and 25% pulses) was associated with reduction in body weight and significant (p<0.01) lowering of HbA1c.\[127\]

- Inclusion of nuts (almond, walnuts, cashews, pistachios, hazelnuts) in diet corresponding to approximately 56 g (1/2 cup) of nuts was associated with significant reduction in HbA1c (mean difference: −0.07% [95% CI: −0.10, −0.03%]; p=0.0003) and fasting glucose (mean difference: −0.15 mmol/L [95% CI: −0.27, −0.02 mmol/L]; p=0.03) in individuals with T2DM versus isocaloric diets without nuts. The improvement was mainly attributed to lowering of GI due to replacement by nuts.\[128\]

- In an analysis of dietary patterns in India, diets rich in rice and pulses were associated with lower risk of diabetes versus diet models that had more sweets and snacks.\[129\]

- Legumes such as chickpeas are also low glycaemic foods and when substituted for similar serving of egg, baked potato, bread, or rice lower the risk of T2DM and may be beneficial in elderly individuals with CV risk.\[130\]

**Consumption of oils among Indian population**

- In the rural South Indian population from the CURES study, highest intake of fats directly correlated with risk of abdominal obesity (p<0.001), hypertension (p=0.04), and impaired fasting glucose (p=0.01). In particular, sunflower oil was found to be most detrimental when compared to traditional oils and palmoilin.\[131\]

- Supporting this finding, the risk of metabolic syndrome was higher among users of sunflower oil (30.7%) versus palmolein (23.2%) or traditional (groundnut or sesame) oil (17.1%, p<0.001) in Asian Indians. Higher percentage of linoleic acid PUFA in sunflower oil was correlated with the risk of metabolic syndrome.\[132\] The observations from these studies are preliminary and should be further investigated.

- Managing dietary intervention by replacing refined cooking oils with those containing high percentage of MUFA (canola and olive oil) in Asian Indians with non-alcoholic fatty liver disease was associated with significant reduction in body weight and BMI (p<0.01, olive oil), improvements in fasting insulin level and homeostasis model of assessment for insulin resistance and β-cell function (p<0.01, olive oil), increase in high-density lipoprotein level (p<0.004, olive oil), and decrease in fasting blood glucose (p=0.03) and triglyceride (p=0.02) level (in canola group).\[133\]
Structured exercises have found to significantly reduce Resistance training either alone or in combination physical activity. *Physical activity* • Behavioural lifestyle intervention • Fibre and diabetes mellitus • Physical activity


each day is recommended, although there is limited data to support this recommendation.**[152]**

**Fibre and diabetes mellitus**

- Increasing the intake of dietary fibres is known to have a favourable effect on the overall metabolic health. Fibre-rich foods contain complex carbohydrates that are resistant to digestion and thereby reduce glucose absorption and insulin secretion.**[79,138,139]**

- In overweight or obese patients with T2DM, a low glycaemic-index, high-fibre diet significantly (<0.001) reduces glucose and insulin area under the curve compared with high-glycaemic index, high carbohydrate diets. The favourable effects on postprandial glucose and insulinemia were sustained through an entire day.**[140]**

- Consumption of high-carbohydrate, low-GI diets that contain high proportions of dietary fibres also mitigate the risk of increase in serum triglyceride levels which is a common consequence of high-carbohydrate diet.**[99]**

- Intake of both soluble and insoluble fibres have been associated with increased post-meal satiety and decrease in consequent hunger episodes.**[141]**

- In randomized, cross-over study in 56 healthy Indian participants, consumption of flatbreads with addition of fibrous flour such as chickpea (15%) and guar gum (3% or 4%) to wheat flour significantly reduced postprandial glucose (p<0.01) and postprandial insulin (p<0.0001) when compared with flatbreads made from control flour (100% wheat flour).**[113]**

- In a dietary assessment study in urban Asian Indians with T2DM, low consumption of dietary fibres (<29 g/day) was associated with higher prevalence of hypercholesterolemia (p<0.01) and higher LDL (p<0.001) than individuals with greater median intake of fibres.**[142]**

- In a randomized study, daily consumption of 3 g of soluble fibre from 70 g of oats in form of porridge or upma for 28 days in mildly hypercholesterolaemic Asian Indians was associated with significant reduction in serum cholesterol (p<0.02) and LDL (p<0.04) versus control group (routine diet).**[114]**

- From a meta-analysis of 17 prospective cohort studies, an inverse relation was observed between dietary intake and risk of T2DM based on which it was recommended that intake of 25 g/day total dietary fibre may T2DM.**[143]**

**Physical activity**

- The International Physical Activity Questionnaire-Long Form and accelerometer can be used to measure and monitor the intensity of physical activity.**[144]**

- Physical inactivity is regarded as a major risk factor for T2DM and evidence suggests that adequate physical activity may reduce the risk by up to 27%.**[110,145]**

- Structured exercises have found to significantly reduce (p<0.001) post interventional HbA1c levels versus control group and this effect was independent of body weight.**[146]**

- In the Indian Diabetes Prevention Program report, lifestyle modification that included a minimum of 30 min/day of physical labour, exercise, or brisk walking showed significant relative risk reductions for T2DM either alone (28.5%; p=0.018) or in combination with metformin (28.2%; p=0.022) versus the control group.**[165]**

- In a cross-sectional comparative study, South Asians were found to need an additional 10-15 min/day of moderate-intensity physical activity more than the prescribed 150 min/week to achieve the same cardio-metabolic benefits as the European adults.**[147]**

- Resistance training either alone or in combination with aerobic exercises or walking has also shown to significantly improve risk factors of T2DM such as waist circumference, abdominal adiposity, HDL levels etc.**[148-150]**

- Based on all available evidence, the ADA and IDF recommend a total of at least 150 min of moderate-intensity physical activity per week that can be a combination of aerobic activities (such as walking or jogging) or resistance training.**[151]**

- For Asian Indians who are predisposed to develop T2DM or CV risks, an additional 60 min of physical activity each day is recommended, although there is limited data to support this recommendation.**[152]**

**Behavioural lifestyle intervention**

- BLI involves patient counselling for strategies such as tailoring goals, self-monitoring, stimulus control etc. that would help motivate patients to integrate the lifestyle management measures into their day-to-day life and identify and manage potential lapses.**[153]**

- BLI approaches have shown to improve adherence to lifestyle changes and achieve more sustained effects.**[154]**

- In patients with T2DM implementation of a six-month BLI program was reported to significantly reduce HbA1c levels from baseline at 3 months (−1.56 ± 1.81, p<0.05) and 6 months (−1.17±2.11, p<0.05). The BLI used cognitive behaviour therapy that mainly involved monitoring of carbohydrate intake (using diet charts) and setting targets for weight loss and physical activity across of 8 sessions (4 face-to-face and 4 telephone sessions) administered by clinical dietitians.**[155]**

- BLI using smartphone or paper-based self-monitoring of patient behaviours on weight loss and glycaemic control (based on Look AHEAD study) in overweight or obese
adults with T2DM showed significant improvements in HbA1c (p=0.01) at 6 months and meaningful weight loss that was not significant.\(^{[156]}\)

- A systematic review of randomized studies evaluating lifestyle-based interventions for T2DM found that robust behavioural strategies were essential for successful implementation of such prevention programs. This study reviewed the Indian Diabetes Prevention Programme that included individual patient counselling and goal setting for diet and exercise.\(^{[65,157]}\)

**TREATMENT 2: ORAL ANTIDIABETIC AGENTS**

**RECOMMENDATIONS**

<table>
<thead>
<tr>
<th>Recommended Care</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General Principles</strong></td>
</tr>
<tr>
<td>- Metformin should be initiated in combination with lifestyle interventions at the time of diagnosis.</td>
</tr>
<tr>
<td>- Maintain support for lifestyle measures throughout</td>
</tr>
<tr>
<td>✓ Consider each initiation or dose increase of OADs as a trial, monitoring the response through glucose monitoring (FPG, PPG, self-monitoring of blood glucose [SMBG] or HbA1c) every 2-3 months.</td>
</tr>
<tr>
<td>✓ Consider CV/heart failure risk, renal/hepatic (NASH) risk while deciding therapy</td>
</tr>
<tr>
<td>✓ Patient-centric approach: consider cost and benefit risk ratio when choosing OADs</td>
</tr>
<tr>
<td>✓ Customise therapy focusing on individualised target HbA1c for each patient based on: age, duration of diabetes, comorbidities, cost of therapy, hypoglycaemia risk, weight gain, durability</td>
</tr>
<tr>
<td>✓ Consider initiating combination therapy if the HbA1c &gt;1.5 above the target</td>
</tr>
<tr>
<td><strong>Initial Therapy</strong></td>
</tr>
<tr>
<td>- Metformin should be initiated in combination with lifestyle interventions at the time of diagnosis unless contraindicated or not tolerated.</td>
</tr>
<tr>
<td>✓ If eGFR is between 45-30 mL/min/1.73m(^2): reduce dose of metformin by 50%; stop metformin if eGFR &lt;30 mL/min/1.73m(^2). Closely monitor renal function every 3 months</td>
</tr>
<tr>
<td>✓ Other options: sulfonylurea (or glinides), dipeptidyl peptidase-4 (DPP-4) inhibitors, SGLT2 inhibitors, or AGIs can be used initially for cases where metformin is contraindicated or not tolerated</td>
</tr>
<tr>
<td>✓ In some cases, dual therapy may be indicated initially if it is considered unlikely that single agent therapy will achieve glucose targets</td>
</tr>
<tr>
<td><strong>Dualtherapy:</strong> Patient-centric approach</td>
</tr>
<tr>
<td>✓ If glucose control targets are not achieved: Add sulfonylurea or thiazolidinediones (TZDs) or sodium-glucose cotransporter 2 inhibitors (SGLT2) inhibitor, or DPP-4 inhibitor, or AGI</td>
</tr>
<tr>
<td>✓ Individualise patient care based on comorbidities</td>
</tr>
<tr>
<td><strong>Tripletherapy:</strong> Patient-centric approach</td>
</tr>
<tr>
<td>✓ If glucose targets are not achieved with two agents: start third oral agent-AGI, DPP-4 inhibitor, SGLT2 inhibitor, or TZDs (depending on second-line agent used) or start insulin or glucagon-like peptide 1 (GLP-1) agonists</td>
</tr>
<tr>
<td>✓ Intensification of therapy: Patients not achieving glycemic targets on 3 oral agents</td>
</tr>
<tr>
<td>✓ Consider GLP-1 agonists or insulin if glucose targets are not achieved with OADs</td>
</tr>
<tr>
<td>✓ Exceptionally, addition of fourth agent may be considered.</td>
</tr>
<tr>
<td>✓ In the presence of IR, addition of TZDs may be considered</td>
</tr>
<tr>
<td>- For patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure, diabetic kidney disease (DKD) or in need of weight reduction consider using SGLT2 inhibitors</td>
</tr>
<tr>
<td>- If postprandial hypoglycaemia is the issue AGI, glinides or SGLT2 inhibitors may be considered</td>
</tr>
<tr>
<td>- In elderly patients with increased risk of hypoglycaemia, use a DPP-4 inhibitor as an alternative to sulfonylurea</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Limited Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>- The principles are same as for recommended care along with considerations for cost and availability of generic therapies. In resource constrained situations, sulfonylurea or metformin or TZDs may be used.</td>
</tr>
<tr>
<td>- Newer sulfonylureas have benefit of low cost and reduced hypoglycaemia (than older OADs); comparable CV safety with DPP4i may be considered. TZDs have established CV safety and may be considered as add on to metformin.</td>
</tr>
</tbody>
</table>
BACKGROUND

T2DM occurs due to a complex interaction between genetic inheritance and risk factors such as obesity and sedentary lifestyle. Diminished insulin secretion, incretin deficiency/resistance, upregulated lipolysis, increased glucose reabsorption from kidney, along with downregulated glucose uptake, neurotransmitter dysfunction, increased hepatic glucose production, and glucagon secretion are the reported metabolic derailments that contribute to hyperglycaemia and T2DM [Figure 2]. Among Indians, high familial aggregation, central obesity, insulin resistance, and lifestyle changes due to rapid urbanization are the primary causes of T2DM. Greater degree of insulin resistance paired with higher central adiposity compared to Caucasians is a characteristic feature of T2DM in Asian Indians. Treatment options for T2DM have been developed in parallel to the increased understanding of underlying pathophysiological defects in T2DM. A patient-centric and evidence-based approach that may take into account all the metabolic derailments accompanying T2DM, is now gaining impetus. Therefore, treatments that target factors beyond glycaemic control, such cardiovascular risks, weight management, along with improvements in quality of life have been introduced. Several guidelines/recommendations provide treatment algorithms on ways in which glucose-lowering agents can be used either alone or in combination. Ideally, treatment decisions should be directed based on glycaemic efficacy and safety profiles, along with impact on weight and hypoglycaemia risk, comorbidities, route of administration, patient preference, as well as treatment costs. Here the guideline is based on clinical evidences and provides overview on available OADs. The treatment algorithms in this chapter attempt to provide practical recommendations for optimal management of T2DM in Asian Indians.

CONSIDERATIONS

The decision on choice of OAD therapy in T2DM patients is based on the cost, safety, and efficacy and comorbidities that were reviewed in Asian Indian context.

RATIONALE AND EVIDENCE

Oral antidiabetic agents [Table 2]

**Biguanides**

Metformin remains the first choice in the management of patients with T2DM. Metformin is efficacious in managing hyperglycaemia, increasing insulin sensitivity, along with beneficial effects in reducing cardiovascular and hypoglycaemia risk, improving macrovascular outcomes, and lowering mortality rates in T2DM. Metformin is a complex drug that exerts its action via multiple sites and several molecular mechanisms. Metformin is known to down regulate the hepatic glucose production, act on the gut to

![Figure 2: Metabolic derailments in T2DM (159)](image)

IR: Insulin resistance; T2DM: Type 2 diabetes mellitus

---

**References:**

159. Chawla, et al.: RSSDI-ESI clinical practice recommendations
158. Diminished insulin secretion, incretin deficiency/resistance, upregulated lipolysis, increased glucose reabsorption from kidney, along with downregulated glucose uptake, neurotransmitter dysfunction, increased hepatic glucose production, and glucagon secretion are the reported metabolic derailments that contribute to hyperglycaemia and T2DM.
160. Among Indians, high familial aggregation, central obesity, insulin resistance, and lifestyle changes due to rapid urbanization are the primary causes of T2DM. Greater degree of insulin resistance paired with higher central adiposity compared to Caucasians is characteristic.
161. Treatment options for T2DM have been developed in parallel to the increased understanding of underlying pathophysiological defects in T2DM. A patient-centric and evidence-based approach is gaining impetus.
162. Therefore, treatments that target factors beyond glycaemic control, such as cardiovascular risks, weight management, along with improvements in quality of life, have been introduced. Several guidelines/recommendations provide treatment algorithms on ways in which glucose-lowering agents can be used either alone or in combination.
163. Ideally, treatment decisions should be directed based on glycaemic efficacy and safety profiles, along with impact on weight and hypoglycaemia risk, comorbidities, route of administration, patient preference, as well as treatment costs. Here, the guideline is based on clinical evidences and provides overview on available OADs. The treatment algorithms in this chapter attempt to provide practical recommendations for optimal management of T2DM in Asian Indians.
164. The decision on choice of OAD therapy in T2DM patients is based on the cost, safety, and efficacy and comorbidities that were reviewed in Asian Indian context.
165. Metformin remains the first choice in the management of patients with T2DM. Metformin is efficacious in managing hyperglycaemia, increasing insulin sensitivity, along with beneficial effects in reducing cardiovascular and hypoglycaemia risk, improving macrovascular outcomes, and lowering mortality rates in T2DM.
166. Metformin is a complex drug that exerts its action via multiple sites and several molecular mechanisms. Metformin is known to down-regulate the hepatic glucose production, act on the gut to
increase glucose utilisation, enhance insulin, increase GLP-1 and alter the microbiome.\cite{167} The UK Prospective Diabetes Study (UKPDS) Group study in overweight T2DM patients suggested that intensive glucose control that metformin lowered the risk of diabetes-related endpoints, diabetes-related deaths, and all-cause mortality in overweight T2DM patients, compared to insulin and sulphonylureas.\cite{168} A 10-year follow-up study of the UKPDS reported continued benefit following intensive glucose control with metformin in terms of reduced diabetes-related endpoints, diabetes-related deaths, and all-cause mortality.\cite{169} Along with substantial improvements in hyperglycaemia, metformin improved endothelial dysfunction, oxidative stress, insulin resistance, lipid profiles, and fat redistribution.\cite{170} Owing to the concerns of lactic acidosis and gastrointestinal effects (nausea, vomiting diarrhoea and flatulence) metformin should be used cautiously in patients with renal insufficiency or elderly patients. In patients with an eGFR <60 mL/min/1.73 m² metformin can be used, but should not be initiated in patients with an eGFR of 30 to 45 mL/min/1.73 m² and must be contraindicated in patients with an eGFR <30 mL/min/1.73 m².\cite{164}

### Sulfonylureas

Sulfonylureas are second line agents used in patients with T2DM patients who are not obese. Sulfonylureas are insulin secretagogues that act on the ATP-sensitive K⁺ channels on the β cells and stimulate endogenous insulin secretion.\cite{171} As a single therapy, sulfonylureas are efficacious in lowering fasting plasma glucose and HbA1c. However, concerns of modest weight gain and moderate to severe hypoglycaemia and cardiovascular risk limit their clinical benefits.\cite{172} As a consequence of closure of cardiac K̅ATP channel, the use of sulfonylureas have also been related to adverse CV effects due to impaired hypoxic coronary vasodilation during increased oxygen demands such as acute myocardial ischemia.\cite{173} The use of glibenclamide was associated with an increased risk of in-hospital mortality in patients with diabetes and acute myocardial infarction.\cite{174} Adverse cardiovascular outcomes with sulfonylureas in some observational studies have raised concerns, although findings from recent meta-analysis that included several RCTs reported that sulfonylureas when added to metformin were not associated with all-cause mortality and CV mortality.\cite{175} New generation sulfonylureas have demonstrated superior safety, mainly due to reducing hypoglycaemia, and improved cardiac profile. Sulfonylureas particularly gliclazide modified release (MR) and glimepiride have a lower risk of hypoglycaemia and are preferred in south Asian T2DM patients.\cite{176} Caution must be exercised while prescribing sulfonylureas for patients at a

### Table 1: Glycaemic values for Indian patients with type 2 diabetes mellitus

<table>
<thead>
<tr>
<th>Glycaemic parameter</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>FPG (mg/dL)</td>
<td>100-125</td>
</tr>
<tr>
<td>2-h PPG during 75-g OGTT (mg/dL)</td>
<td>140-199</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>5.7-6.4</td>
</tr>
<tr>
<td>2-h PPG: 2-h postprandial glucose, FPG: Fasting plasma glucose, HbA1c: Glycosylated haemoglobin, OGTT: Oral glucose tolerance test</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2: Profile of available oral antidiabetic agents

<table>
<thead>
<tr>
<th>Effect on weight</th>
<th>CV effects</th>
<th>Significant side effects</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight loss/ neutral</td>
<td>Beneficial CV effects, reduces LDL-C and increases HDL-C; however, reports of caution indicated particularly in older patients with CHF</td>
<td>Lactic acidosis</td>
<td>First-line drug therapy of choice for T2DM Acceptable CV safety profile</td>
</tr>
<tr>
<td>Gain</td>
<td>Increased risk of CV mortality and all-cause mortality</td>
<td>Hypoglycaemia, weight gain</td>
<td>Second-line drug therapy</td>
</tr>
<tr>
<td>Gain</td>
<td>Increased risk of MI, CHF, Increased levels of LDL-C, triglycerides</td>
<td>Weight gain, CV outcomes</td>
<td>To be avoided in patients with or at risk for heart failure</td>
</tr>
<tr>
<td>Weight neutral</td>
<td>Neutral effect on CV outcomes</td>
<td>GI effects, pancreatitis</td>
<td>Caution to be exercised while prescribed in patients with heart failure</td>
</tr>
<tr>
<td>Weight neutral</td>
<td>Neutral effect on CV outcomes</td>
<td>Flatulence, diarrhoea</td>
<td>Low risk of hypoglycaemia. CV safety to be evaluated</td>
</tr>
<tr>
<td>Weight loss</td>
<td>Beneficial CV effects</td>
<td>Mycotic infections of the genital tract and osmotic diuresis</td>
<td>Favoured as the second-line agent of choice in T2DM patients with a history of CVD</td>
</tr>
</tbody>
</table>

AGIs: Alpha-glucosidase inhibitors, CHF: Congestive heart failure, CV: Cardiovascular, HDL-C: High-density lipoprotein-cholesterol, DPP-4: Dipeptidyl peptidase, GI: Gastrointestinal, MI: Myocardial infarction, LDL-C: Low-density lipoprotein-cholesterol, SGLT2i: Sodium-glucose co-transporter 2 inhibitors, DM: Diabetes mellitus T2DM, Type 2 DM, TZDs: Thiazolidinediones, SU: Sulfonylureas, CVD: CV disease
high risk of hypoglycaemia, older patients and patients with CKD.\textsuperscript{177} Shorter-acting secretagogues, the meglitinides (or glinides), also stimulate insulin release through similar mechanisms and may be associated with comparatively less hypoglycaemia but they require more frequent dosing. Moreover, modern sulfonylureas exhibit more reductions of HbA1c than glinides.\textsuperscript{178}

**Thiazolidinediones**

Pioglitazone and rosiglitazone are peroxisome proliferator activated receptor γ activators that improve insulin sensitivity by increasing insulin-mediated glucose uptake in skeletal muscle, suppressing hepatic glucose output, and improving the secretory response of insulin in pancreatic β-cells.\textsuperscript{179} The risk of hypoglycaemia is negligible and TZDs may be more durable in their effectiveness than sulfonylureas.\textsuperscript{180} TZDs have been constantly under the authority scrutiny for their cardiovascular safety. A meta-analysis considering data from 42 trials and 27,847 patients indicated that treatment with rosiglitazone was associated with an increase in the odds of MI (odds ratio 1.43, 95% CI 1.03 to 1.98, p=0.03) and a nonsignificant increase in the odds of cardiovascular death (odds ratio 1.64, 95% CI 0.98: 2.74, p=0.06) compared with a control group (active comparator or placebo).\textsuperscript{181} The RECORD study evaluated the effect of rosiglitazone (plus metformin or sulfonylurea) in lowering the combined end point of hospitalization or cardiovascular death versus metformin plus sulfonylurea. Although, rosiglitazone did not increase the risk of overall cardiovascular morbidity or mortality it increased the risks of heart failures causing admission to hospital or death when compared to the active controls (HR: 2.10, 95% CI, 1.35:3.27).\textsuperscript{182} Conversely, pioglitazone is known to exert pleotropic effects on cardiovascular event; pioglitazone improves endothelial dysfunction, lowers hypertension, improves dyslipidaemia, and lowers circulating levels of inflammatory cytokines and prothrombotic factors.\textsuperscript{183} In the PROactive study, pioglitazone lowered the composite of all-cause mortality, non-fatal myocardial infarction, and stroke in T2DM patients with at risk of macrovascular events along with improvements in HbA1c, triglycerides, LDL, and HDL levels. However, rate of heart failure was increased.\textsuperscript{184} TZDs have demonstrated beneficial effects in attenuating dyslipidaemia commonly observed in patients with chronic T2DM. Rosiglitazone treatment with metformin showed an HDL increase of 13.3%, LDL increase of 18.6% and a neutral effect on total cholesterol, following 26 weeks of treatment.\textsuperscript{185} Furthermore, the IRIS trial was among the 1st studies to document the CV benefits of TZDs in non-diabetic individuals. Pioglitazone improved CV outcomes (recurrent stroke and MI) and prevented the development of T2DM in insulin-resistant, non-diabetic patients with cerebrovascular disease.\textsuperscript{186} In a recent post hoc study of the IRIS trial, conducted in prediabetic population, pioglitazone effectively lowered the risk of stroke, MI, acute coronary syndrome, and hospitalization for heart failure.\textsuperscript{187} Pioglitazone had been linked with a possible increased risk of bladder cancer, possibly in a dose-and time-dependent manner.\textsuperscript{188,189} However data from a retrospective study in India involving 2222 (pioglitazone users, n = 1111; pioglitazone non-users, n = 1111) T2DM patients found no evidence of bladder cancer in any of the group, including patients with age >60 years, duration of diabetes >10 years, and uncontrolled diabetes.\textsuperscript{190} Recognized side effects of TZDs include weight gain (3–5 kg), fluid retention leading to oedema, and/or heart failure in predisposed individuals and patients with increased risk of bone fractures.\textsuperscript{180,184,190}

**Dipeptidyl peptidase-IV inhibitors**

Vildagliptin, saxagliptin, gemigliptin, evogliptin sitagliptin, teneligliptin, and linagliptin are incretin enhancers; they enhance circulating concentrations of active GLP-1 and gastric intestinal polypeptide (GIP).\textsuperscript{191} These incretins stimulates insulin secretion, suppresses glucagon synthesis, lower hepatic gluconeogenesis, and slow gastric emptying. Their major effect is the regulation of insulin and glucagon secretion; they are weight neutral.\textsuperscript{192} DPP-4 inhibitors are efficient in improving glycaemia both as monotherapy and as add-on to metformin, sulfonylurea and TZDs in patients with inadequate glycaemic control. A reduction in HbA1c levels from baseline of 8.1% was observed with sitagliptin monotherapy (100 mg:-0.5%, 200 mg:-0.6%) in 521 patients treated for 18 weeks. Additionally, homeostasis model assessment of beta cell function index, fasting proinsulin-insulin ratio which are the markers of insulin secretion, and beta cell function were also improved significantly.\textsuperscript{193} The overall incidence of adverse events with sitagliptin is comparable to other OADs when used as monotherapy or as add-on to existing OADs.\textsuperscript{194} Adverse effects (AEs) such as constipation, nasopharyngitis, urinary tract infection, myalgia, arthralgia, headache, and dizziness are the commonly reported AEs with the use of these agents.\textsuperscript{195} Cardiovascular outcomes trial (CVOT) studies with DPP-4 inhibitors have shown that these agents are safe in patients with established CVD and those at increased risk of CVD except for increased risk of heart failure risk.\textsuperscript{196} Results of the SAVOR-TIMI study and EXAMINE Study have reported higher rates of hospitalization for heart failure with saxagliptin and alogliptin, respectively.\textsuperscript{197,198} Owing to the increased risk of hospitalization due to heart failure in patients with cardiovascular disease, the US FDA issued a warning, suggesting the associated risk to be a "class-effect" of the DPP-4 inhibitors and issued a warning for their use.\textsuperscript{199} However, some landmark studies have been conducted to evaluate relationship between these drugs and the adverse effects. In the CARMELINA study, linagliptin demonstrated a long-term CV safety profile in patients with T2D, including those with CV and/or kidney disease and no increased risk of
hospitalisation for heart failure versus placebo was reported. The CAROLINA study was designed to evaluate the long-term CV safety profile of linagliptin versus glimepiride in patients with early T2D at increased CV risk. Recently released top line results highlight a non-inferiority between linagliptin versus glimepiride in time to first occurrence of CV death, non-fatal MI, or non-fatal stroke (3P-MACE) with a median follow-up of more than 6 years.[201]

**Sodium-glucose co-transporter 2 inhibitors**

They provide insulin-independent glucose-lowering by blocking glucose reabsorption in the proximal renal tubule. The capacity of tubular cells to reabsorb glucose is reduced by SGLT2 inhibitors leading to increased urinary glucose excretion and consequently, correction of the hyperglycaemia.[202] Dapagliflozin, canagliflozin, empagliflozin, and remogliflozin are the 4 Drug Controller General of India (DCGI) approved agents used in patients with T2DM.[203,204] The EMPA-REG OUTCOME trial evaluated the non-inferior cardiovascular safety and benefits of empagliflozin in high-CV-risk T2D patients with an estimated glomerular filtration rate (eGFR) of at least 30 mL/min/1.73 m². Empagliflozin reduced the rate of new onset or worsening nephropathy, which were defined as new-onset microalbuminuria, doubling of creatinine, and eGFR ≤45 mL/min/1.73 m², initiation of renal replacement therapy, and death due to renal disease (hazard ratio [HR]: 0.61, 95% CI: 0.53, 0.70; p<0.0001). A secondary analysis of CANTASU study confirmed the renoprotective effects of canagliflozin. The eGFR decline was significantly slower in patients receiving canagliflozin than in those receiving glimepiride (0.5 mL/min/1.73 m² per year with 100 mg daily [95% CI: 0.0, 1.0] and 0.9 mL/min/1.73 m² per year with 300 mg daily [95% CI: 0.4, 1.4], compared with glimepiride (3.3 mL/min/1.73 m² per year [95% CI: 2.8, 3.8])). The CANVAS Program integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk. Treatment with canagliflozin showed a possible benefit with respect to the progression of albuminuria (HR: 0.73; 95% CI: 0.67, 0.79) and the composite outcome of a sustained 40% reduction in the estimated glomerular filtration rate, the need for renal-replacement therapy, or death from renal causes (HR: 0.60; 95% CI: 0.47, 0.77).[207] Canagliflozin in combination with metformin significantly improved glycaemic control in patients with T2DM and significant weight loss along with low incidence of hypoglycaemia have been reported.[208] A recent meta-analysis concluded that SGLT2 inhibitors, as a class, significantly reduce 24-h ambulatory blood pressure further substantiating their favourable cardiovascular profile.[209] The most common AEs involving this class are genital mycotic infections, which are believed to be mild and respond favourably to anti-fungal therapy.[210-214]

**Alpha glucosidase inhibitors**

These agents delay the absorption of consumed carbohydrates by competitively inhibiting the a-glucosidase enzymes at the enterocyte brush border. This inhibition delays the digestion of starch and sucrose and maintains levels of postprandial blood glucose excursions.[215] The action of these agents is independent of insulin action and hence are devoid of hypoglycaemic adverse effects. In the Essen-II Study, conducted in 96 patients, acarbose significantly lowered HbA1c levels when compared with placebo and treatment with acarbose was associated with a weight reduction of-0.8 kg.[216] When added to background of metformin, treatment with acarbose led to HbA1c reduction of 0.7%.[217] The AGIs have demonstrated an acceptable safety profile with major complaints being of flatulence and diarrhoea.

The glucose-lowering effectiveness of OADs is said to be high with metformin, sulfonylureas, and TZDs (expected HbA1c reduction ~ 1.0–1.5%) and comparatively lower for meglitinides, DPP4 inhibitor, SGLT2 inhibitor, AGIs. However, older drugs have typically been tested in clinical trial participants with higher baseline HbA1c, which is associated with greater treatment emergent glycaemic reductions, irrespective of therapy type. In head-to-head trials, any differential effects on glucose control between different OADs are small. So agent and patient-specific properties, such as ease of administration, dosing frequency, side effect profiles, cost, and other benefits, often help in their selection.

- Two-drug combination therapies with metformin (such as metformin plus TZDs, metformin plus sulfonylureas, metformin plus SGLT2 inhibitors, and metformin plus DPP4 inhibitors, DPP4+ SGLT2) were more effective in reducing HbA1c than metformin monotherapy by about 1%.[218] In addition, triple FDC of metformin and sulfonylurea plus pioglitazone are also available in India.
- RSSDI wheel given along with this recommendation book will help a practitioners choose an ideal drug for his patient based on cost, weight, hypoglycaemia risk, and other comorbid conditions.
TREATMENT 3: INJECTABLES

RECOMMENDATIONS

Recommended Care

- Insulin therapy should be considered in all patients failing to achieve glycemic targets on three oral agents.
- Consider initiating insulin in type-2 diabetes patients with symptomatic severe hyperglycemia or unstable state.
- A three step protocol involving initiation, titration, and intensification is recommended for all patients requiring insulin.
- Initiation
  - “Providers should avoid using insulin as a threat or describing it as a sign of personal failure or punishment and should work to alleviate patient anxiety about hypoglycaemia, dependence, injection-site pain etc., commonly attributed to insulin”
  - Therapeutic choice of regimen, preparation, and delivery device, should be made through a process of shared, informed decision making.
  - Initiate with once-daily basal insulin, once-daily premixed/co-formulation insulin, or twice-daily premixed insulin, either alone or in combination with or other OADs, based upon patient’s age, clinical features, glucose profile, risk of hypoglycaemia, and patient preference. Basal insulin may also be initiated in combination with GLP-1 analogues.
  - Basal bolus insulin regimens may be needed in severe hyperglycaemia, and in life threatening or organ/limb threatening clinical situations.
  - Analogue insulins may be used in preference to human insulins with possible lower risk of nocturnal and symptomatic hypoglycaemia; however, economic considerations must be taken into account.
  - Match timing of insulin and meals.
  - Counselling/education about SMBG and hypoglycaemia prevention, recognition and treatment are recommended to all patients initiating with insulin.
  - Provide guidance for adjusting insulin dose adjustments, administration, storage and other practical aspects.
- Titration
  - Initiate insulin as defined in the algorithm, using a self-titration regimen (dose increases of 2-4 unit (U) units every three days or biweekly) or with more frequent contact with a healthcare professional.
  - Aim for pre-meal glucose levels of <115 mg/dL and PPG levels of 140-160 mg/dL. These targets can be individualized, based upon the risk of hypoglycaemia and the urgency for glycaemic control.
  - Titration should be done at regular and short intervals, to attain glycaemic goals without causing hypoglycaemia and as guided by the physician or HCPs.
  - Titration should be done to control FBG first, followed by prandial control of meal with highest glycaemic excursion in sequential order.
- Intensification
  - Intensification of insulin therapy is recommended when patients fail to achieve glycaemic goals even after optimal dose titration.
  - Several options can be considered during intensification. In patients on basal insulin-
    - Switch to premix insulin twice-daily or premix analogues twice or thrice-daily.
    - Switch to insulin co-formulation based regimen.
    - Add prandial insulin (basal plus or basal bolus) with largest meal of the day.
    - Add GLP-1 analogues.
  - The choice of intensification strategy should be based upon dietary pattern, lifestyle, risk of hypoglycaemia and weight gain, affordability, as well as patient preference.
  - Basal plus regimen can be used as a stepwise approach to insulin intensification, leading to basal-bolus prescription. It is associated with lesser risk of hypoglycaemia and weight gain than basal bolus regimen.
  - Both premix insulin therapy and co-formulation insulins are acceptable methods of intensification. Co-formulation insulin offers the advantage of lower risk of hypoglycaemia and nocturnal hypoglycaemia.
  - Follow insulin intensification as recommended in the algorithm.
- GLP-1 analogues
  - GLP-1 analogues with proven CV benefit should be considered to reduce the risk.
  - Viable second-line or third-line options for the management of patients with uncontrolled hyperglycaemia.
  - Can be considered in overweight/obese patients as second line therapy in patients with metformin inadequacy and as first line therapy in patients with metformin intolerance.
  - To be added to insulin therapy preferably basal insulin only if glycaemia goals are not achieved with reasonably high doses of insulin, or if unacceptable weight gain or hypoglycaemia occurs. Dose reduction of insulin may be needed in such cases. Transient gastrointestinal side effects may occur.

Limited Care

- All conventional insulins have similar glycaemic lowering efficacy as analogues but with slight increased risk of hypoglycaemia and lack of flexibility of administration.
- Insulin supplies should be assured and be of consistent quality and type.
BACKGROUND
Most of treatments available to control glycaemia impact the pathways targeting β-cells or IR and are dependent upon the presence of insulin for their therapeutic effect. The durability of these medications varies and their safety is occasionally under scrutiny. Over a period, patients fail to achieve or maintain HbA1c levels even with multiple OADs and will require insulin therapy. Although insulin is the most effective option for glycaemic control, it should not be used as first-line treatment in T2DM, as it can predispose hypoglycaemia, weight gain, and large doses over prolonged duration might increase the risk of malignancy and cardiovascular diseases. However, it is equally important to ensure timely initiation of insulin without delay once optimal combinations of oral hypoglycaemic drugs have failed to achieve the target HbA1c.

Most guidelines recommend early short term insulin therapy in patients with high HbA1c at the time of presentation.[219-221] Landmark trials in last decade suggest that glycaemic control should be intensive in early stages of diabetes, preferably in first four years of diagnosis.[222-224] The traditional postponement of insulin therapy up to prolonged failure of lifestyle and oral agents to achieve glycaemic control has been revised in the last decade to incorporate insulin therapy much earlier, often in combination with OADs or GLP-1 analogues. Non-insulin injectables such as GLP-1 analogues and amylin analogues (pramlintide) have been approved in various countries. The GLP-1 analogues improve glycaemic control through multiple mechanisms, with low risk of hypoglycaemia, and clinically relevant weight loss.[225] As pramlintide is not available in India, it will not be covered in these recommendations.

CONSIDERATIONS
• The decision on choice of injectable therapy in T2DM patients is based on clinical, pharmacological and psychosocial factors [Table 3]. Additionally, local factors such as cost, quality, cold chain maintenance, and perennial availability of insulin preparations as well as delivery devices, must be considered in the Indian context.
• If a study of adequate doses of two to three non-insulin agents for 3–6 months fails to achieve HbA1c targets, or if organ dysfunction contraindicates use of oral agents, addition of insulin may be justified. This idea is supported by the landmark studies suggest that achieving intensive glycaemic control (if not contraindicated) in initial few years of diagnosis is of profound benefit.
• In these cases, insulin may be started as monotherapy or with metformin if the latter is not contraindicated and is well tolerated. As the patient’s glucose toxicity resolves, the regimen can potentially be de-escalated, and a switch over to oral therapy may be considered.
• HbA1c targets must be determined as per criteria set for individualized therapy and efficacy of each agent as combination therapy must be considered.[226]
• Near-normal glycaemic targets should be considered for younger patients with recent onset of T2DM with few or no micro or macrovascular complications, while slightly higher HbA1c targets may be considered for older patients with long-standing T2DM and evidence of CVD, end organ failure, and terminal illnesses.[227]
• While initiating insulin, doses of OADs should modified as following:
  ▫ No change in dose of metformin, DPP4i, SGLT1, AGI, TZDs
  ▫ Dose of sulphonurea should be reduced when prandial insulin is introduced.
• Adequate doses of oral agents do not necessarily mean the highest administrable doses because, in most of the cases, doubling the doses of these medicines does not necessarily increment their effects.

RATIONALE AND EVIDENCE
The insulin strategy
• While initiating the insulin therapy, the following features have to be considered in a sequential order: choosing the right regimen, identifying the appropriate preparation, prescribing the available strength of the preparation, matching it with the correct delivery device, deciding the proper insulin dose, and following the optimal titration strategy.
• Ideally, an insulin treatment program should be designed specifically for an individual patient, to match the supply of insulin to his or her dietary/exercise habits, and prevailing glucose trends, as revealed through self-monitoring. Anticipated glucose-lowering effects should be balanced with the convenience of the regimen, in the context of an individual’s specific therapy goals.

Patient education
• Proper patient education regarding monitoring of glucose, insulin injection technique, insulin storage, recognition/

<table>
<thead>
<tr>
<th>Table 3: Clinical situations where use of injectables is recommended</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Short term insulin</strong></td>
</tr>
<tr>
<td>Catabolic symptoms</td>
</tr>
<tr>
<td>High glycaemic parameters: HbA1c &gt;9.0%, FPG &gt;200 and/or PPG &gt;300 mg/dL</td>
</tr>
<tr>
<td>Acute diabetic complications/medical conditions</td>
</tr>
<tr>
<td>Hospitalised patients not suitable for OADs: Perioperative, transplants, critical care units, Pregnancy</td>
</tr>
</tbody>
</table>

CKD: Chronic kidney disease, CV: Cardiovascular, CVD: CV disease, HbA1c: Glycosylated haemoglobin, OADs: oral antidiabetics, FPG: Fasting plasma glucose, GLP-1: Glucagon-like peptide 1, PPG: Postprandial glucose
treatment of hypoglycaemia, and sick day management is imperative. Where available, certified diabetes educators can be invaluable in guiding the patient through treatment course of diabetes.

Adverse events and barriers

- Hypoglycaemia is a major safety concern with insulin treatment and can be a barrier for initiation or intensification. Addition of Sulphonylurea and TZDs can accentuate the risk of weight gain with insulin treatment and therefore agents which are weight neutral or weight reducing should be combined with insulin where weight gain is a concern. Combination with DPP4 inhibitors resulted in weight neutrality and combination with metformin or AGIs produced weight loss compared to insulin monotherapy.

- Various barriers to insulin use prevail in society. A recent National Insulin Summit (NIS) consensus lists the barriers to insulin therapy as related to patient/community, physician/provider, and drug/device and proposes different bridges to overcome these hurdles. Patient-related barriers such as inability to inject, monitor, or titrate the insulin dose, weight gain, hypoglycaemia, and lack of awareness of uncontrolled diabetes can be bridged with patient education and training, support, and counselling, and social marketing. Physician and provider barriers such as inadequate communication or motivation skills, inability to initiate, optimize or intensify insulin, and lack of awareness may be addressed through relevant skill development training, and continuing medical education (CME). Furthermore, drug or device-specific barriers such as suboptimal effects of insulin, lack of flexibility, and device discomfort can be surmounted through CME, flexible insulin regimens, and preparations and modern devices.

Initiation of insulin therapy [Figures 3 and 4]

- As initial therapy, unless the patient is passing through an acute medical, surgical or obstetric crisis, or in metabolic decompensation, premixed or basal insulin is typically initiated. General concept is to first correct the fasting hyperglycaemia with a dinner/bed time injection, and then address postprandial hyperglycaemia.

- Choice of initial insulin is often dictated by subjective features such as disease severity, and ability of the patient to self-inject at specific times of the day. Even though FPG and PPG measurements together provide sufficient information to choose an insulin type, it is difficult to make an appropriate decision when they are considered separately. Similarly, choice of insulin on the basis of HbA1c value alone can be challenging.

- All international and Indian guidelines recommend insulin initiation either with a basal or premixed/co-formulation insulins except ADA/EASD and AACE guidelines which prefer basal insulin for initiation.

Intensification of Insulin therapy [Tables 7 and 8]

- Although most of the patients with T2DM requiring insulin therapy can be successfully treated with one or two doses

---

**Table 4: Choice of insulin therapy**

<table>
<thead>
<tr>
<th>Basal insulin</th>
<th>Premixed/co-formulation OD or BID</th>
<th>Prandial insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human NPH; glargine U100; glargine U300; detemir; degludec</td>
<td>All have equal efficacy</td>
<td>Human regular; Lispro Aspart; glulisine; FiASP</td>
</tr>
<tr>
<td>Duration of action: Degludec gr argine U300 &gt; glargine U100 &gt; detemir &gt; NPH</td>
<td>Most patients should be initiated with premixed 30/70 or 25/75, if there is uncontrolled PPG-premixed 50/50 can be used before meal showing highest excursion</td>
<td>To be administered when an individual fails to achieve glycemic targets following basal insulin</td>
</tr>
<tr>
<td>NPH, detemir and glargine U100 may need to be given twice-daily</td>
<td>Starting dose: 10 U OD or 6 U BID followed by weekly or biweekly titration</td>
<td>HbA1c above target with ~0.5 U/kg/day of daily basal insulin</td>
</tr>
<tr>
<td>High doses of glargine U100 beyond 0.5 U/kg body weight should be split to avoid hypoglycaemia</td>
<td>Degludec and glargine U300 cause least hypoglycaemia with no tailing effect of hyperglycaemia</td>
<td>Elevated HbA1c despite normal FPG (in the absence of available PPG readings) with basal insulin</td>
</tr>
<tr>
<td>Starting dose: 10 U of basal insulin followed by weekly or biweekly titration</td>
<td>Degludec and glargine U300 cause least hypoglycaemia with no tailing effect of hyperglycaemia</td>
<td>FPG with basal insulin is within targeted range, but PPG is persistently above goal</td>
</tr>
<tr>
<td>Degludec and glargine U300 cause least hypoglycaemia with no tailing effect of hyperglycaemia</td>
<td>Glargine U300 requires 20% extra doses but lesser volume is required</td>
<td>Further increase in basal insulin results in hypoglycaemia</td>
</tr>
<tr>
<td>Glargine U300 requires 20% extra doses but lesser volume is required</td>
<td>All have equal efficacy</td>
<td>BID: Twice daily, BiAsp: Biphasic insulin aspart, IDegAsp: Mix of insulin degludec and insulin aspart, NPH: Neutral protamine Hagedorn, OD: Once daily, HGP: Hepatic glucose production, FPG: Fasting plasma glucose, HbA1c: Glycated haemoglobin, PPG: Postprandial glucose</td>
</tr>
</tbody>
</table>
of insulin, some, because of progressive diminished in their insulin secretory capacity, will require prandial insulin therapy as well. This is typically achieved with regular insulin administered about 30 min before meals or rapid insulin analogues such as insulin lispro (ILis), insulin aspart (IAsp), or insulin glulisine (IGlu), which can be injected just before or with the meal. They result in better PPG control than human regular insulin.

**Glucagon-like peptide 1 analogues**

- The injectable GLP-1 analogues like liraglutide, exenatide, lixisenatide, dulaagliptide and albiglutide imitate the effects of endogenous GLP-1, thereby stimulating pancreatic insulin secretion in a glucose dependent fashion, suppressing pancreatic glucagon output, slowing gastric emptying, and decreasing appetite. Their main advantage is weight loss, which can be significant in some of the patients. Limiting side effects of these agents are nausea and vomiting, particularly early in the course of treatment.[235]
- In combination with basal insulin they have proved to be extremely useful option for intensification because of complimentary action (IDegLira, Lixilan). Titate as per dose
- There have been concerns regarding an increased risk of pancreatitis with GLP-1 analogues but recently published

---

**Figure 3:** Approaches for initiating insulin. OD: Once daily; BID: Twice daily; TID: Three times a day; GLP-1 RA: Glucagon like peptide-1 receptor agonist; IAsp: Insulin aspart; IDegAsp: Mix of insulin degludec and insulin aspart; A1c: Glycated haemoglobin; DPP-4i: Dipeptidyl peptidase-4 inhibitors; FPG: Fasting plasma glucose; GLP-1 RA: Glucagon like peptide-1 receptor agonist; SGLT2i: Sodium glucose co-transporter 2 inhibitors; TDD: Total daily dose.
Table 5: Steps for initiating basal insulin

<table>
<thead>
<tr>
<th>Glucose value</th>
<th>TDD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Step 1: Initiation with basal insulin*</td>
<td>HBa1c &lt; 8%</td>
</tr>
<tr>
<td></td>
<td>HBa1c &gt; 8%</td>
</tr>
<tr>
<td>Step 2: Titration# (every 2-3 days to reach glycaemic goals)</td>
<td>Fixed regimen</td>
</tr>
<tr>
<td></td>
<td>Adjustable regimen</td>
</tr>
<tr>
<td></td>
<td>FPG &gt; 180 mg/dL</td>
</tr>
<tr>
<td></td>
<td>FPG 140-180 mg/dL</td>
</tr>
<tr>
<td></td>
<td>FPG 110-139 mg/dL</td>
</tr>
<tr>
<td>Step 3: Monitor for hypoglycaemia</td>
<td>BG &lt; 70 mg/dL</td>
</tr>
<tr>
<td></td>
<td>BG &lt; 40 mg/dL</td>
</tr>
</tbody>
</table>

*Consider discontinuing SU therapy and basal analogues should be preferred over NPH insulin.
#For most patients with T2DM taking insulin, glucose goals are HBa1c <7% and fasting and premeal BG <110 mg/dL in the absence of hypoglycaemia. HBa1c and FPG targets may be adjusted based on patient age, duration of diabetes, presence of comorbidities, diabetic complications, and hypoglycaemia risk. DM: Diabetes mellitus, BG: Blood glucose, FPG: Fasting plasma glucose, HBa1c: Glycosylated haemoglobin, NPH: Neutral protamine Hagedorn, SU: Sulfonylureas, T2DM: Type 2 DM, TDD: Total daily dose

Table 6: Titration algorithm

<table>
<thead>
<tr>
<th>Basal insulin</th>
<th>Prandial insulin</th>
<th>Premixed insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Given preferably at bedtime to achieve adequate suppression of HGP</td>
<td>Initiate along with meal with highest glycaemic excursion</td>
<td>Calculate the total dose</td>
</tr>
<tr>
<td>Target: FPG &lt; 120</td>
<td>Start with 4 U and increase by 1 U/day or 3 U/3 days till</td>
<td>Start with 6 U BID day for analogues and 2/3 dose in morning and 1/3 dose in evening for human insulin</td>
</tr>
<tr>
<td>Initiate with 10 U at bedtime and check FBSL</td>
<td>Next meal with highest glycaemic excursion should be</td>
<td>Titration can be done for morning dose based on pre-dinner values and for evening dose based on FBG</td>
</tr>
<tr>
<td>Increase dose by 1 U/day or 3 U every 3 days by patient self-titration till target FBSL is achieved</td>
<td>Full basal bolus can be considered for effective prandial control after all meals</td>
<td>Titration can be done by 1 U/day or 3 U/day to achieve required BG targets</td>
</tr>
</tbody>
</table>

BID: Two times daily, BG: Blood glucose, FBSL: Fasting blood sugar level, FPG: Fasting plasma glucose, HGP: Hepatic glucose production, PPG: Postprandial glucose

LIFESTYLE MODIFICATIONS (healthy diet, control of weight and adequate physical activity)

Figure 4: Steps for initiating premixed insulin. OAD: Oral antidiabetic agents; GLP-1 RA: Glucagon like peptide-1 receptor agonist; OD: Once-daily; BID: Twice-daily; TID: Thrice-daily; TZD: Thiazolidinedione; DPP-4I: Dipeptidyl peptidase-4 inhibitors
ELIXA and LEADER study do not show any increased risk of pancreatitis, pancreatic cancer, or thyroid cancer with lixisenatide or liraglutide.\cite{236,237}

- Furthermore, in the LEADER trial, the primary composite outcome of first occurrence of death from CV causes, non-fatal MI, or non-fatal stroke was significantly less with liraglutide as compared to placebo (HR, 0.87; 95% CI: 0.78, 0.97; p<0.001 for non-inferiority; p=0.01 for superiority).\cite{237} On the basis of this result, liraglutide is approved for its CV benefits as well by FDA “as an adjunct to standard treatment of CV risk factors to reduce the risk of major adverse CV events (CV death, non-fatal MI, or non-fatal stroke) in adults with T2DM and high CV risk.”\cite{238}

### Implementation

Timely initiation and appropriate intensification of injectable therapy is a challenging aspect of diabetes care. This must be addressed by focusing on patient education and motivation, as well as updating knowledge of health care professionals. Lifestyle modification, self-monitoring, and insulin education, should be integral parts of insulin therapy in T2DM. Structured guidelines and protocols should be shared, and glycaemic audits of persons on oral medications performed to address the issue.

### Table 7: Insulin intensification options

<table>
<thead>
<tr>
<th>Insulin regimen</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal plus regimen</td>
<td>One basal insulin along with one prandial insulin before the meal showing largest PPG excursion&lt;br&gt;Advantages: Flexibility and can be further intensified to cover 2 or 3 meals (full basal bolus regimen)&lt;br&gt;Disadvantages: Needs two insulins, two pens, and two different titrations for individual components bringing in complexity in the regimen</td>
</tr>
<tr>
<td>Premixed insulins BID or TID</td>
<td>If used thrice-daily then afternoon dose should be 4-6 U to start with and morning dose to be reduced by 10%-20%&lt;br&gt;BID is sufficient and has been found to be as effective as basal bolus regimen&lt;br&gt;Can be given before any two large meals of the day so long as the interval between two injections is 6 h (corresponding to the time action profile of aspart component)&lt;br&gt;Compared with Basal plus regimen twice-daily, IDegAsp causes similar efficacy, lesser nocturnal hypoglycaemia and has the convenience of one insulin and one pen&lt;br&gt;Compared with basal bolus regimen, IDegAsp causes similar reductions in HbA1c, lesser hypoglycaemia, requires lesser doses, lesser weight gain, and is simple to administer</td>
</tr>
<tr>
<td>Co-formulation IDegAsp</td>
<td>Compared with basal bolus regimen twice-daily, IDegAsp causes similar efficacy, lesser nocturnal hypoglycaemia and has the convenience of one insulin and one pen&lt;br&gt;Compared with basal bolus regimen, IDegAsp causes similar reductions in HbA1c, lesser hypoglycaemia, requires lesser doses, lesser weight gain, and is simple to administer</td>
</tr>
<tr>
<td>Basal bolus regimen</td>
<td>Most physiological and most effective regimen for intensification&lt;br&gt;Requires one or two injections of basal insulin, and 3 injections of prandial insulins&lt;br&gt;Complex regimen and requires understanding of different titration schedules for basal and prandial components&lt;br&gt;Knowledge of carbohydrates counting is desirable for proper dosing of prandial component&lt;br&gt;Needs very frequent monitoring which could be painful and expensive</td>
</tr>
</tbody>
</table>

BID: Twice daily, IDegAsp: Mix of insulin degludec and insulin aspart, PPG: Postprandial glucose, TID: Thrice daily, HbA1c: Glycosylated haemoglobin

### Table 8: Steps for intensification of insulin therapy

<table>
<thead>
<tr>
<th>Therapeutic option</th>
<th>TDD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Step 1: Add prandial insulin</td>
<td>When glycaemic targets are unmet&lt;br&gt;TDD 0.3-0.5 U/kg (40%-50% basal: 50%-60% prandial)*&lt;br&gt;Increase TDD by 2 U/day</td>
</tr>
<tr>
<td>Step 2: Titration* (every 2-3 days to reach glycaemic goals)</td>
<td>FPG &gt;180 mg/dL&lt;br&gt;FPG 140-180 mg/dL&lt;br&gt;FPG 110-139 mg/dL&lt;br&gt;2-h PPG or next premeal glucose &gt;180 mg/dL&lt;br&gt;Premixed insulin&lt;br&gt;FPG/premeal BG &gt;180 mg/dL&lt;br&gt;Fasting hypoglycaemia&lt;br&gt;Night time hypoglycaemia&lt;br&gt;Between meal hypoglycaemia&lt;br&gt;Reduce previous premeal short/rapid acting insulin</td>
</tr>
<tr>
<td>Step 3: Monitor for hypoglycaemia</td>
<td>Increase TDD by 10%&lt;br&gt;Reduce basal insulin dose&lt;br&gt;Reduce basal insulin or reduce short/rapid-acting insulin taken before supper or evening snack</td>
</tr>
</tbody>
</table>

*B: Basal insulin analogues preferred over NPH + regular insulin or premixed insulin, *For most patients with T2D taking insulin, glucose goals are HbA1c <7% and fasting and premeal BG <110 mg/dl in the absence of hypoglycaemia. HbA1c and FPG targets may be adjusted based on patient’s age, duration of diabetes, presence of comorbidities, diabetic complications, and hypoglycaemia risk. BG: Blood glucose, FPG: Fasting plasma glucose, NPH: Neutral protamine Hagedorn, 2-h PPG: 2-h postprandial glucose, TDD: Total daily dose, FPG: Fasting plasma glucose, T2D: Type 2 diabetes, HbA1c: Glycosylated haemoglobin
**Recommendations**

**ABCD (EFGH) approach for diabetes management**

Choice of any OADs agent should take into account the patient’s general health status and associated medical disorders. This patient centric approach may be referred to as the ABCD (EFGH) approach for diabetes management. As shown in the Figure 1 and Table 2 for any T2DM patients, first line of therapy should be metformin unless it is not tolerated by the patient or contraindicated.

**Individualized treatment**

- For patients who have been diagnosed with diabetes, consider a combination of metformin and one of the treatment options based on patients Age, BMI, CKD, Duration of diabetes, Established CVD, Financial condition, Glycaemic status and Hypoglycaemia concern.
- Drug choice should be based on patient preferences as well as presence of various comorbidities and complications, and drug characteristics, with the goal of reducing blood glucose levels while minimizing side effects, especially hypoglycaemia and weight gain.
- A comparative effectiveness meta-analysis suggests that most of available non-insulin agents added to metformin therapy lowers HbA1c around 0.9-1.1%. Moreover, current National Insulin Summit (NIS) consensus from India report that all oral anti-diabetic agents and GLP-1 agonists can reduce HbA1c to a range of 0.5–2.0% and insulin can reduce HbA1c up to 3.5% when used as monotherapy.

**Age**

- DPP-4 inhibitors may be a suitable addition to metformin for elderly patients (65 years) to avoid hypoglycaemia and weight gain, however, the dosage should be adjusted as per eGFR. Recent double-blind RCTs have reported that gliptins are efficacious and safe with minimal tolerability issue, when used as an add-on therapy in elderly patients with T2DM.
- Agents belonging to AGIs could also be important choice in elderly patients. These agents have modest efficacy and do not cause hypoglycaemia, but the major limiting factor for their use is the gastrointestinal side-effects, such as flatulence and diarrhoea. A double-blind RCT revealed that compared to diet alone, addition of acarbose improved the glycaemic profile and insulin sensitivity in elderly patients with T2DM.
- The use of glitazones is restricted in elderly T2DM patients owing to the anticipated complications like weight gain, fluid retention, peripheral oedema, aggravation of congestive heart failure, and osteoporosis in post-menopausal women. Newer SUs like gliclazide MR and low-dose glimepiride (due to low risk of hypoglycaemia) can be safely used in elderly patients with T2DM.
- Evidence regarding the use of GLP-1 agonists and SGLT2i in elderly T2DM patients has been made recently available. The available data suggests that agents of both the classes provide good glycaemic control in patients with T2DM and can reduces CV risk. However, certain drawbacks such as cost, discomfort of injection with GLP-1 agonists, and increased risk of genital mycotic infections and urinary tract infections, hypovolaemia, postural hypotension and weight loss with SGLT2i may limit their usage in some frail elderly T2DM patients.
- Evidence suggests that basal insulin analogues such as glargine, detemir and degludec are effective and safe with less risk of hypoglycaemia and weight gain compared to NPH or Premix insulins. Moreover, a pooled analysis from RCTs revealed that addition of modern insulin analogues compared to NPH insulin to oral antidiabetic drugs in older adults was effective with regards to lower risk of hypoglycaemia.
- Individualization of therapy is highly desirable based on risk of hypoglycaemia, comorbidities, functionality, cost, and personal preference in elderly diabetics.

**Body mass index**

- While prescribing pharmacological treatments for overweight or obese patients with T2DM, providers should first consider anti-diabetes medications which cause either weight loss or weight neutrality. GLP-1 agonists, SGLT2i are associated with weight loss while DPP-4 inhibitors and AGIs appear to be weight neutral. A systematic review and meta-analysis of 62 randomized trials revealed that, when compared to other antidiabetic agents, SGLT2i and GLP-1 agonists were associated with clinically significant body weight loss (range, 1.15–2.26 kg) as add-on to metformin.
- GLP-1 agonists and/or SGLT2i seems to be the best add on therapy for those having high BMI. This group of medications has highest weight reducing property in addition to excellent efficacy. A recent systematic review and mixed treatment comparison meta-analysis report thatGLP-1 agonists are associated with weight loss (~1.62 kg to –1.01 kg) in overweight or obese patients with T2DM with no difference in weight loss between different types of GLP-1 agonists.
- SGLT2i also have a weight reduction property. Evidence suggests that SGLT2i were associated with weight loss in patients with T2DM. Agents of this class have an additional advantage of acceptable tolerance and can be given orally. However, a careful consideration should be taken with regards to known side effects such as recurrent genital infections, postural hypotension and dehydration especially in summer seasons.
- Gliptins are weight neutral and thus can be used as third line of agents. Newer agents such as teneligliptin treatment once daily led to significant and clinically meaningful reductions in HbA1c and PPG in Indian patients with T2DM.
• Use of newer SUs such as gliclazide MR and glimepiride compared to older SUs and other OADs do not result in significant weight gain in patients with T2DM.

• The lean patients with T2DM with low-normal body mass index (<18), are a distinct group of patients. These patients are usually younger at onset, have more prevalent use of insulin, higher prevalence in males and higher rates of cigarette smoking and alcohol abuse.

Complications (diabetic kidney disease)

• In patients with renal impairment, preference of therapy would be glitins as add on therapy with metformin. Few of the gliptins need dose adjustment as per eGFR; linagliptin and teneligliptin does not require any dose adjustment in renal disease.

• Repaglinide is another agent which may be used across all stages of renal insufficiency. Similarly pioglitazones may be used in CKD; however, one has to be careful about fluid retention and CCF.

• Short acting SUs like glipizide and gliclazide can be preferred in patients with moderate/severe renal impairment. Furthermore, in mild/moderate renal impairment, gliclazide MR and glimepiride can also be used, preferably at lower doses.

• Although GLP-1 agonists, especially liraglutide and dulaglutide are recommended up to eGFR 15 ml/min, however, owing to their GI adverse effect, their use in renal insufficiency patients is practically limited.

• AGIs can be used in patients with mild to moderate renal disease up to eGFR>3 ml/min.

• Insulin can be used in any stages of renal insufficiency. Insulin analogues are preferred over conventional insulins, however, insulin doses may require reduction with falling eGFR and individualized HbA1c targets.

• Refer to DKD section for the dose modification for SGLT2i in patients with DKD.

Duration of diabetes

• Patients with long-standing T2DM are difficult to treat because these patients often lack sufficient β-cell function to respond to secretagogues. Additionally they may have other comorbidities including renal impairment.

• Insulins are often used in patients with long-standing diabetes to address insulinoenic states.

• Incretin-based therapies, particularly GLP-1 agonists, also lowers HbA1c significantly and have lower risks of hypoglycaemia than insulin. Longer-acting GLP-1 agonists may be preferred over DPP-4 inhibitors as they are more effective than gliptins.

• SGLT2i may also be useful as second add on agent due to their insulin independent action.

• AGI’s can be also effective sometime owing to their beta-cell independent actions.

Established cardiovascular diseases

• UKPD-33 have suggested that intensive glycaemic control can reduce cardiovascular risk and microvascular complications in patients with T2DM.

• In patients with established CVD, GLP-1 analogues and SGLT2i with proven efficacy may be preferred.

• In patients with heart failure and CKD, SGLT2i or GLP-1 agonists may be preferred unless contraindicated.

• Pioglitazone has been shown in few studies to reduce CVD risk. However, pioglitazone should not be used in patients with subclinical heart failure or patients with low ejection fraction.

• Linagliptin, glimepiride and gliclazide MR can be preferred over conventional sulfonylureas in patients at increased risk of CVD or with CVD.

Financial concern

• Considering that many Indian patients do not have medical insurance and treatment needs to be continued lifelong, cost of therapy also plays a crucial role in T2DM patients from Indian subcontinent.

• Sulphonylureas can be good partner to metformin considering their cost in the light of recent CAROLINA trial demonstrating the CV neutrality of glimepiride compared to linagliptin. Pioglitazone or inexpensive DPP-4 inhibitors or SGLT2i can also be considered when combinations of SUs and metformin cannot achieve the desired target. Conventional insulin can be used at any stage considering its efficacy and cost.

Glycaemic status

• The order of glucose lowering agents according to their efficacy of HbA1c reduction are insulin, GLP-1 agonists, SGLT2i, pioglitazone, DPP-4 inhibitors, SUs, glinides and AGIs.

• Pioglitazone or inexpensive DPP-4 inhibitors or SGLT2i with proven efficacy may be preferred.

• In patients with established CVD, GLP-1 analogues and SGLT2i with proven efficacy may be preferred.

• A meta-analysis reported that SUs (relative risk [RR]: 4.57), and glinides (RR: 7.50), were associated with increased risk of hypoglycaemia, compared to thiazolidinediones (RR: 0.56), AGIs (RR: 0.42), DPP-4 inhibitors (RR: 0.63), and GLP-1 agonists (RR: 0.89).

• While initiating DPP-4 inhibitor on a background of secretagogues such as SUs, the dose of secretagogues needs to be reduced and close monitoring of blood glucose is required.
is necessary.\cite{209} Similarly, while initiating SGLT2i on a background of insulin or secretagogues, the dose of insulin or secretagogues needs to be reduced.\cite{210}

- In patients with history of hypoglycaemia or for those at high risk of hypoglycaemia, GLP-1 agonists or SGLT2i or DPP-4 inhibitors or AGIs or pioglitazone should be considered as first choice with metformin.\cite{211}

- Patients prone to hypoglycaemia should not preferably be put on glinides, SUs or insulin, since there are high chances of hypoglycaemia with these agents.

- Patients in whom hypoglycaemia further poses risk include:
  - Patients with established cv disease
  - Elderly patients
  - Patients suffering from CKD with or without retinopathy and cannot perform SMBG without the help of others
  - Patients who stay alone, especially in remote areas
  - Patients who are having poor longevity
  - Patients who are having documented hypoglycaemia unawareness
  - Patients who met with severe symptomatic hypoglycaemia requiring hospitalization.

**IMPLEMENTATION**

The physical impact of T2DM is well known, and its management has substantial effects on individual and societal health, psychological well-being, and quality of life, as well as economic repercussions. Clinical practice recommendations in diabetes management are tools for healthcare providers that can ultimately improve health across populations; however, for improved outcomes, diabetes care must also be individualized for each patient. There is not a one-size-fits-all treatment pattern for patients with T2DM, and diabetes management planning should be individualized. The ADA also highlights the importance of patient-centred care, defined as care that is respectful of and responsive to individual patient preferences, needs, and values and that ensures that patient values guide all clinical decisions.\cite{212} An individualized therapy for T2DM could serve as a “real-world” approach, providing care that is responsive to individuals’ specific and unique needs, preferences, and values, and also helping to combat negative long-term outcomes.
Note: Hydroxychloroquinone is approved by DCGI for the treatment of T2DM as third line therapy.
**Recomendations**

### Recommended Care

- Postprandial hyperglycaemia is defined as having postprandial glucose level higher than the target after usual meal and on medications (if any).
- PPG should be measured 2-h after a usual meal and medications (if any).
- Target PPG: 160 mg/dL as long as hypoglycaemia is avoided.
- Both non-pharmacologic and pharmacologic therapies should be considered
  - MNT: diet with low glycaemic load is recommended
  - AGIs (acarbose, miglitol or voglibose), DPP4 inhibitors, SGLT2 inhibitors or GLP-1 analogues (preferably short acting) as the first add on to metformin therapy
  - Glinides and short acting sulfonylureas as alternative options
  - Rapid acting insulin analogues may be considered over the regular insulin when postprandial hyperglycaemia is a concern especially when the risk of hypoglycaemia is high.
  - Combination therapy of AGI with other agents may be considered.
  - SMBG should be considered as it is the most practical method for monitoring postprandial glycaemia.
- Efficacy of treatment regimens should be monitored frequently to guide therapy towards achieving PPG targets.

### Background

Patients with poorly controlled diabetes frequently develop micro- and macro-vascular complications and evidence from large controlled clinical studies suggest that intensive glycaemic control can significantly reduce their risk of development and/or progression. [168,222,294-296] Until recently, the predominant focus of diabetes treatment has been on lowering HbA1c levels, with emphasis on FPG. [297,298] However, control of fasting hyperglycaemia alone is insufficient to obtain optimal glycaemic control as evidence suggests that reducing PPG excursion is as important, or perhaps more important for achieving desired glycaemic targets. [299] It is understood that HbA1c is largely impacted by FPG when it is away from target. As it comes closer to the target, PPG starts taking upper hand and contributes predominantly. Therefore, patients who achieved 2-h PPG within the reference limit will better accomplish target HbA1c values than patients realized FPG within recommended range. [300] In Indians, the PPG remains relatively high all across the HbA1c spectrum and very high even at higher HbA1c values. [301-303] Relative contribution of postprandial hyperglycaemia to HbA1c levels in patients with T2DM is higher than FPG levels when HbA1c is <7.5% and it decreases progressively as HbA1c levels increase. [304] Therefore targeting both PPG and FPG is an ideal strategy for achieving optimal glycaemic control. The purpose of these recommendations is to assist clinicians in developing strategies to consider and effectively manage post-meal glucose in people with T2DM in Asian countries.

### Considerations

India has a high prevalence of diabetes and onset of diabetes is a decade early. Postprandial hyperglycaemia is more prominent in Indians due to high traditional diets with high glycaemic index. Literature is limited regarding postprandial hyperglycaemia despite its definite role in micro- and macro-vascular complications.

### Rationale and Evidence

#### Definition of postprandial hyperglycaemia

- ADA 2019 and the IDF 2018 define postprandial hyperglycaemia as a 2-h plasma glucose level of >200 mg/dL (11.1 mmol/L) during an oral glucose tolerance test (OGTT). It recommends the use of glucose load equivalent to 75 g anhydrous glucose dissolved in water as prescribed by WHO. [1,238]
- Asian Indians displayed a marked rise in prandial glucose excursion after consumption of 75 g of bread meal compared to their Caucasian counterparts. [305,306]
- Elevations in PPG are due to decreased first-phase insulin secretion, reduced insulin sensitivity in peripheral tissues, and consequent decreased suppression of hepatic glucose output after meals, unsuppressed glucagon levels and deficiency of intestinal incretin hormones GLP-1 and (glucose-dependent insulinotropic polypeptide) GIP. [297]
- The causes of postprandial hyperglycaemia are influenced by many factors which include a rapid flux of glucose from the gut, impaired insulin release, endogenous glucose production by the liver and peripheral IR. [309]
- Recent evidences suggest that the value of glycaemia at 1-h during an OGTT is a stronger predictor for developing diabetes than the value at 2-h. [310-312] Therefore, in clinical practice, targeting PPG at 1-h instead of 2-h could have significant impact on reducing...
the risk for CVD. The 1-h PPG has been correlated with increased left ventricular mass, left ventricular diastolic dysfunction, and carotid intima-media thickness (CIMT). \(^{(313-316)}\)

- Evidence from an Indian study based on patients with a history of T2DM for more than 25 years, suggests that postprandial hyperglycaemia was associated with increased risk of both diabetic nephropathy and neuropathy. \(^{(301,317)}\) and Kumamoto study suggested reductions in retinopathy and nephropathy with reduced PPG [Figure 5]. \(^{(296,318)}\)

**Addressing postprandial hyperglycaemia**

- Currently, there is lack of data linking improved clinical outcomes with that of correcting postprandial hyperglycaemia. The HEART2D (Hyperglycaemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus) and the NAVIGATOR (Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research) study could demonstrate direct benefit of lowering postprandial hyperglycaemia in reducing CVD in patients with T2DM. \(^{(319,321)}\)

- However, emerging evidence indicates that agents that target PPG show significant positive trends in risk reduction for all selected CV events. Findings from the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) trial highlight that treating people with IGT with acarbose was associated with a significant reduction in the risk of CVD and hypertension. \(^{(322)}\) The Acarbose Cardiovascular Evaluation (ACE) trial, highlighted that there was no significant impact of acarbose therapy in reducing the risk of major CV events. However, the incidence of diabetes was reduced, which may mitigate cardiovascular risk in the longer term by delaying the onset of T2DM in the high-risk population. \(^{(323)}\)

- Postprandial hyperglycaemia is an important pathophysiological state contributing to the several secondary complications including CV events. Management of postprandial hyperglycaemia is central to long-term glycaemic control and an essential part of CVD prevention in IGT and T2DM. Therefore, it should be routinely monitored in T2DM patients using 2-h post-
OGTT. Thus, screening for prediabetes and monitoring the glycaemic control in patients with T2DM should include PPG as a predictive marker for all-cause premature death, CV risks, along with FPG and HbA1c levels.\cite{324-326} The level of implementation of routine screening for post-meal hyperglycaemia, using the OGTT, should be improved in the Asia-Pacific region, combined with wider use of effective interventions to manage postprandial hyperglycaemia.\cite{327}

**Strategies to prevent postprandial hyperglycaemia**

**Non-pharmacological**
- Physical activity and MNT [Figure 6] are the cornerstones of non-pharmacologic therapy in T2DM patients.\cite{318}
- A randomized crossover study showed that in T2DM patients, walking after meals is more effective for lowering postprandial glycaemia.\cite{328}
- Traditional Asian Indian and Chinese diets are carbohydrate-rich (as high as 80% of the macronutrient composition) with high glycaemic index values.\cite{329} Consumption of rice is very high in South India which is associated with 4–5 fold increase in risk of diabetes.\cite{107} The higher carbohydrate load in the Indian diet leads to greater PPG excursion, increased glucosidase and incretin activity in the gut, which leads to higher lipaemic peaks and associated CVD.\cite{329} Evidence suggests that diets with low glycaemic index values are beneficial in controlling postprandial hyperglycaemia.\cite{297,330,331} For details please refer to the MNT and lifestyle section

**Pharmacological**
- Based on limited Indian evidence available from literature, the panel relied on expert opinion for pharmacological management of postprandial hyperglycaemia which includes the following:
- GLP-1 analogues are effective in controlling postprandial glucose either when used in association with metformin or part of a combination therapy including basal insulin. The short acting GLP-1 agonists (exenatide and lixisenatide) are preferred when isolated postprandial hyperglycaemia is present.
- The ultrafast acting insulin analogue (FiAsp) has demonstrated significant benefits in reducing 1-h PPG following mealtime administration.
- DPP-4 inhibitors have shown significant benefits in reducing PPG excursions and lowering HbA1c.
- Use of glinides is limited to the treatment of postprandial hyperglycaemia only if sulfonylureas are contraindicated or economic consideration prohibits the use of newer and expensive agents.
- AGIs (acarbose, miglitol, and voglibose) can be used as first-line drug in early T2DM, as well as in combination with nearly all established OADs and insulin. Moreover, AGIs tend to inhibit carbohydrate absorption from gut which can be of particular importance in Indian settings where there are increased odds for PPG and lipid excursion due to consumption of diets with high glycaemic index.

**IMPLEMENTATION**

Frequent monitoring of glucose levels using techniques such as SMBG can significantly improve glycaemic control besides detecting PPG excursion. SMBG is currently the optimal method for assessing plasma glucose levels and evidence suggests that structured SMBG followed by therapeutic interventions result in greater HbA1c reduction in individuals with T2DM compared with programs without structured SMBG.\cite{332-334} Therefore, the panel suggest to include SMBG with appropriate patient education for optimal management of post-meal hyperglycaemia. Although, SMBG estimates the average glucose accurately, it underestimates the glucose excursions. Continuous glucose monitoring system (CGMS) provides information on glucose levels, patterns and trends, thereby reflecting the effects of medication, meals, stress, exercise and other factors that affect glucose levels. The CGMS could also be a useful method to detect postprandial hyperglycaemia and to improve therapeutics management in patients with T2DM.\cite{303,335-337}
**ACUTE METABOLIC COMPLICATIONS**

**Hyperglycemic Crisis (Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State)**

**RECOMMENDATIONS**

**Recommended Care**

- Treatment individualization based on careful clinical and laboratory assessment is needed.
- Management goals should include:
  - Restoration of circulatory volume and tissue perfusion
  - Correction of electrolyte imbalance and reversal of ketosis
  - Resolution of hyperglycaemia
  - Identification and prompt treatment of precipitating events
  - Avoiding complications of therapy, particularly cerebral oedema
  - Prevention of recurrent episodes
- Meticulous monitoring of clinical and biochemical response including a flow chart is essential to document hour-by-hour clinical observations, intravenous and oral medications, fluids, and laboratory results.
- Admission to intensive care unit or comparable setting with adequately trained nursing and medical staff and 24 h laboratory services for frequent monitoring is warranted for children <2 years of age and in case of compromised circulation, coma, and risk of cerebral oedema.
- Emergency assessment should follow the general guidelines of advanced life support, with particular attention to airway and breathing patterns, severity of dehydration, mental status, source of infection, level of consciousness (Glasgow coma scale), frequent monitoring of clinical and laboratory parameters.
- If laboratory measurement of serum potassium is delayed, perform an electrocardiogram for baseline evaluation of potassium status. A cardiac monitor should be used for continuous electrocardiographic monitoring to assess T waves for evidence of hyper- or hypo-kalaemia and monitor for arrhythmias.
- In the unconscious or severely obtund patient, secure the airway and empty the stomach by continuous nasogastric suction to prevent pulmonary aspiration.
- A peripheral intravenous catheter should be inserted for convenient and painless repetitive blood sampling.
- Fluid replacement should begin before starting insulin therapy to restore peripheral circulation.
- Adequate oxygenation should be maintained using supplemental oxygen to patients with severe circulatory impairment or shock.
- Give antibiotics to febrile patients after obtaining appropriate cultures of body fluids.
- The rate of fluid administration should not exceed 1.5-2 times the usual daily maintenance requirements.
- Insulin administration should begin at a dose of 0.05-0.1 U/kg/h, 1-2 h after starting fluid replacement therapy.
- In critically ill and mentally obtund patients, continuous intravenous insulin is the standard-of-care.
- Bicarbonate administration is not recommended except for treatment of life-threatening hyperkalaemia.
- In patients with multiple risk factors for cerebral oedema, have mannitol or hypertonic saline at the bedside and the dose to be given calculated beforehand. If neurologic status deteriorates acutely, hyperosmolar therapy should be given immediately.

**BACKGROUND**

Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycaemic state (HHS) represent the most common and serious acute metabolic complications of diabetes. Both DKA and HHS are associated with substantial morbidity and mortality despite well-developed diagnostic criteria and treatment protocols. The overall DKA mortality recorded is <1%, but a higher rate is reported among patients aged >60 years and individuals with concomitant life-threatening illnesses. HHS typically occurs in older patients with T2DM with an intercurrent illness such as infection, surgery or ischemic events, and is associated with higher mortality rate than DKA. Mortality rate with HHS is almost 10-fold higher when compared with DKA.

Pathogenesis of these life-threatening hyperglycaemic emergencies is related to absolute or relative insulin deficiency and increase in insulin counter regulatory hormones that lead to an altered metabolism of carbohydrate, protein, and fat and varying degrees of osmotic diuresis and dehydration, ketosis, and acidosis. Termed together as decompensated diabetes, the prevalence and mortality for DKA and HHS remains indistinct across various age, gender, and racial groups of hospitalized diabetics. If not interrupted by exogenous insulin, fluid and electrolyte therapy, it would...
lead to fatal dehydration, hypoperfusion, and ultimately metabolic acidosis.

In DKA, insulin deficiency and ketoacids are the prominent features of the clinical presentation, and insulin therapy is the cornerstone of therapy [Tables 9 and 10]. Severe hyperglycaemia, osmotic diuresis and dehydration with altered mental status in the absence of significant acidosis characterize HHS. Fluid replacement remains the cornerstone of therapy for HHS. A significant overlap has been reported in more than one-third of patients who exhibit mixed features of both DKA and HHS [Table 11]. Because the three-pronged approach to therapy for either DKA or HHS consists of fluid administration, intravenous insulin infusion, and electrolyte replacement, and mixed cases are managed using the same approach. ICU admission is indicated in the management of DKA, HHS, and mixed cases in the presence of cardiovascular instability, inability to protect the airway, obtundation, the presence of acute abdominal signs or symptoms suggestive of acute gastric dilatation, or if there is not adequate capacity on the floor unit to administer the intravenous insulin infusion and to provide the frequent and necessary monitoring that must accompany its use [Figure 7 and Table 11].

**Considerations**

Treatment of patients with DKA and HHS is associated with substantial mortality and healthcare costs. In a developing country like India, due to poor socio-economic status, many patients with T2DM tend to have poor compliance and poor glycaemic control, thus any precipitating factor tends to land them in a state of hyperglycaemic emergencies including DKA and HHS.

---

**Figure 7:** Algorithm for the management of DKA and HHS. DKA: Diabetic ketoacidosis; HHS: Hyperglycaemic hyperosmolar state; IV: Intravenous; SC: Subcutaneous

**Table 10: Monitoring of clinical signs and biochemical investigations**

<table>
<thead>
<tr>
<th>Plasma glucose and HbA1c levels</th>
<th>Venous pH</th>
</tr>
</thead>
<tbody>
<tr>
<td>BUN, creatinine, electrolytes (including bicarbonates) with calculated anion gap, and hematocrit</td>
<td>Fluid input and output</td>
</tr>
<tr>
<td>Serum osmolality</td>
<td>Vital signs (heart rate, respiratory rate, BP)</td>
</tr>
<tr>
<td>Serum and urinary ketones</td>
<td>Neurological observations for warning signs and symptoms of cerebral oedema</td>
</tr>
<tr>
<td>Arterial blood gases</td>
<td>ECG, chest X-ray, USG abdomen and pelvis</td>
</tr>
</tbody>
</table>

---

Chawla, et al.: RSSDI-ESI clinical practice recommendations
Table 11: Management of acute metabolic complications

<table>
<thead>
<tr>
<th>Fluid replacement therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>In the absence of cardiac compromise, isotonic saline (0.9% NaCl) is infused at a rate of 15-20 mL/kg/h or 1-2 l over 1-2 h for prompt recovery of hypotension and/or hypoperfusion</td>
</tr>
<tr>
<td>Continue with 0.9% NaCl at a similar rate if patient is hyponatraemic or switch to 0.45% NaCl infused at 250-500 mL/h if the corrected serum sodium is normal (eunatraemia) or elevated (hypernatraemia)</td>
</tr>
<tr>
<td>When plasma glucose level is ~200 mg/dL, change to 5% dextrose in saline</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Insulin therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Start insulin infusion 1-2 h after starting fluid replacement therapy (after initial volume expansion) and serum potassium restored to&gt;3.3 mEq/l</td>
</tr>
<tr>
<td>Regular human insulin IV bolus of 0.1-0.15 U/kg followed by continuous insulin infusion at 0.1 U/kg/h</td>
</tr>
<tr>
<td>IV bolus is avoided in children as it may increase the risk of cerebral oedema and can exacerbate hypokalaemia</td>
</tr>
<tr>
<td>When glucose level reaches 200 mg/dL in DKA or 300 mg/dL in HHS, reduce insulin rate to 0.02-0.05 U/kg/h. Thereafter, adjust rate to maintain glucose level 150-200 mg/dL in DKA and 250-300 mg/dL in HHS</td>
</tr>
<tr>
<td>Continue insulin infusion until resolution of ketoacidosis</td>
</tr>
<tr>
<td>Subcutaneous rapid-acting insulin analogues (lispro and aspart) every 1-2 h. might be an alternative to IV insulin in patients with mild to moderate DKA</td>
</tr>
<tr>
<td>Initial dose subcutaneous: 0.3 U/Kg, followed 1 h later at 0.1 U/Kg every 1 h, or 0.15-0.2 U/kg every 2 h</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Potassium replacement</th>
</tr>
</thead>
<tbody>
<tr>
<td>If patient is hypokalaemic, start potassium replacement at the time of initial volume expansion and before starting insulin therapy. Otherwise, start after initial volume expansion and concurrent with insulin therapy</td>
</tr>
<tr>
<td>With initial rapid volume expansion, a concentration of 20 mmol/l should be used</td>
</tr>
<tr>
<td>The maximum recommended rate is 0.5 mmol/kg/h</td>
</tr>
<tr>
<td>The treatment goal is to maintain serum potassium levels of 4-5 mEq/l</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bicarbonate therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not routinely recommended; only indicated in adults with severe acidosis with pH &lt;6.9</td>
</tr>
<tr>
<td>If pH &lt;6.9, consider 100 mmol (2 ampules) in 400 ml sterile water with 20 mEq KCl administered at a rate of 200 mL/h for 2 h until pH is ≥7.0.</td>
</tr>
<tr>
<td>If the pH is still &lt;7.0 after this is infused, we recommend repeating infusion every 2 h. until pH reaches ≥7.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Transition to subcutaneous insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>To prevent recurrence of ketoacidosis or rebound hyperglycaemia, consider overlap of IV insulin for 15-30 min (with rapid-acting insulin) or 1-2 h (with regular insulin) or longer (with intermediate or long-acting insulin) after subcutaneous insulin is given</td>
</tr>
<tr>
<td>Most convenient time to change to subcutaneous insulin is just before a mealtime</td>
</tr>
<tr>
<td>For patients treated with insulin before admission, restart previous insulin</td>
</tr>
<tr>
<td>Regimen and adjust dosage as needed</td>
</tr>
<tr>
<td>For patients with newly diagnosed DM, start total daily insulin dose at 0.5-0.8 U/kg/day. Consider multi-dose insulin given as basal and prandial regimen</td>
</tr>
</tbody>
</table>

DKA: Diabetic ketoacidosis, HHS: Hyperosmolar hyperglycaemic state, IV: Intravenous, DM: Diabetes mellitus

**HYPOGLYCAEMIA**

**Recommended Care**

- Risk of hypoglycaemia should be assessed in every visit in patients with T2DM by using questionnaires.
- Patient should be well educated and informed regarding:
  - The symptoms, causes, and risks associated with hypoglycaemia
  - Usage of SMBG tools with frequent monitoring especially patients taking insulin
  - Insulin dose adjustment considering blood glucose values
- A strict monitoring of hypoglycaemic episodes is recommended for patients taking insulin, sulfonylureas or meglitinides alone or in combination.
- Modern insulins or modern sulfonylureas should be used instead of respective traditional drugs in patients with high risk of hypoglycaemia.
- Oral glucose (15-20 g) is preferred in conscious hypoglycaemic patients (glucose alert value of <70 mg/dL). Repeat the treatment, if SMBG shows continued hypoglycaemia after 15 min. Patient should consume a meal or snack once SMBG returns to normal, to prevent recurrence of hypoglycaemia
- Intramuscular glucagon or intravenous glucose is preferred for unconscious patients or patients with clinically significant hypoglycaemia (glucose alert value of <54 mg/dL). Repeat intramuscular or subcutaneous glucagon dose of 0.5 mg if there is no symptomatic improvement.
- Glucagon to be avoided in patients with sulfonylurea induced hypoglycaemia.
- Treatment should be modified in the event of hypoglycaemia occurring repeatedly at a particular time of the day or in the event of hypoglycaemia unawareness.
- Hypoglycaemia occurring in the setting of advanced kidney disease (CKD stage 4 or 5) requires relatively longer observation for avoidance of recurrence even long after initial corrective measure are taken.
Limited Care

- All patients with risk of hypoglycaemia should be enquired about symptomatic and asymptomatic hypoglycaemia at each visit.
- Patients along with their family members should be well educated about identification and management of hypoglycaemia, especially night-time hypoglycaemia.
- Hypoglycaemia should be strictly managed and monitored in special situations such as elderly, pregnancy, fasting, and metabolic disorders.

BACKGROUND

Hypoglycaemia is a major cause of concern with some antidiabetic drugs during the course of glycaemic management in patients with T2DM.[345] However, the extent of hypoglycaemia varies with different antidiabetic drugs pertaining to their pharmacokinetic and pharmacodynamics properties. The International Hypoglycaemia Study Group categorizes hypoglycaemia into three categories basing upon the glycaemic criteria.[346]

- Glucose alert value (level 1): <70 mg/dL (3.9 mmol/L)
- Clinically significant hypoglycaemia (level 2): <54 mg/dL (3.0 mmol/L)
- Severe hypoglycaemia (level 3): no specific glucose threshold.

The prevalence of hypoglycaemia in patients with T2DM in India is quite high. A recent cross-sectional study reports that nearly 96% of patients (out of 366 patients) were associated with at least one or other symptoms of hypoglycaemia (dizziness, weakness). Furthermore, patients taking insulin in addition to OADs were at higher risk than patient taking OADs alone (OR, 2.3; p <0.01).[347] Meanwhile, another cross-sectional study including 1650 patients from South India revealed that the cumulative incidence of institutional hypoglycaemia was 12.36%; among which, 26.96% had asymptomatic episodes.[348]

Severe hypoglycaemia can lead to several diabetes-related short-and long-term complications such as neurocognitive dysfunction, retinal cell death, and loss of vision[349] and may lead to coma or death if not reversed.[345] The ACCORD and ADVANCE trials and other evidences reported that severe hypoglycaemia was directly associated with mortality in patients with T2DM.[350-352] Furthermore, Kalra et al. stated that diabetes patients with severe hypoglycaemia are associated with sixfold increase in deaths over those not experiencing it.[349] Therefore, urgent steps need to be taken with some corrective measures against hypoglycaemia in T2DM patients to minimize the burden. Following are some of the causes and risk factors of hypoglycaemia [Table 12].[349]

<table>
<thead>
<tr>
<th>Causes</th>
<th>Risk factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolic defects</td>
<td>Glucose-lowering drugs (especially SU/insulin)</td>
</tr>
<tr>
<td>Autoimmune conditions</td>
<td>Increased glucose utilization or decreased glucose production</td>
</tr>
<tr>
<td>Dietary toxins</td>
<td>Female gender</td>
</tr>
<tr>
<td>Alcohol consumption</td>
<td>Inborn errors of metabolism</td>
</tr>
<tr>
<td>Stress</td>
<td>Sleep</td>
</tr>
<tr>
<td>Infections</td>
<td>Long duration of diabetes</td>
</tr>
<tr>
<td>Starvation</td>
<td>Extremes of age</td>
</tr>
<tr>
<td>Severe excessive exercise</td>
<td>Progressive insulin deficiency</td>
</tr>
<tr>
<td>Hypoglycaemia thresholds</td>
<td>Intensive glycaemic control on OADs and insulin (alone in combination)</td>
</tr>
<tr>
<td>Glucose alert value (level 1)</td>
<td>Skipping of meals</td>
</tr>
<tr>
<td>Clinically significant hypoglycaemia (level 2)</td>
<td>DKD, hepatic impairment</td>
</tr>
<tr>
<td>Severe hypoglycaemia (level 3)</td>
<td>Cortisol Insufficiency</td>
</tr>
<tr>
<td>No specific glucose threshold</td>
<td>Autonomic Failure</td>
</tr>
<tr>
<td>in patients with T2DM.</td>
<td>Cognitive impairment</td>
</tr>
</tbody>
</table>

Rationale and Evidence

Identification

- Symptoms of hypoglycaemia include, but are not limited to, excess sweating and hunger, dizziness, blackout, fainting, fatigue, light-headedness or shakiness, nausea or vomiting, mental confusion or unresponsiveness, and dry-nose or tingling lips.[345]
- Nocturnal hypoglycaemia to be suspected in case of night-time sweating, hunger and anxiety. Nightmares, early morning headaches and labile morning sugars should also alert the physician.[354,355]
- Some endocrinologists or diabetologists use a three-step approach (Whipple’s Triad) for diagnosis of hypoglycaemia. It includes:
  - Low blood glucose level
  - Symptoms of hypoglycaemia at the time of the low glucose level
  - Symptom relief with treatment of hypoglycaemia.

Management

- Management of hypoglycaemia can be subdivided into three aspects:
  - Prevention of hypoglycaemia
  - Treatment of hypoglycaemia
  - Adjustment or withdrawal or modification of current antidiabetic regimen.

Considerations

Several factors such as the intensity of hypoglycaemic risk, patient characteristics, drug usage, fasting, and patient education should be considered during framing the recommendations for hypoglycaemia management in patients with T2DM.
Prevention of hypoglycaemia

• Prevention of hypoglycaemia is preferable than treatment, as it is much more likely to avoid severe events and economic burden.\textsuperscript{[356]} Hypoglycaemia prevention requires a combined effort from physician as well as patient. Patient education, patient counselling, and continuous blood glucose monitoring are the critical factors that need to be considered for the prevention of hypoglycaemia in patients with diabetes. Evidence suggests that a proper and structured diabetes education helps in reducing diabetic complications including hypoglycaemia.\textsuperscript{[357-360]}

• Furthermore, interventions targeting health beliefs and attitudes about hypoglycaemia and diabetes self-management can be more effective than knowledge-centred patient education, which focuses on symptom perception in reducing hypoglycaemia unawareness.\textsuperscript{[349]} Patients receiving insulin for the treatment of T2DM can be benefitted by adjusting insulin doses following SMBG procedure.\textsuperscript{[349,361]} In addition, a cross-sectional study from India reports that 85% of patients were taking timely meals to prevent hypoglycaemia.\textsuperscript{[347]} Stratifying patients according to age and avoiding very tight glucose control in elderly patients (>70 years) and very young children (<5 years of age) will help to prevent hypoglycaemia in these high-risk people.

Adjustment or withdrawal or modification of ongoing antidiabetic regimen

• Majority of the antidiabetic agents can produce hypoglycaemia; however, the intensity depends upon their mechanism of action. Insulin, sulfonylureas, and meglitinides due to their glucose-independent mechanism of action cause a high risk of hypoglycaemia.\textsuperscript{[349]}

• The UK Hypoglycaemia Study Group report that the incidence of severe hypoglycaemia increased from 7% to 25% in patients treated with insulin for <2 years with those treated for >5 years.\textsuperscript{[362]} However, modern insulin analogues report lower incidence of hypoglycaemia than traditional human insulins.\textsuperscript{[363-365]}

• Among all sulfonylureas, modern sulfonylureas like gliclazide MR and glimepiride are associated with lesser hypoglycaemic episodes.\textsuperscript{[366,367]} Meglitinides were reported to inflict high rates of hypoglycaemia.\textsuperscript{[329]} In special situations like elderly, fasting, metabolic disorders, and pregnancy, the dose of these drugs should be adjusted or modified to avoid further complications. Furthermore, avoid/reduce the dose of insulin in people with CKD who have a tendency to develop hypoglycaemia.

Treatment of hypoglycaemia

• Fifteen to 20 g of carbohydrate (four teaspoons of sugar or glucose) can be given orally to a conscious patient with hypoglycaemia; if unconscious, glucagon injection intramuscularly or glucose injection intravenously can be preferred.\textsuperscript{[345,349]} Glucagon to be avoided in sulfonylurea induced hypoglycaemia.

• Caretakers of hypoglycaemia-prone diabetes patients (family members, roommates, school personnel, childcare providers, correctional institution staff, or co-workers) should be well instructed on the use of glucagon kits including where the kit is located and when and how to administer glucagon.\textsuperscript{[345]}

• Acute glycaemic response correlates better with the glucose content than with the carbohydrate content of food. Therefore, pure glucose is the preferred treatment.\textsuperscript{[345]} Fifteen minutes after glucose administration, an SMBG should be done and the treatment should be repeated if hypoglycaemia persists. Patient should be advised to eat a regular meal or have a snack to prevent recurrence of hypoglycaemia.\textsuperscript{[368]}

IMPLEMENTATION

Patient empowerment with hypoglycaemia monitoring tools, hypoglycaemia risk awareness, and the available preventive strategies together with physician-patient collaboration plan of treatment can reduce the frequency and intensity of hypoglycaemia.

CHRONIC COMPLICATIONS 1: RETINOPATHY, NEUROPATHY, DIABETIC KIDNEY DISEASE

Retinopathy

RECOMMENDATIONS

Recommended Care

• Documentation of formal history of vision and visual acuity either by recording it on sheet or electronic medical record (EMR) should be made mandatory first at the time of diagnosis and then periodically.

• Ensure that examination of the eyes of people with T2DM is performed around the time of diagnosis and then routinely every 1-2 years as part of a formal recall process:

  • Measure and document visual acuity, corrected with glasses or pinhole

  • Record ocular pressure and assess the condition of the iris and lens

Contd...
Assess retinopathy:
- Using retinal photography through dilated pupils, performed by an appropriately trained healthcare professional, or
- Through examination by an ophthalmologist
- Discuss the reasons for eye examination with the person with diabetes.
- Counseling must include components on smoking, diet, alternative medicines, exercise, and appropriate choice of drugs for BP and lipids.
- Counsel women who are planning pregnancy on the risk of progression of retinopathy during pregnancy, especially if there is pre-existing retinopathy.
- Ensure regular follow-up throughout pregnancy and up to 1 year post-partum.
- Use tropicamide to dilate pupils, unless contraindicated (rule out history of glaucoma), after discussing the implications and obtaining agreement of the person with diabetes.
- Classify the findings of eye examination as required: routine review, earlier review or referral to an ophthalmologist (if not making the examination).
- The following frequency of screening is suggested:
  - 1-2 years, if no retinopathy, depending on clinical situation
  - 12 months, if minimal unchanged retinopathy
  - 2-4 months, after any active ophthalmic intervention
  - 3-6 months, if worsening since last examination
  - More often during pregnancy
- The following situations require specialist referral:
  - The same day:
    - Sudden loss of vision
    - Evidence of retinal detachment
  - Within one week:
    - Evidence of pre-retinal and/or vitreous haemorrhage
    - New vessel formation or rubeosisiridis
    - Inability to see or assess disc or fovea
    - Raised ocular pressure
  - Within 1-2 months:
    - Advanced retinal lesions (4:2:1 rule)
    - Microaneurysms or retinal haemorrhages in 4 quadrants
    - Venous beading in two quadrants
    - IRMAs in one quadrant
    - Unexplained deterioration of visual acuity
    - Macular oedema
    - Unexplained retinal findings
    - Cataract
    - Inability to visualize fundus
  - Stepped approach should be adapted to manage hyperglycemia, as intensive glycemic control can cause transient (early) worsening of symptoms and even lead to cotton wool spots.
  - GLP-1 agonists may initially worsen diabetic retinopathy, and hence must be used with caution.
  - Advice that good control of blood glucose, BP and blood lipids, and cessation of smoking can help to reduce the risk of development or worsening of eye complications.
  - Advice that DR is not a contraindication for use of aspirin, if this is indicated for prevention of CVD.
  - Advise that tests of intraocular pressure should be done periodically.
  - Explain guarded prognosis about regaining vision after intra-ocular lens (IOL) surgery in mature/hypermature cataract because of poor assessment of retina in the presence of mature cataract.
  - Discourage use of alternative medicines as they can cause further complications.

**Limited Care**

- Use direct fundoscopy through dilated pupils, performed by a member of the health-care team who is properly trained and has appropriate experience to assess retinopathy.
- Check visual acuity.
- Repeat review, referral and preventative therapy are as for recommended care.
- Less-frequent examinations (every two years) may be considered following one or more normal eye examinations.
- Discourage use of alternative medicines as they can cause further complications.

**BACKGROUND**

Diabetic eye disease comprises of a group of eye conditions that affect people with diabetes such as diabetic retinopathy (DR), diabetic macular edema (DME), cataract, and glaucoma. DR is a microvascular complication of diabetes and one of the leading causes of blindness or vision impairment in India.\cite{369,370} It affects retinal blood vessels and is the most common cause of vision loss among people with diabetes and the leading cause...
of vision impairment and blindness among working-age adults. Visual loss from DR could be due to diabetic macular edema (DME: swelling in the retinal macula) or proliferative diabetic retinopathy (PDR). Factors such as longer duration of diabetes and poorer glycaemic and BP control were found to be strongly associated with DR.\textsuperscript{[371,372]} In a cross-sectional study carried out by All India Ophthalmological Society, prevalence of DR was 21.7% and the rate was high in men (p<0.007), in patients with diabetes duration $\geq$5 years (p=0.001), in patients with age $\geq$40 years (p=0.01), in insulin users (p=0.001), and in patients with history of vascular accidents (p=0.0014).\textsuperscript{[369]} Furthermore, in the cross-sectional survey of Indian patients with T2DM in CINDI (chronic complications in newly diagnosed patients with type 2 diabetes mellitus in India) and CINDI2 (cardiovascular risk factors, micro and macrovascular complications at diagnosis in patients with young onset type 2 diabetes in India), DR was prevalent in 6.1% and 5.1% patients, respectively.\textsuperscript{[373,374]} Moreover, the socioeconomic burden resulting from DR induced visual impairment or blindness, particularly in the working age group, is a serious concern.\textsuperscript{[375]} Therefore it is high time to devise the means of managing DR and bring the problem under control.\textsuperscript{[376]} A systematic approach to health education and creating awareness among patients and various health personnel and matching it with appropriate screening and service delivery mechanisms will go a long way in. Early detection and management of DR with quick referrals and a highly coordinated teamwork between the endocrinologists, ophthalmologists, neurologist and nephrologist could reduce the prevalence of DR in India.\textsuperscript{[377]} Important therapeutic measures in the management of DR include optimum glycaemic levels, lipid, and hypertension control. In severe cases of preproliferative DR, laser panretinal photocoagulation (PRP) is indicated with the aim of preventing progression of DR and vision loss.\textsuperscript{[378]} Of note, implementation of intensive glycaemic control can cause transient (early) worsening, mostly due to the development of small arteriolar infarcts which result in the well-known cotton wool spots, particularly in patients with poor control and long-standing disease are at risk. There for a calculated and stepped approach should be adapted to manage hyperglycaemia is patients with DR.\textsuperscript{[379]}

### Rationale and Evidence

#### Screening

- Several guidelines emphasize on eye screening in T2DM, however, it appears they are divided on the frequency of screening. Some recommend annual screening (NICE-UK) while others recommend screening every 1–2 years (Canadian-Canada, Australian-Australia and SIGN-Scotland).
- With regard to frequency of screening in limited care setting, the panel endorsed the ADA recommendation which suggests less-frequent examinations (every 2–3 years) following one or more normal eye examinations.\textsuperscript{[380]}
- Screening methods for DR include direct and indirect ophthalmoscopy, slit-lamp biomicroscopy, stereoscopic colour film fundus photography, mydriatic or nonmydriatic digital colour, and monochromatic photography.\textsuperscript{[381,382]}
- In-person clinical exam by an eye care provider is the gold standard for diagnosing DR, faster digital retinal imaging acquisition and grading of DR using fundus images obtained with a nonmydriatic fundus camera is now being considered an effective, cost-sparing, and feasible screening tool for the early detection of DR, and preventing blindness.\textsuperscript{[383]}

#### Counselling pregnant women

- DR is the foremost cause of blindness in women during the antenatal period, and pregnancy increases the short-term risk of DR progression.\textsuperscript{[382]} The possible relationship between DR and the perinatal outcome has been addressed in several studies.\textsuperscript{[384,385]} Women with more severe DR were more likely to develop obstetric complications\textsuperscript{[385,386]} and those with proliferative changes accounted for higher incidence of congenital malformations and/or foetal death.\textsuperscript{[385]}
- As pregnancy can induce progression of DR, the panel recommended pre-conception counselling for women, clearly explaining about the risk of progression of DR during pregnancy especially if they already have proliferative retinopathy. They should be advised on maintaining good glycaemic control before and throughout pregnancy under the guidance of a healthcare professional. In addition, the panel emphasized on the need for close follow-up during pregnancy and up to 1 year post-partum and monitoring for progression of DR and co-existing hypertension and renal disease, if any.

#### Guarded prognosis after intra-ocular lens surgery

- Though surgical interventions are crucial for cataract management, in most of the patients, particularly those with complicated cataracts, vision may not be restored. These patients eventually develop corneal decompensation, glaucoma and optic atrophy.\textsuperscript{[387]} Because the prognosis of retina is poor especially in the presence of mature cataract, the panel suggested that it is important to educate the patient about guarded prognosis for regaining vision after IOL surgery.

#### Evidence

Though evidence from past studies suggests that prevalence of DR is low in Indians compared to other ethnic groups, emerging data indicate significant increase in prevalence of retinopathy in South Asians compared to Caucasians.\textsuperscript{[388]} Data from a population-based study (CURES) indicate that the overall prevalence of DR in urban south Indian population was 17.6%, with higher prevalence among men than in women (21.3% vs. 14.6%; p<0.0001) and among subjects with proteinuria (p=0.002).\textsuperscript{[389]} Similarly, prevalence of DR in western India was found to be 33.9%.\textsuperscript{[389]} Data from a recent population-based cross-sectional study suggests that one of 10 individuals in rural South India, above the age of 40 years, had evidence of DR.\textsuperscript{[391]} A meta-analysis of seven studies from India found 14.9% of known diabetes patients aged $\geq$30 years and 18.1% among those aged $\geq$50 years had DR. Furthermore, no linear trend was observed between age and the proportion with DR.\textsuperscript{[392]} Duration of diabetes, HbA1c, male gender, macro-albuminuria and insulin therapy
were found to be strongly associated with increased risk of DR among South Indians.\textsuperscript{[393,394]} Moreover, the risk of nephropathy (OR: 5.3, \textit{p}<0.0001) and neuropathy (OR: 2.9, \textit{p}<0.0001) was significantly higher among T2DM patients with DR compared to those without DR.\textsuperscript{[395]} After adjusting for age, gender, HbA1c, SBP, serum triglycerides, and duration of diabetes, DR was significantly associated with nephropathy (\textit{p}=0.005) than with neuropathy.\textsuperscript{[396]} Another study showed HbA1c, BMI, duration of diabetes, microalbuminuria and peripheral neuropathy are contributing factors in the degree of retinopathy (\textit{p}=0.001) and this correlation was explained by common mechanisms involved in tissue damage by all these factors. Microalbuminuria was positively correlated with the presence of retinopathy in T2DM patients and may be a marker for the risk of severe and proliferative retinopathy development. Microalbuminuria was associated cross-sectionally with the presence of retinopathy in patients with T2DM. This study suggests that microalbuminuria may be a marker for the risk of proliferative retinopathy development.\textsuperscript{[396]}

\textbf{IMPLEMENTATION}

Sufficient number of trained general ophthalmologists and general physicians are required to develop an integrated DR model that facilitates early detection and create awareness on DR. Medical camps should be conducted for screening of diabetes and retinopathy, which will help to identify people at risk of sight-threatening DR and initiate treatment including laser photocoagulation or vitreous surgery. Mobile vans with a fundus camera or other low cost tools that can be used in remote rural areas should also be explored. However, successful implementation of program requires team approach, involving both administrative and voluntary organizations.

Telemedicine based DR screening costs less ($10 vs $25) than conventional retinal examination and the telemedicine-based digital retinal imaging examination has the potential to provide an alternative method with greater convenience and access for the remote and indigent populations. This cost effective technology driven model would prevent the screening costs and also help in the early detection of DR and prevent a common cause of blindness. Telemedicine should be encouraged to improve access, increase compliance with annual evaluation, at a low cost for patients with diabetes.\textsuperscript{[397]} Tele-diabetes shares some of the same attributes of tele-monitoring for other chronic conditions, such as congestive heart failure, stroke, and chronic obstructive pulmonary disease. In a pilot study conducted in Hungary on patients with diabetes, 30\% of the patients had never participated in any ophthalmological screening, while 25.7\% had DR of some grade based upon a standard fundus camera examination and UK-based DR grading protocol (Spectra\textsuperscript{TM} software). Large majority of the patients were satisfied with the screening and found it reliable and acceptable to undertake examination under pupil dilation; 67.3\% were willing to undergo nonmydriatic fundus camera examination again. Participants found digital retinal screening to be reliable and satisfactory. Telemedicine can be a strong tool, supporting eye care professionals and allowing for faster and more comfortable DR screening.\textsuperscript{[398]}

\textbf{NEUROPATHY}

\textbf{RECOMMENDATIONS}

\textbf{Recommended Care}

- All patients with T2DM should be assessed for diabetic neuropathy at the time of initial diagnosis and annually
- Diagnose sensorimotor nerve damage by history and examination (10 g monofilament with or without temperature, non-traumatic pin-prick, vibration [128 Hz tuning fork], ankle reflexes), and/or simple quantitative testing (e. g. biothesiometer vibration perception). Use serum B12, thyroid function tests, creatinine/urea, and alcohol abuse and medication history to exclude other causes.
- Diabetic Neuropathy Symptom Score (NSS) and Neuropathy Disability Score (NDS) in T2DM population has been found to be a useful resource in evaluating diabetic sensorimotor polyneuropathy as an important bed side tool.
- Diagnose symptomatic (painful) diabetic neuropathy by excluding other possible causes of the symptoms. Manage by stabilizing blood glucose control, and treatment with tricyclic antidepressants, if simple analgesia is not successful. If a one month trial of tricyclic therapy is not successful, further treatment options include pregabalin/gabapentin and duloxetine, then tramadol and oxycodone.
- Weight gain and lifestyle measures need a reinforcement with the use of antidepressants and gabapentin and pregabalin.
- Further management normally requires referral to a pain control team. Be aware of the psychological impact of continuing symptoms, particularly if sleep is disturbed. In patients with diabetic neuropathy and co-morbid depression, anxiety and sleep loss, duloxetine should be preferred.
- A visual record of simple graphic tool to measure response to therapy must be mandated, which will save patients from over/unnecessary treatment.
- Tools e. g. pain scale should be encouraged in clinical practice.
- Diagnose erectile dysfunction by history (including medication history), exclusion of endocrine conditions (measure prolactin and testosterone), and a trial of a phosphodiesterase type-5 (PDE5) inhibitor (where not contraindicated by nitrate therapy). Consider other approaches such as intra-urethral or intracavernosal drugs and sexual and relationship counselling, where PDE5 inhibitors fail or cannot be used.
- Discourage use of alternative medicines as they can cause further complications.
- Diagnose gastroparesis by history, trial of a prokinetic drug (metoclopramide, domperidone) and if troublesome, by gastric emptying studies.
- Diagnose CV autonomic neuropathy by resting heart rate and heart rate response to provocation tests (lying-standing, Valsalva, deep breathing), and by lying and standing BP. Inform anaesthetists when relevant, where this is present.
- Every patient must undergo a simple assessment e. g. questionnaire-based assessment for depression.
BACKGROUND
Neuropathy is among the most common life-threatening complication of diabetes that involves both peripheral and autonomic nerves, affecting up to half of all diabetic patients. Hyperglycaemia-induced polyol pathway, injury from AGEs, and enhanced oxidative stress have been implicated in its pathogenesis.[399,400] Peripheral neuropathy in diabetes appears in several forms depending on the site, manifesting as sensory, focal/multifocal, and autonomic neuropathies. Diabetic neuropathy has resulted in more than 80% amputations after foot ulceration or injury. It is among the most common, expensive and disabling complications of diabetes, affecting approximately 30% of hospitalized patients with diabetes and 25% of patients with diabetes in the community.[401]
Approximately 30% patients either with known or newly diagnosed diabetes are suffering from diabetic neuropathy.[402,405] In the cross-sectional survey of Indian patients with T2DM in CINDI and CINDI2 studies, diabetic neuropathy was prevalent in 13.15% and 13.2% patients, respectively.[373,374] As per the Toronto Consensus Panel, diabetic polyneuropathy is a “symmetrical, length-dependent sensorimotor polyneuropathy attributable to metabolic and micro-vessel alterations as a result of chronic hyperglycaemia exposure and cardiovascular risk covariates”.[406] The most common form of diabetic neuropathy is the distal symmetrical polyneuropathy that involves both tibial and sural nerves.[405] Presence of neuropathy is associated with significant morbidity, including recurrent foot infection and ulcers; impotence in men with diabetes, and sudden death in individuals with CV autonomic neuropathy. Neuropathic pain in patients with diabetes is commonly encountered in clinical practice.[405,406] The present recommendations provide insights on the management aspects of diabetic neuropathy while exploring newer therapeutic options that have emerged in recent years.

RATIONALE AND EVIDENCE
Detection of sensorimotor polyneuropathy
• Though nerve conduction studies are powerful tools for identifying cases of diabetic neuropathy,[407] NSS[408] and NDS[409] in T2DM patients was found to be a useful resource for evaluating diabetic sensorimotor polyneuropathy as a bedside tool.[410,411] A cross-sectional study in T2DM patients that examined the nerve conduction velocities of motor and sensory nerves, using NSS and NDS in patients of clinically detectable neuropathy showed significant electrophysiological changes with duration of T2DM.[411] Similar results were observed in another study where NSS and NDS together helped in prompt evaluation of diabetic sensorimotor polyneuropathy and also in diagnosing subclinical cases.[412-414] A study that validated the use of NSS and NDS for clinical diagnosis of peripheral neuropathy in middle aged 855 T2DM patients showed that NSS and NDS can detect diabetic neuropathy with a sensitivity of 71.1% and specificity of 90% and was found to be simple, acceptable, reproducible and validated method for early diagnosis of diabetic neuropathy.[294,410]
• The panel emphasized on neurological examination using NSS and NDS as it is important bed side tool and a useful resource in evaluating diabetic sensorimotor polyneuropathy.

Management of diabetic neuropathy [Figure 8]
Diabetic peripheral neuropathic pain can be managed with several classes of drugs including tricyclic antidepressants, anticonvulsants, serotonin-norepinephrine reuptake inhibitors, opiates and opiate-like substances, and topical medications.
• Tricyclic antidepressants are recommended as first-line therapy for diabetic peripheral neuropathic pain in appropriate patients.
• Gabapentin is an anticonvulsant that is structurally related to γ-aminobutyric acid (GABA), a neurotransmitter that plays a role in pain transmission and modulation. In patients with a history of pain attributed to diabetic neuropathy gabapentin monotherapy was efficacious for the treatment of pain and sleep interference associated with diabetic peripheral neuropathy along with positive effects on mood and quality of life.[413]
• Duloxetine and pregabalin were approved by the USFDA in 2004 and tapentadol extended release was approved in 2012 for the treatment of painful diabetic neuropathy (PDN).[416]
• Pregabalin is a potent gabapentinoid used in the management of PDN. Several double-blind placebo-controlled trials have reported the dose dependent (600 mg/daily) efficacy of pregabalin; however a number of side effects including mood disturbance, ankle oedema and sedation also have been reported.[417-419]
• Both duloxetine and pregabalin are effective; however, a significant improvement in QoL of patients was obtained by duloxetine with comparatively mild increase in the price.[420]
Duloxetine is a selective inhibitor of reuptake of both 5-hydroxytryptamine and norepinephrine. Results from randomized-controlled clinical trials reveal that duloxetine provides significantly more diabetic neuropathic pain relief than either placebo or routine care with higher degree of safety and tolerability. Moreover, a recent Cochrane collaboration review including data from eight studies and 2728 participants report that both 60 mg and 120 mg daily doses of duloxetine were efficacious, but lower doses were not associated with improvement in the PDN management.

Tapentadol, an opioid analgesic, may act via opioid spinal-supraspinal synergy, as well as intrinsic spinally mediated μ-opioid receptor agonist-norepinephrine reuptake inhibitor effect. The efficacy and safety of tapentadol was also published in several clinical trials. Tramadol may also be used for pain management however, there is only modest information about the use of tramadol in neuropathic pain, primarily from small, largely inadequate studies. Further, a fixed-dose combination of tramadol/paracetamol might be a useful pharmacological option for chronic pain management, particularly in elderly patients.

Neuropathic pain can be severe and can impact quality of life, limit mobility, and contribute to depression and social dysfunction. Management of underlying depression is a must to improve QoL. Tricyclic antidepressants, venlafaxine, carbamazepine, and topical capsaicin, although not approved for the treatment of painful diabetic neuropathy, may be effective and considered for the treatment.

Capsaicin has been used with some success in the treatment of patients with PDN. It binds to the receptor that opens the TRPV1 causing sodium and calcium influx and substance P release occurs. Repeated TRPV1 exposure to capsaicin causes substance P depletion and TRPV1 desensitization and defunctionalization.

Lidocaine blocks the voltage-gated sodium channels and stabilizes the neuronal membrane potential, resulting in a reduction of ectopic discharges and raised peripheral ectopic discharge threshold causing reduced pain transduction.

**Diabetic Kidney Disease**

**Recommendations**

**Recommended Care**

- Kidney function should be assessed at diagnosis and annually by:
  - Urine test for albuminuria
  - Measurement of serum creatinine and calculation of eGFR
- Urinary albumin to creatinine ratio (ACR) measurement in an early morning first void (mid-stream) spot specimen is the preferred method for assessment of microalbuminuria/proteinuria. Where a first void specimen is not possible or practical, a random spot urine specimen is acceptable. ACR can be measured in the laboratory or at site-of-care.
- Control hyperglycaemia, exclude urinary or systemic infections, or pyrexia and avoid strenuous exercise before testing for albuminuria.
- If ACR is raised (microalbuminuria) i.e. ACR >30 mg/g creatinine, repeat ACR twice over the following four months.

**Implementation**

Appropriate protocols should be developed for sensory testing and may include formal assessment using the NSS and NDS. Recommended medications should be available according to the level of resources. Medical teams need to remain trained in the diverse manifestations of autonomic neuropathy.
Chawla, et al.: RSSDI-ESI clinical practice recommendations

- Microalbuminuria is confirmed if ACR is elevated in two out of three tests, in the absence of infection or overt proteinuria
- If both repeat tests are not raised, check again annually
- An ACR >300 mg/g indicates macroalbuminuria
- DKD is diagnosed on the basis of a raised urine albumin/protein or a reduced eGFR (<60 mL/min/1.73 m²) calculated from the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. CKD-EPI is the preferred formula.
- The Modification of Diet in Renal Disease (MDRD) formula for calculation of eGFR is not validated above 70 years age and in Indian patients.
- For patients <18 years of age (including infants, toddlers, children, and teens), the Bedside Schwartz equation should be used.
- Individuals with DKD should be managed as follows:
  - Identified high-risk individuals (hypertensives, duration of diabetes >3-5 years, family history of nephropathy/HF/ASCVD) must get preference for SGLT2 inhibitors for glycemic management if feasible and accepted by patients (eGFR >30 mL/min/1.73 m²)
  - Use angiotensin converting enzyme (ACE)-inhibitors or angiotensin receptor blockers (ARBs) in individuals with micro-or macro-albuminuria, titrated to maximum tolerated dose
  - Intensify management of BP (target ≤130/80 mm Hg) using BP lowering medications and dietary modification (low salt and reduced protein intake)
  - Intensify management of blood glucose
  - Monitor ACR, eGFR and serum potassium
  - Advise limiting protein intake to 1 g/kg of high biological value protein daily. In those with advancing CKD, restrict to 0.8 g/kg daily with advice for caution in patients consuming non-vegetarian diet
  - Intensify other renal and CV protection measures
  - Assessment and management of anaemia and bone disease and appropriate vaccination
  - Smoking leads to progression to end-stage renal disease (ESRD) in diabetes so patients must be counselled for quitting smoking
  - Consider referral to nephrologists when there is uncertainty about the aetiology of kidney disease, difficult management issues (stress, obesity, high uric acid, UTIs, anaemia for timely use of Erythropoietin analogues, BP control stressed)
  - Agree to a referral criteria for specialist renal care between local diabetes specialists and nephrologists. Referral criteria might include eGFR<30 mL/min/1.73 m², progressive deterioration of kidney function, persistent proteinuria, biochemical or fluid retention problems or difficult diagnosis (to rule out non diabetic renal disease where fundus is normal and no proteinuria).
  - Rule out non-diabetic kidney disease in patients with early onset of nephropathy (<5 years), absence of retinopathy, heavy proteinuria, presence of active urinary sediments or unexplained rapid decline in eGFR.

<table>
<thead>
<tr>
<th>Limited Care</th>
</tr>
</thead>
</table>
| - Check annually for proteinuria in an early morning urine sample (or a random sample) using a dipstick. If test is positive exclude UTIs by microscopy (and culture if possible).
| - Measure serum creatinine and calculate eGFR annually.
| - A simple inexpensive screening procedure for urinary protein excretion which can be used as a diagnostic test in outpatient has been reported in Indian population. Estimated proteinuria is useful in serial evaluation of kidney function.
| - Manage those with proteinuria as follows:
| - Consider use of ACE inhibitors or ARBs and SGLT2 inhibitors unless contraindicated or issues with tolerability
| - Aim for BP ≤130/80 mm Hg using any BP lowering medication and control of salt intake [Table 13]
| - Aim to achieve targets for blood glucose control
| - Aim to improve lipid profile using available medications
| - Check proteinuria status annually
| - Measure serum creatinine and calculate eGFR annually

**Background**

Previously known as diabetic nephropathy, DKD is defined as diabetes with albuminuria (ratio of urine albumin-to-creatinine ≥30 mg/g), impaired glomerular filtration rate (<60 mL/min/1.73 m²), or both and is now recognised as the strongest predictor of mortality in patients with diabetes.[439] It is a leading cause of ESRD affecting ∼20–30% diabetes patients, and is associated with increased CV mortality.[440]

It affects 10–40% of T2DM patients who eventually suffer from kidney failure.[441,442] In the cross-sectional survey of Indian patients with T2DM in CINDI and CINDI2 studies diabetic nephropathy was prevalent in 1.06% and 0.9% patients respectively.[373,374] Cost of treatment for advanced CKD is substantial. Less than 10% of ESRD patients have access to any kind of renal replacement therapy.[443,444] Thus, in a country with limited resources, it becomes appropriate to direct efforts toward prevention of DKD rather than the treatment.

**Pathophysiology of diabetic kidney disease**

The pathophysiological mechanisms of DKD are complex and are often evident by intrarenal hypertension, compromised GFR and microalbuminuria. Microalbuminuria, is the first and most critical manifestation of diabetic nephropathy, which when progressed to overt albuminuria (increased albumin levels in the urine) indicates severe renal dysfunction culminating to renal failure.[445] The presence of microalbuminuria is a powerful marker of cardiovascular disease and all-cause mortality.[446] Thus, the presence of diabetes, particularly accompanied by microalbuminuria, is most often considered a warning signal for CV risks in patients with diabetes.
DKD is characterized by a constellation of histopathological changes beginning from glomerular hyperfiltration causing glomerular basement membrane thickening, progressive accumulation of extracellular matrix in glomerular mesangium and tubulointerstitium, causing mesangial expansion and Kimmelstiel–Wilson nodules (an aggregation of mesangial cells and mesangial matrix), arterial hyalinosis, and tubulointerstitial changes. Additionally, podocyte dropout is also a critical factor for DKD development. Podocytes are known to distort and change their size and shape to accommodate or cover the openings created by the basement membrane thickening causing them to shift or dropout.

In India, with increase in the prevalence of diabetes, it becomes imperative to evolve definite guidelines for detection of diabetic nephropathy and suggest practical clinical recommendations to combat it.

Improving glycaemic control, aggressive antihypertensive treatment, and the use of ACE inhibitors or ARBs will slow down the rate of progression of nephropathy. In addition, protein restriction and other treatment modalities such as phosphate lowering may have benefits in selected patients. A due consideration should be given to normoalbuminuric kidney disease in patients with T2DM. Although the serum creatinine is usually normal, most of the normoalbuminuric patients with DKD according to fact have an eGFR <60 mL/min/1.73 m² per the MDRD formula. However, as expected, because of normoalbuminuria and other favorable characteristics, their risk for DKD progression or death is lower.

**Rationale and Evidence**

**Identification and monitoring and diabetic kidney disease**

Persistent microalbuminuria is the earliest sign of diabetic nephropathy or DKD. The diagnostic reference standard for defining microalbuminuria is detection of 30 to 300 mg of albumin in a 24-h urine sample and is the first-line annual screening test for most persons with diabetes. It is recommended that once a screening test detects microalbuminuria, it should be confirmed with additional spot urine tests over the next three to six months. The Kidney Disease Outcomes Quality Initiative (KDOQI)-Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease by the National Kidney Foundation (NKF), recommend that patients with diabetes should be screened annually for DKD: 5 years after the diagnosis of type 1 diabetes and from onset/diagnosis of type 2 diabetes. The presence of albuminuria must be evaluated based on the UAE concentration or Urinary albumin-to-creatinine ratio (UACR) in untimed (spot) urine specimens and by estimating the glomerular filtration rate from serum creatinine measurements by using prediction equations. The ADA recommends identifying and monitoring DKD based upon assessments of kidney function with an estimated GFR (eGFR), 60 L/min/1.73 m², or kidney damage by estimation of albuminuria 30 mg/g creatinine along with annual screening for microalbuminuria. Clinical recommendation by the ADA for DKD screening also suggest that persons with type 1 or 2 diabetes and microalbuminuria should continue to be tested.
for albuminuria annually to monitor disease progression and response to therapy.[459]

- EPE is a method of estimating ACR in a random urine sample to assess renal function in patients with diabetes. EPE was found to be useful in serial evaluation of kidney function in Indian patients with diabetes.[456,457] Moreover, EPE is a simple and inexpensive screening procedure for urinary protein excretion, which can be used as a diagnostic test in outpatient wards, particularly in developing countries like India.

- As EPE is an inexpensive screening procedure to assess kidney function, the panel recommended it for use in Indian population who are at risk of diabetic nephropathy.

- Screening of microalbuminuria and estimation of glycated albumin can help in the clinical management of diabetic nephropathy.[458] Screening for albuminuria by measuring urine albumin concentration or estimating ACR is acceptable in Asian population.[459] However, evidence suggests that vigorous exercise even for short periods (15–20 min) leads to ACR above the microalbuminuria threshold even in healthy participants.[460,461]

- On the basis of evidence, the panel suggested that physicians should ask about recent vigorous exercise and avoid measuring urine albumin excretion for at least 24 h in the presence of same.

- Microalbuminuria shows a strong association with increased CVD risk in diabetic patients in Indian population.[462-464]

Management of hyperglycaemia in patients with diabetic kidney disease

In patients with DKD, when selecting and dosing glucose-lowering drugs, renal function has to be assessed and periodically monitored during treatment to detect changes that may affect drug metabolism and excretion. While mild renal insufficiency can be treated with most OADs, patients with DKD stage 3-5, most often require treatment adjustments according to the degree of renal insufficiency.

Combinations of therapies are available for the management of hyperglycaemia in patients with type 2 diabetes. Metformin is a first-line agent in all patients, including patients with DKD. Second generation sulphonylureas are also commonly used. Although, reduction in HbA1c is modest with an average between 0.5-1.0 %, DPP-4 inhibitors can be safely used at the appropriate dose in DKD. SGLT2 inhibitors and DPP-4 inhibitors are responsible choices in moderate to severe cases of DKD [Table 14].

Oral antidiabetics that exert renoprotection

- Evidence suggests that two oral hyperglycaemic agents DPP-4 inhibitors[465] and SGLT2 inhibitors, exert renoprotective effects in patients with diabetes. SGLT2 inhibitors are indicated to improve glycaemic control in adults with T2DM by reducing the reabsorption of filtered glucose. They can also lower the renal threshold for glucose, thereby increasing urinary glucose excretion.

- While these medications have been used safely in patients with Stage 3 CKD (eGFR down <30 mL/min), the glycaemic reduction response to the SGLT2 inhibitors declines with decreasing kidney function, as a decrease in eGFR results in a decrease in urinary glucose excretion.

- Canagliflozin has been approved for use in patients with eGFR>45 mL/min/1.73 m², with dose limited to 100 mg once daily in patients with eGFR 45≤60 mL/min/1.73 m². Empagliflozin can also be used in patients with an eGFR down to 45 mL/min/1.73 m², while dapagliflozin is approved in patients with an eGFR down ≥60 mL/min/1.73 m². Regular assessment of renal function is recommended with use of any of these SGLT2 inhibitors.

- Recently completed CREDiT study reported that at a median follow-up of 2.62 years, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group.[460] In the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program study, canagliflozin treatment was associated with a reduced risk of sustained loss of kidney function, attenuated eGFR decline, and a reduction in albuminuria. These encouraging results suggest that canagliflozin exerts renoprotective effect in patients with T2DM.[467]

- The EMPA-REG OUTCOME trial evaluated the non-inferior cardiovascular safety of empagliflozin in high-CV-risk T2D patients with an estimated glomerular filtration rate (eGFR) of at least 30 mL/min/1.73 m². Empagliflozin reduced the rate of new onset or worsening nephropathy, which were defined as new-onset microalbuminuria, doubling of creatinine, and eGFR ≤ 45 mL/min/1.73 m², initiation of renal replacement therapy, and death due to renal disease (hazard ratio [HR]: 0.61, 95% confidence interval [CI]: 0.53–0.70; p < 0.0001).[468]

- Results of the DECLARE–TIMI 58 cardiovascular outcomes trial suggest that, in patients with T2DM, Dapagliflozin prevented and reduce the progression of renal disease.[281]

Protein restriction

- IDF recommends limiting protein intake to 1 g/kg body weight daily among individuals with DKD, if they are found proteinuric. Similarly, ADA recommends protein intake should be 0.8 g/kg body weight/day in patients with DKD.[451] In the Indian context, the source of protein is mainly from vegetable and animal oils and daily protein intake should be 0.8 g/kg/body weight/day in patients with DKD. SGLT2 inhibitors and DPP-4 inhibitors are responsible choices in moderate to severe cases of DKD [Table 14].

Oral antidiabetics that exert renoprotection

- Evidence suggests that two oral hyperglycaemic agents DPP-4 inhibitors[465] and SGLT2 inhibitors, exert renoprotective effects in patients with diabetes. SGLT2 inhibitors are indicated to improve glycaemic control in adults with T2DM by reducing the reabsorption of filtered glucose. They can also lower the renal threshold for glucose, thereby increasing urinary glucose excretion.

- While these medications have been used safely in patients with Stage 3 CKD (eGFR down <30 mL/min), the glycaemic reduction response to the SGLT2 inhibitors declines with decreasing kidney function, as a decrease in eGFR results in a decrease in urinary glucose excretion.

- Canagliflozin has been approved for use in patients with eGFR>45 mL/min/1.73 m², with dose limited to 100 mg once daily in patients with eGFR 45≤60 mL/min/1.73 m². Empagliflozin can also be used in patients with an eGFR down to 45 mL/min/1.73 m², while dapagliflozin is approved in patients with an eGFR down ≥60 mL/min/1.73 m². Regular assessment of renal function is recommended with use of any of these SGLT2 inhibitors.

- Recently completed CREDiT study reported that at a median follow-up of 2.62 years, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group.[460] In the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program study, canagliflozin treatment was associated with a reduced risk of sustained loss of kidney function, attenuated eGFR decline, and a reduction in albuminuria. These encouraging results suggest that canagliflozin exerts renoprotective effect in patients with T2DM.[467]

- The EMPA-REG OUTCOME trial evaluated the non-inferior cardiovascular safety of empagliflozin in high-CV-risk T2D patients with an estimated glomerular filtration rate (eGFR) of at least 30 mL/min/1.73 m². Empagliflozin reduced the rate of new onset or worsening nephropathy, which were defined as new-onset microalbuminuria, doubling of creatinine, and eGFR ≤ 45 mL/min/1.73 m², initiation of renal replacement therapy, and death due to renal disease (hazard ratio [HR]: 0.61, 95% confidence interval [CI]: 0.53–0.70; p < 0.0001).[468]

- Results of the DECLARE–TIMI 58 cardiovascular outcomes trial suggest that, in patients with T2DM, Dapagliflozin prevented and reduce the progression of renal disease.[281]

Protein restriction

- IDF recommends limiting protein intake to 1 g/kg body weight daily among individuals with DKD, if they are found proteinuric. Similarly, ADA recommends protein intake should be 0.8 g/kg body weight/day in patients with DKD.[451] In the Indian context, the source of protein is mainly from vegetable and animal oils and daily protein consumption is about 0.6–0.8 g/kg body weight.[469] Furthermore, protein content in non-vegetarian diet was found to be higher when compared to the vegetarian diet.[470] In addition, evidence suggests that animal protein may aggravate the risk of diabetes.[471] Therefore the panel emphasized on protein restriction and avoiding extra protein intake, particularly in non-vegetarians with nephropathy.

Smoking

- Smoking is associated with hyperglycaemia, dyslipidemia and decline in GFR which leads to the progression of ESRD in patients with diabetes.[472,473] Smoking tends to induce albuminuria and abnormal renal function through formation of advanced glycated end products (AGEs), which are responsible for advanced vascular permeability and
kidney damage. A recent systematic review reported that consumption of ≥15 packs of cigarettes/year increases the risk of progression of DKD. Moreover, data from a recent study in India suggests that compared to non-smokers the prevalence of microalbuminuria in smokers was 4-fold higher.

- The panel opined that patients must be counselled against tobacco use and encouraged to quit smoking to reduce the risk of progression to ESRD.

### Referral to specialist
- The panel endorsed IDF recommendation on referral criteria; however, it was suggested that, most of the patients at this stage of diabetic nephropathy require a specialist care which may not be available at primary care or single physician centre. Hence, local diabetes specialists should refer the patient to specialist renal care centre/nephrologist. Likewise, nephrologists should refer patients to specialist renal care if the patient presents with the following condition:
  - eGFR < 30 mL/min/1.73 m²
  - progressive deterioration of kidney function
  - persistent proteinuria, biochemical or fluid retention problems or
  - difficulty in diagnosis (to rule out non diabetic renal disease where fundus is normal and proteinuria is not present).

#### Indian evidence
- Prevalence of microalbuminuria is strongly associated with age, DBP, HbA1c, FPG and duration of diabetes.
- A positive co-relation between urine albumin excretion rate and eGFR < 60 mL/min/1.73 m² was observed indicating that these two parameters provide a complimentary benefit in management of CKD.
- Vitamin D deficiency can have significant impact on albuminuria. Therefore supplementation with calcitriol should be considered in these patients as it has been shown to provide beneficial effects on microalbuminuria.

### IMPLEMENTATION
Management of DKD requires access to healthcare professional, laboratory for ACR and creatinine estimations, and availability of multiple blood-pressure-lowering medications in particular renin-angiotensin system blockers.

#### Table 13: Stratifying target blood pressure as per clinical condition

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADA 2019[451]</td>
<td>&lt;140/90 mmHg is recommended to decrease CVD mortality and slow down DKD progression. Lesser targets such as &lt;130/80 mmHg might be considered in individuals with albuminuria and at increased risk of CVD and CKD progression. While achieving &lt;130 mmHg SBP target, especially in old people, care should be taken to avoid DBP levels &lt;60-70 mmHg.</td>
</tr>
<tr>
<td>KDIGO 2012[452]</td>
<td>In DKD patients, not requiring dialysis, with UAE &lt;30 mg/day and office BP consistently below 140/90 mm Hg, a target of ≤130/80 mmHg is recommended. In DKD patients, not requiring dialysis, with UAE &gt;30 mg/day and office BP consistently &gt;130/80 mm Hg, a target of ≤130/80 mmHg is recommended.</td>
</tr>
</tbody>
</table>

Table 14: Dose adjustment for oral antidiabetics agents for patients with diabetic kidney disease

<table>
<thead>
<tr>
<th>Class</th>
<th>Dose adjustments</th>
</tr>
</thead>
</table>
| Metformin | Metformin can be used till to GFR 30.  
GFR ≥45-59: use caution with dose and follow renal function.  
GFR ≥30-44: max dose 1000 mg/day or use 50% dose reduction. Follow renal function every 3 months.  
GFR: <30: avoid use. |
Glimipiride: GFR <60: Use with caution; <30: Avoid use.  
Glyburide: Avoid use.  
Gliclazide-upto GFR 30: No dose adjustment; <30: Low dose preferred. |
| TZD | No dose adjustment. |
| Alpha-glucosidase inhibitors | Acarbose: Serum creatinine >2 mg/dL: Avoid use.  
Miglitol: GFR <25 or serum creatinine >2 mg/dL: Avoid use. |
| DPP-4 inhibitor | Sitagliptin: GFR≥50: 100 mg daily; GFR 30-49: 50 mg daily.  
GFR <30: 25 mg daily.  
Saxagliptin: GFR ≥50: 2.5 or 5 mg daily; GFR ≤50: 2.5 mg daily.  
Linagliptin: No dose adjustment.  
Alogliptin: GFR ≥60: 25 mg daily; GFR 30-59: 12.5 mg daily; GFR <30: 6.25 mg daily.  
Tenagliptin 20 mg/day - No dose adjustment. |
| SGLT2i | Canagliflozin: GFR 45–<60: Maximum dose 100 mg OD; GFR<45: avoid use.  
Dapagliflozin: GFR ≤40: Avoid use.  
Empagliflozin: GFR ≤45: Avoid use. |

GFR: Glomerular filtration rate, SU: Sulfonylureas, OD: Once daily, TZD: Thiazolidinedione, DPP-4: Dipeptidyl peptidase, SGLT2i: Sodium-glucose co-transporter 2 inhibitors
CHRONIC COMPLICATIONS 2: DIABETIC FOOT AND PERIPHERAL ARTERIAL DISEASE

Diabetic Foot

RECOMMENDATIONS

Recommended Care

- Assess feet of patients with diabetes at every visit for lesions requiring active treatment and for risk factors for ulcer and amputation:
  - History of previous foot ulceration or amputation, symptoms of peripheral arterial disease (PAD), physical or visual difficulty in self-care
  - Foot deformity (hammer or clawed toes, bone prominences), visual evidence of neuropathy (dry skin, dilated veins) or incipient ischemia, callus, nail deformity or damage. Patient footwear should also be assessed
  - Detection of neuropathy by 10 g Semmes Weinstein monofilament (or 128 Hz tuning fork); a biothesiometer (to assess vibration perception threshold) is an option for quantitative assessment (cut-off point for ulcer risk >25 volts) and non-traumatic pin-prick.
  - Palpation of foot pulses (dorsalis pedis and posterior tibial). Doppler ultrasound examination or ankle: brachial pressure (ABI) ratio (<0.9 for occlusive vascular disease) may be used where pulses are diminished to quantify the abnormality.

- Discuss the reasons for foot review with each patient with diabetes, as part of the foot-care educational process.

- Must emphasize to completely refrain from walking bare foot, including at visits to religious places.

- Timely screening and early detection of diabetic neuropathy may help in prevention of the progression to diabetic foot.

- Must emphasize to completely refrain from walking bare foot, including at visits to religious places.

- Classify and manage according to risk classification level based on findings of foot assessment:
  - Must emphasize to completely refrain from walking bare foot, including at visits to religious places.
  - Palpation of foot pulses (dorsalis pedis and posterior tibial). Doppler ultrasound examination or ankle: brachial pressure (ABI) ratio (<0.9 for occlusive vascular disease) may be used where pulses are diminished to quantify the abnormality.

- Agree upon a foot-care plan based on the findings of annual foot review with each person with diabetes. Assess and provide necessary foot-care education according to individual needs and risks of ulcer and amputation.

- Classify and manage according to risk classification level based on findings of foot assessment:
  - People with foot ulceration or infection require the following management:
    - Pressure off loading
    - Refer to multidisciplinary foot-care team within 24 h for:
      - Appropriate wound management, dressings and debridement as indicated
      - Infections should be classified as mild (superficial with minimal cellulitis), moderate (deeper than skin or more extensive cellulitis), or severe (accompanied by systemic signs of sepsis). Consideration of systemic antibiotic therapy (often longer term) for extensive cellulitis or bone infection as indicated.
      - First-line medications: generic penicillin, cephalosporins, macrolides, clindamycin and/or metronidazole, as indicated
      - Second-line medications: amino-quinolones co-amoxicillin, imipenem.
      - Probing to bone, radiology and scans, magnetic resonance imaging and biopsy where indicated for suspected osteomyelitis
      - Reduce weight bearing, relief of pressure (walking with crutches, rest) off loading and optimal pressure distribution (casting, if indicated)
      - Investigation and treatment (referral) for vascular insufficiency
    - Specialist therapeutic footwear and orthotic care (e. g. insoles) and individualized discussion of prevention of recurrence, when ulcer has healed
    - Optimal blood glucose control
    - Amputation should not be considered unless:
      - A detailed vascular evaluation has been performed by the vascular team
      - Ischemic rest pain cannot be managed by analgesia or revascularization
      - A life-threatening foot infection cannot be treated by other measures
      - A non-healing ulcer is accompanied by a higher burden of disease that would result in amputation.

Risk classification level

<table>
<thead>
<tr>
<th>Risk classification level</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>No added risk:</td>
<td>□ Provide structured foot-care education and annual review.</td>
</tr>
<tr>
<td>No risk factors; no previous history of foot ulcer or amputation</td>
<td></td>
</tr>
<tr>
<td>At risk:</td>
<td>□ Foot-care team to regularly review every 6 months.</td>
</tr>
<tr>
<td>One risk factor; no previous history of foot ulcer or amputation</td>
<td>□ At each review:</td>
</tr>
<tr>
<td></td>
<td>□ Inspect both feet - ensure provision of local management as indicated</td>
</tr>
<tr>
<td></td>
<td>□ Educate patient to wash feet daily (with careful drying, particularly between the toes), use emollients to lubricate dry skin, cut toe nails straight across, and avoid using chemical agents or plasters or any other technique to remove callus or corns</td>
</tr>
<tr>
<td></td>
<td>□ Evaluate footwear - provide appropriate advice</td>
</tr>
<tr>
<td></td>
<td>□ Enhance foot-care education</td>
</tr>
<tr>
<td>High risk:</td>
<td>□ Foot-care team to frequently review every 3-6 months.</td>
</tr>
<tr>
<td>≥2 risk factors; previous ulcer or amputation (very high risk)</td>
<td>□ Educate patient to self-monitor foot skin temperatures once per day to identify any early signs of foot inflammation to prevent a first or recurrent planter foot ulcer.</td>
</tr>
<tr>
<td></td>
<td>□ At each review:</td>
</tr>
<tr>
<td></td>
<td>□ Inspect both feet - ensure provision of local management as indicated</td>
</tr>
<tr>
<td></td>
<td>□ Evaluate footwear - provide advice and specialist insoles and shoes if indicated</td>
</tr>
<tr>
<td></td>
<td>□ Consider need for vascular assessment or referral, if indicated</td>
</tr>
<tr>
<td></td>
<td>□ Evaluate and ensure appropriate provision of intensified foot-care education</td>
</tr>
</tbody>
</table>
**Limited Care**

- Risk assessment and classification: Similar to ‘recommended care’ but with sensory assessment by 10 g monofilament or tuning fork, with or without non-traumatic disposable pin-prick only and peripheral circulation assessment by palpation of pedal pulses.
- NSS and NDS in T2DM population have been found to be a useful resource and an important bed-side tool in evaluating diabetic sensorimotor polyneuropathy.
- Classification of infection: Similar to ‘recommended care’ but antibiotic therapy would be with generic penicillin, quinolones, macrolides and/or metronidazole, given intravenously for deep tissue infections and adjusted by response or culture results.
- Vascular referral would be according to findings and local revascularization facilities.

**BACKGROUND**

Peripheral neuropathy, peripheral vascular disease (PVD), if occurs only in the arteries, it is called PAD, gait disorders, ischemia, foot ulcers, infections, gangrene, Charcot neuroarthropathy and lower extremity amputations are some of the lower limb complications observed in patients with diabetes. Lack of sanitation and hygiene, socio-cultural practices such as barefoot walking in doors and at religious places, walking on fire, a lack of awareness on the use of proper footwear and a dearth of foot care clinics, together with economic factors exacerbate diabetic foot complications in India.

**Diabetic foot ulcers and peripheral arterial disease**

In India, DFUs [Figure 10] affect 25% of total diabetic patients during their lifetime and is one of the most common reasons for hospitalization and amputation in patients. The cost of diabetic foot care in India is one of the highest in the world (~5.7 years of average annual income).

Neuropathy and PVD are important risk factors in diabetic foot infections that are a major cause of amputation and mortality amongst patients with diabetes. While the prevalence of neuropathy has been estimated to be ~15%, PVD prevalence varies across geographies. A lower prevalence has been reported among Indians compared to Western countries (13% versus 48%); a younger patient population, shorter lifespan of patients with diabetes, along with a lower proportion of smokers could be plausible reasons for this difference. Presence of PVD and claudication in patients with diabetes is an indication of PAD, which leads to a higher risk of cardiovascular mortality and morbidity.

Despite prevalence of PAD being estimated to be 50-60% amongst patients with DFU, appropriate and timely diagnosis of PAD [Figure 11] is still a major concern and a leading cause of amputation in patients with diabetes [Annexure 3].

**Charcot neuroarthropathy**

The Charcot neuroarthropathy is a major consequence of diabetic neuropathy that leads to bone deformities, subluxation and dislocation resulting in inflammation characterized by a reddish, hot, swollen foot: the Charcot foot. The classic “rocker-bottom” foot is an example of end-stage disease with severe fracture dislocation, collapse of the midfoot, dorsal dislocation of the metatarsals and plantar dislocation of the tarsal bones. The prevalence ranges from 0.4%-13% among patients with diabetes, with a mortality rate of 28%. Using X-ray and MRI, the detection rates increase to ~30% and 75%, respectively.

Diagnosis of Charcot foot is often delayed or missed and can lead to severe foot deformity, ulceration, infection and/or lower extremity amputation. Initial diagnosis includes testing for sensory neuropathy done using a 128-Hz tuning fork or a 10-g monofilament or by testing light-touch perception. Treatment is mostly conservative, with early treatment options being off-loading with total contact casting (TCC) and non-weight bearing in a cast or wheelchair until the acute inflammatory process subsides (may take weeks or months). A prefabricated orthosis device such as a Charcot Restraint Orthotic Walker (CROW) may also be used. Overall, the period of fixation depends on reduction of edema and a drop in skin temperature below 2°C compared to contralateral extremity. Late treatment requires reconstructive surgery to repair the deformity and obtain a plantar-grade foot. Off-loading using therapeutic footwear that off-loads the foot by at least 30% may be associated with lower risk of recurrence.

**Diabetic foot infections**

Compared to non-diabetics, patients with diabetes are more susceptible to infections due to their impaired inflammatory response, inferior wound healing owing to inadequate phagocytic clearance, increased oxidative stress and down regulation of different growth factors resulting in defective angiogenesis. The Infectious Diseases Society of America (IDSA) recommends that the antibiotic regimen in patients with diabetic foot infections should be based upon culture and susceptibility analysis. Additional therapies may include the use of antibiotic impregnated beads, application of negative pressure wound therapy (NPWT) and hyperbaric oxygen [Figure 12].

In 2014, The Society for Vascular Surgery (SVS) published the Threatened Limb Classification System [Figure 13], based on 3 major risk factors associated with limb amputation: Wound, Ischemia and Foot Infection (WIfI). Strategies aimed at preventing foot diseases are cost-effective and can even be cost-saving if increased education and efforts...
are focused on those patients with recognized risk factors for the development of foot problem. The management of diabetic foot disease may seem poorly defined by comparison with complications such as nephropathy, hyperlipidaemia and retinopathy, for which clear guidelines exist. A multidisciplinary team approach, particularly in specialized diabetic foot clinics, can reduce the burden of diabetic foot complications in developing countries like India. Patients not conforming to the foot care advice suffer and develop new problems and/or require surgical procedures. Present guideline focuses on the various mechanisms of managing diabetic foot disease.

**Considerations**

Identifying a diabetic patient at-risk of a foot ulcer is an important step in the timely management of future complications. The panel recommended IWGDF 2019\(^\text{[501]}\) risk stratification system for risk assessment and the corresponding frequency of foot screening and examination [Table 15].

The panel endorsed the IDF 2017 recommendations for diagnosis and management of diabetic foot complications. However, few of the recommendations were modified based on local factors such as limited resources and lack of quality assurance in laboratories, which were reviewed in an Indian context.
Detection and timely screening

- Vibration perception threshold (VPT) is considered as a gold standard for diagnosis of diabetic peripheral neuropathy. However, use of simple clinical scores such as NSS and diabetic neuropathy examination (DNE) scores were found to be simple and useful tools for the diagnosis of peripheral neuropathy in patients with diabetes.\[502,503\] Moreover, a good correlation between VPT score with tuning fork, monofilament and ankle reflex was found suggesting that simple bedside tests are useful in clinical practice, even in those subjects in whom foot care practices are not followed.\[504,505\]
- Using NSS and NDS in T2DM patients has been found to be a useful resource in evaluating diabetic sensorimotor polyneuropathy as an important bed side tool.\[411,506,507\]
- Graduated RydelSeiffer tuning fork has a high specificity and a fairly good sensitivity in the diagnosis of diabetic foot problems.\[508\]
- Tip-therm, a device which tests for temperature discrimination, was compared with two validated methods for detection of neuropathy-a monofilament and biothesiometry in a study comprising 910 diabetic patients. Tip-therm was found to be an inexpensive, highly sensitive and specific device for detection of diabetic neuropathy when compared with biothesiometry and a monofilament.\[509\]
- Evidence suggests that abnormal plantar foot pressure may exist in diabetic patients before there is evidence of neuropathy (determined by biothesiometry and monofilament tests). Podotrack, a novel, inexpensive method can be used as a screening test for abnormal plantar foot pressure in this patient population.\[510\]
- Gait variations and restrictions in subtalar and first metatarsophalangeal joint have been reported in cases of diabetic neuropathy even before the onset of foot deformity and could be used as an aid for early diagnosis.\[511\]
- ABI and tcPO2 may be used as predictors of ulcer healing and amputation, respectively; ABI = 0.6 was found to have 100% sensitivity and 70% specificity and tcPO2 = 22.5 was found to have 75% sensitivity and 100% specificity in predicting wound healing.\[512\]

Avoid walking bare foot

- Sociocultural practices like bare foot walking indoors and other religious places, use of improper footwear and lack of knowledge regarding foot-care are significant contributors of diabetic foot complications in India.\[484,488,513\] Therefore, the panel emphasized on educating patients on problems associated with walking bare foot and advice on the use of appropriate/therapeutic footwear, particularly those at high-risk to prevent the development of foot deformities and ulceration.\[514\]
- A questionnaire-based study evaluating the foot care knowledge and practices with foot complications in 300 Indian patients suggests that majority of these patients were not educated previously about foot care and walked indoors without foot wear. The study emphasized that poor knowledge of foot care and poor footwear practices are important risk factors for foot problems in diabetes and called for a joint effort from doctors and footwear industry to educate patients about foot care and improve their choice and selection of footwear so as to reduce foot problems.\[515\]

Management of diabetic foot complications

- MRI has emerged as the most accurate method of diagnosing bone infection, but bone biopsy for culture and histopathology remains the criterion standard.\[516\]
- Neuropathy increases the risk of amputation 1.7-fold; 12-fold if there is deformity and 36-fold if there is...
a history of previous ulceration. Antioxidants have been shown to be effective in the prevention and treatment of neuropathy. Recent evidence suggests that physiological antioxidants like alpha-lipoic acid, along with chromium and inositol may be beneficial in reducing glycaemic load and replenishing myoinositol stores, respectively.  

- A phase 3 multicentre study has provided evidence to support the safety and efficacy of rhEGF formulated gel; the gel healed diabetic foot ulcers faster than treatment with placebo.
- A peptide mimetic of the C-terminus of Cx43 (gapjunctional protein), alpha connexincarboxy-terminal (ACT1), when incorporated into the standard-of-care protocols, was found to be associated with a greater percentage of participants achieving 100% ulcer re-epithelization and a reduced median time-to-complete-ulcer closure.
- Imipenem was found to be the most potential antimicrobial against both Gram Positive Cocci and Gram Negative Bacilli. Among combination therapies, ceftime-tazobactum and cefoperazone-sulbactum were the most effective. Antimethicillin-resistant Staphylococcus aureus (MRSA) antimicrobials such as linezolid and vancomycin and anti-extended spectrum of beta-lactamase (ESBLs) like imipenem and meropenem can be given to patients producing MRSA or ESBL.

**Adjunctive treatment options**

- In a small study comprising 6 patients with DFU, hyperbaric oxygen therapy showed a positive effect in initiating ulcer healing compared to standard treatments like offloading, wound debridement and glucose control.

**Pressure off-loading**

- Pressure modulation commonly referred to as ‘off-loading’ is an important component in the management and treatment of diabetic foot ulcers. It involves mitigation of pressure at an area of high vertical or shear stress. Combining effective, easy to use off-loading devices such as total contact casts and removable cast walkers ensures patient compliance, heal foot ulcers and avert limb amputations.

- Mandakini off-loading device and Samadhan off-loading system were found to be most economical, easy to apply and effective methods to re-distribute the pressure in ulcerative areas.

- A recent systematic review and meta-analysis report that compared with standard dressing changes, negative-pressure wound therapy had a higher rate of complete healing of ulcers (RR: 1.48; 95% CI: 1.24, 1.76; p<0.001), shorter healing time (MD:-8.07; 95% CI:-13.70,-2.45; p=0.005), greater reduction in ulcer area (MD: 12.18; 95% CI: 8.50, 15.86; p<0.00001), greater reduction in ulcer depth (MD: 40.82; 95% CI: 35.97, 45.67; p<0.00001), fewer amputations (RR: 0.31; 95% CI: 0.15, 0.62; p=0.001) and no effect on the incidence of treatment-related adverse effects (RR, 1.12; 95% CI: 0.66, 1.89; p=0.68).

- The risk of amputation increases with increasing severity and location of the deformity and complexity/stage of Charcot neuroarthropathy, as per Roger’s Charcot foot classification system.

- Patients who use therapeutic footwear have demonstrated lower foot pressure, while those who use nontherapeutic footwear show an increased foot pressure, implying that therapeutic footwear is useful in reducing new ulceration and consequently the amputation rate in the diabetic population.

- Patients with diabetic peripheral neuropathy and/or prior foot ulcers report a higher incidence of falls compared to non-diabetics. Specialty off-loading devices, along with decreased sensorimotor function, musculoskeletal/neuromuscular deficits and pharmacological complications are implicated as reasons for this high incidence observed. Novel technological advancements, such as virtual reality proprioceptive training, may help in reducing the risk of such falls.

**IMPLEMENTATION**

Availability of basic equipment, appropriate protocols, structured records and recall systems need to be supported by appropriate training for professionals providing screening and management services. Standard care of diabetic foot complications [Annexure 4 and 5] includes maintaining adequate vascular supply, preventing and treating soft-tissue and bone infection, performing initial excisional debridement and maintenance debridement as inducted, adhering to high-quality off-loading. Liaison needs to be established with orthoptists, footwear suppliers and cast technicians. Multidisciplinary management programs should be initiated focusing on prevention, education, regular foot examinations, aggressive intervention and optimal use of therapeutic footwear.
DIABETES AND CARDIOVASCULAR DISEASES

RECOMMENDATIONS

Recommended Care

- Cardiovascular risk factors that should be assessed in all patients at diagnosis and annually including
  - Dyslipidemia
  - Hypertension
  - Smoking status
  - Family history of premature coronary disease
  - Presence of albuminuria
  - Body mass index (BMI) ≥25
  - Presence of hyperuricemia
- Current or previous CVD events, age, body weight, BP and pulse, of patients should be recorded during their first and subsequent visits
- UKPDS risk engine and QRISK3 are simple and effective tools for identifying and predicting CVD risks in patients with T2DM and should be recommended for identifying high risk individuals*
- Patients with diabetes and CVD risk should follow the ABC treatment goals**
  - A (HbA1c): <7%
  - B (BP): <130/80 mmHg
  - C (Cholesterol -LDL): <100 mg/dL
- All patients should be managed with lifestyle intervention including physical exercise and medical nutrition therapy
- Yoga has shown efficacy in improving the dyslipidemia state and lower BMI, in selected patients with T2DM.
- In high risk patients, low dose aspirin therapy should be administered along with lifestyle intervention
- Statins should be added to lifestyle intervention in all patients with CVD risk, if not contraindicated. The intensity can be modified or titrated according to patient’s CVD risk, age, side-effects, tolerability, LDL-C levels etc.
- Glycemic control with glucose lowering drugs that are proven to be CV safe and beneficial should be recommended to reduce CVD risk and complications in patients with T2DM. SGLT2 inhibitors and GLP-1 receptor agonists are approved by various regulatory authorities for CV risk reductions, apart from their glucose lowering ability.
- Weight control should be an important consideration, while choosing glucose lowering therapy in overweight/obese persons
- Pharmacological antihypertensive therapy with subsequent titration in addition to lifestyle therapy should be initiated in patients with confirmed office-based BP of >140/90 mmHg
- Pharmacological therapy for patients with diabetes and hypertension should comprise a regimen that includes ACE inhibitor/ARB, thiazide diuretics, calcium channel blockers, and selective β blockers. If one class is not tolerated, it should be substituted with other class; however, FDCs of different drug classes may be preferred in patients with diabetes to reduce CVD risks and complications
- ACE inhibitors are the drug of choice for diabetes, if not contraindicated; and ARBs may be used if ACE inhibitors are not tolerated
- Other medications for dyslipidemia (fibrates, ezetimibe, concentrated omega-3 fatty acids, PCSK9 inhibitors) can be considered in patients failing to reach targets with conventional lipid lowering medications

*The treatment target goals should be individualized according to age, risk and comorbidity. **Risk factor: Low-density lipoprotein (LDL)-cholesterol ≥100 mg/dL (2.6 mmol/L), high blood pressure (> 140/90 mmHg), smoking, overweight/obese, lack of physical activity

Limited Care

- Cardiovascular risk factors like albuminuria and hypertension should be assessed in all patients at diagnosis and annually
- Cardiovascular risk may be calculated by using different assessment tools for people with diabetes as recommended

BACKGROUND

Patients with T2DM are always at higher risk for several CVDs such as CAD, CHF, stroke, PAD, and cardiomyopathy. Furthermore, compared to patients without diabetes, T2DM patients have a considerably higher risk of CV morbidity and mortality.[533] In addition, the coexistence of risk factors like hypertension, dyslipidemia, obesity and smoking with T2DM may increase the burden and complications of CVD.[534] In India, CVD attributes to nearly 25% of all deaths. Furthermore, according to the Global Burden of Disease study, age-standardized CVD mortality rate was 272 per 100000 population in India, which was higher than the global average of 235 per 100000 population.[535] An Indian population-based study in 6198 patients with T2DM that evaluated the prevalence of CVD risk factors reported that, compared to participants with diabetes versus those without it, prevalence of hypertension was 73.1% (95% CI: 67.2 to 75.0) vs 26.5% (25.2 to 27.8), hypercholesterolemia was 41.4% (38.3 to 44.5) vs 14.7% (13.7 to 15.7), hypertriglyceridemia was 71.0% (68.1 to 73.8) vs 30.2% (28.8 to 31.5), low HDL-C was 78.5% (75.9 to 80.1) vs 37.1% (35.7 to 38.5), and incidence of smoking/smokeless tobacco use was 26.6% (23.8 to 29.4) vs 14.4% (13.4 to 15.4; p<0.001).[536] Several landmark studies have reported that patients with T2DM are at increased risk for several cardiovascular complications. A brief overview of the CINDI studies, INTEHEART and INTERSTROKE is presented in Table 16. [537,537,537,538]
Therefore, aggressive control of these risk factors may delay or reduce the incidence of CVDs in T2DM patients.

**Considerations**

When framing recommendations for diabetes and CV risk, following factors should be reviewed: hypertension, smoking, obesity, increased fasting insulin and IR, lifestyle intervention, atherogenic lipid profile (abnormal cholesterol, high triglycerides).

Primary prevention of CVDs aims at preventing patients from the event of CHD/CVD. This includes engaging in moderate physical activity, maintaining normal body weight, limiting alcohol consumption, reduction of sodium intake, maintaining adequate intake of potassium, and consumption of a diet rich in fruits, vegetables, and low-fat dairy products with less saturated and total fat. Secondary prevention of CVDs in patients with diabetes plans to reduce the mortality and morbidity and prevent the repeated CVD event. This comprises treatment with aspirin, β-blockers, ACE inhibitors and statin. The tertiary prevention intends at rehabilitation, preventing complications, and improving QoL. This can be achieved with some interventional surgical procedures. Quaternary prevention targets at preventing over diagnosis, over medicalization, over labelling and over treatment.

### Rationale and Evidence

**Identification**

Cardiovascular risk factors such as dyslipidemia, hypertension, smoking, high body-mass index (BMI), family history of premature coronary disease and the presence of albuminuria and hyperuricemia should be assessed at least annually in all patients with T2DM.[534,539,540] Even the CINDI and CINDI 2 studies in Indian population recommend screening of CV complications at the time of diagnosis.[373,374]

The following tools have been used by several physicians for assessment of the CVD risk in individuals with diabetes and CVD.

- QRISK3 Risk Score[541,542]
- UKPDS Risk Engine.[543]

Recently, the DISCOVER observational study (N=15,992) has been initiated to collect realworld data from 38 countries to understand patterns of T2DM care in patients who initiated a second-line glucose-lowering therapy. Data from several lower-middle and upper-middle income countries will be collected for the first time through DISCOVER. This might help in preparing informed clinical guidelines and prepare effective healthcare policies globally.[544]

<table>
<thead>
<tr>
<th>Study characteristic</th>
<th>CINDI (India, 2014)</th>
<th>CINDI 2 (India, 2016)</th>
<th>INTERHEART (Global, 2004)</th>
<th>INTERSTROKE (Global, 2016)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study population</td>
<td>4600 newly diagnosed patients with T2DM (men: 67%)</td>
<td>1500 newly detected young-onset diabetes patients (men: 74%)</td>
<td>15,152 cases with acute MI, 14,820 controls from 52 countries</td>
<td>13,447 cases (10,388 with ischemic stroke and 3059 intracerebral hemorrhage) and 13,472 controls from 32 countries (men: 59.6%)</td>
</tr>
<tr>
<td>Study objective</td>
<td>To assess patients for diabetic complications, hypertension, dyslipidemia, BMI, diagnosis of retinopathy, neuropathy and nephropathy</td>
<td>To evaluate patients for complications of diabetes and CV risk factors such as BMI, hypertension, dyslipidemia, and smoking</td>
<td>To assess relationship between smoking, history of hypertension or diabetes, WHR, dietary patterns, physical activity, consumption of alcohol, blood Apo, and psychosocial factors to MI Diabetes, along with smoking raised ApoB/ApoA1 ratio, history of hypertension, abdominal obesity, psychosocial factor, lack of daily consumption of fruits and vegetables regular alcohol consumption, and lack of regular physical activity were all significantly related to acute myocardial infarction (P&lt;0.001 for all risk factors and)</td>
<td>To assess relationship between stroke and its risk factors including hypertension, physical activity, ApoB/ApoA1 ratio, diet, WHR, psychosocial factors, current smoking, alcohol consumption and diabetes</td>
</tr>
<tr>
<td>Results overview</td>
<td>Hypertension, obesity and dyslipidemia were present in 23.3%, 26% and 27% patients, respectively</td>
<td>Hypertension, dyslipidemia, BMI &gt;23 kg/m², and smoking were present in 27.6%, 62.4%, 84.2 and 24% patients. Diabetic retinopathy, neuropathy, and nephropathy were seen in 5.1%, 13.2%, and 0.9%. Ischemic heart disease, PVD, and stroke were presented in 0.7%, 2%, and 0.1%. 95.33% needed statin therapy</td>
<td>Previous history of hypertension or BP of 140/90 mm Hg or higher, regular physical activity, WHR, psychosocial factors, smoking, cardiac causes, alcohol consumption and DM were all associated with stroke. Hypertension was more associated with intracerebral hemorrhage than with ischemic stroke, whereas current smoking, diabetes, Apo, and cardiac causes were more associated with ischemic stroke (P&lt;0.001)</td>
<td></td>
</tr>
</tbody>
</table>

**MANAGEMENT**

**Lifestyle intervention**

Early identification of metabolic syndromes such as AO, elevated BP, hypertriglyceridemia, reduced HDL cholesterol, borderline high-risk LDL cholesterol and IFG (110 to 126 mg/dL) and design interventions to reduce the CVD risks are the major goals of the primary prevention.[545] Furthermore, close monitoring and maintaining recommended targets for BP (130/80 mmHg), lipid control (LDL <100 mg/dL), and glycaemia (A1C <7%) is important for the prevention of CVD in patients with T2DM.[545,546] In addition, physical exercise, weight control, lifestyle modification with changing food habits, and cessation of smoking also prevents the CVD risk in T2DM patients.[545]

- **Diet:** In the PURE study (N=135,335), a diet rich in carbohydrates was shown to be associated with higher risk of total mortality. Surprisingly, both, total fat and individual fat type were not correlated with CVD, CVD-related mortality or MI. In fact, saturated fat had an inverse correlation to stroke.[547] Therefore, a high carbohydrate intake is a potent risk factor of CVD and mortality. Current nutritional recommendations for patients with T2DM propose restricting the total carbohydrate intake to ~45-50% of the total energy. Moreover, there is increased focus on the quality of carbohydrate intake, with an emphasis on including complex carbohydrates like brown rice and whole grain wheat into the diet.[548]

- **Substitution of dietary saturated fat with PUFAs is reported to be associated with improved CV outcomes.** Moreover, American Family Physicians (AFP) advocates that the Mediterranean diet can reduce CV mortality and the DASH eating plan is associated with a reduced risk of CHD.[549] Moreover, the following dietary adaptations can be made to lessen the development of CVDs in T2DM patients: reductions in caloric intake (by 500 kcal/day to 800 kcal/day), total fat intake (especially saturated fat) and food portion sizes, increased consumption of dietary fiber, and moderate alcohol use.[550]

- **Physical activity:** It is an independent and protective risk factor associated with reduced CV morbidity and mortality (OR, 0.86; p<0.0001), and physical inactivity accounts for 12.2% of the population-attributable risk for acute MI and 8% of CHD with an estimated 0.68 year reduction in life expectancy.[549] The exercise-based cardiac rehabilitation (CR) is the cornerstone for secondary prevention of CVD. CR is associated with a 13% and 26% lower all-cause and CVD mortality, respectively and a 31% reduction in hospital admissions at 12 months in patients with CHD.[549] Hence, AFP guidelines recommend that physical activity for adults should be at least 150 minutes of moderate-intensity aerobic activity per week, 75 minutes of vigorous-intensity aerobic activity per week, or an equivalent combination.[551]

- **Yoga:** A randomized parallel study in India compared efficacy of yoga in addition to OADs and reported a significant reduction in total cholesterol, triglycerides, LDL-C, and body weight in patients after yoga.[552] Furthermore, evidence suggests that yoga also helps in reducing the blood glucose levels.[553-555] Lipid levels,[555,554] body weight, and BP[554] in patients with T2DM.

- **Stress management:** Evidence state that psychosocial stress has an association with the etiology and pathogenesis of CVDs.[556] Most notably, the INTERHEART and INTERSTROKE studies report that psychological factors have a strong effect towards MI (OR: 2.67, PAR 32.5%, p<0.0001) and ischemic stroke (OR: 2.20, 1.78, 2.72; 17·4%, 13·1, 22·6) respectively.[537,538] In an RCT, cognitive behavioral therapy (CBT) had a 41% lower rate of fatal and non-fatal first recurrent CVD events (HR:0.59; 95% CI: 0.42,0.83; p=0.002), 45% fewer recurrent acute MI (HR: 0.55, 95% CI: 0.36, 0.85; p=0.007), and a non-significant 28% lower all-cause mortality (HR: 0.72, 95% CI: 0.40, 1.30; p=0.28) than the reference group after adjustment for other outcome-affecting variables during a mean 94 months of follow-up period.[557] Nonetheless, a recent Cochrane review did not find such associations of CVD events with the psychological interventions in CHD patients.[558]

**Pharmacological management**

- **Medical treatment with pharmacotherapies like aspirin, lipid lowering drugs and BP controlling agents improves survival, extends QoL, reduces the need for intervention procedures, such as angioplasty and coronary artery bypass graft surgery, and decreases the incidence of subsequent MI.[559]**

**Antiplatelet therapy**

- **Aspirin is widely used for secondary prevention of CVD however; its use in primary prevention is still controversial.[534] In the recent ASCEND study, aspirin use prevented serious vascular events in patients with diabetes with no evident cardiovascular disease at trial entry. However, these preventive benefits were counterbalanced with major bleeding hazards.[560] Furthermore, a meta-analysis demonstrated 35% reduction in MI among men (RR: 0.65; 95% CI: 0.51,0.82; p<0.01), but the results were not significant in women (RR: 0.90; 95% CI: 0.71, 1.14; p=0.37).[561] However, a systematic review including 10 RCTs reported no CVD benefit and trials with diabetes subgroup analyses also did not show any effect.[562] Similarly, a recent meta-analysis evaluated aspirin for primary prevention of CVD in patients with diabetes and reported no difference with respect to the risk of all-cause mortality (OR: 0.93, 95% CI: 0.81, 1.06), individual atherosclerotic events, bleeding, gastrointestinal bleeding, or hemorrhagic stroke rates compared to placebo.[563] Furthermore, a meta-analysis (n = 4000) by the Antithrombotic Trialists’ (ATT) collaborators showed...
that the effects of aspirin on major vascular events were similar for patients with or without diabetes: (RR: 0.88, 95% CI: 0.67, 1.15) and (RR: 0.87, 95% CI: 0.79, 0.96), respectively.\[564\]

- In patients with aspirin intolerance/allergy or patients at very high-risk for CVD, clopidogrel is recommended.\[534,565\] Evidence suggests that clopidogrel was significantly more effective than aspirin in secondary prevention of CVD in patients with diabetes.\[565\] Furthermore, dual antiplatelet therapy may be reasonable for up to a year after ACS.\[534\]

- A Cochrane systematic review demonstrated that use of clopidogrel plus aspirin was associated with a reduction in the risk of CV events and an increased risk of bleeding compared with aspirin alone. However, only in patients with acute non-ST coronary syndrome, benefits outweigh harms.\[566\]

**Lipid lowering agents**

- A high prevalence of lipid abnormality in patients with T2DM positions them at high risk category in the CVD risk stratifications. Elevated levels of atherogenic cholesterol (AC), generally measured as non HDL-C, plays a central role in CVD, especially among Asian Indians.\[567\]

- For management of dyslipidemia, the primary goal is to reduce LDL-C levels to <100 mg/dL by addition of drug therapy (statins) to maximal diet therapy. Furthermore, fibrates may be added if triglycerides remain >200 mg/dL in patients receiving statin therapy.\[559\] Statins reported a significant benefit in CV risk reduction and showed significant primary and secondary prevention of CVD/CAD deaths in patients with diabetes.\[568-570\]

- A recent meta-analysis investigating 4,351 diabetes patients reported that compared with placebo, standard-dose statin treatment resulted in a significant RRR of 15% in the occurrence of any major CV or cerebrovascular event (RR: 0.85, 95% CI: 0.79, 0.91). Compared with standard-dose statin treatment (simvastatin 20 mg, pravastatin 40 mg or atorvastatin 10 mg), intensive-dose statin (simvastatin 80 mg or atorvastatin 80 mg) treatment resulted in an additional 9% RRR.\[571\]

- Moreover, statins were reported to produce similar results in various studies in India.\[572,573\] Evidence advocates atorvastatin has negligible or no ability to increase HDL-C, which is the key feature in patients with diabetes. Thus, other statins should probably be preferred to atorvastatin in patients with diabetes/MS.\[574\]

- In addition ADA recommend that, either high intensity or moderate intensity statin therapy should be used together with lifestyle intervention according to patient age and ASCVD risk factors\[2,534\]. The details have been given in Annexure 6. The Lipid Association of India expert consensus statement 2016 revealed that statin therapy is highly effective in lowering NHDL-C, LDL-C, apolipoprotein B, and remnant cholesterol, besides being remarkably safe.\[575\] Recent evidence shows a clear CVD benefit of lowering LDL-C with ezetimibe on top of a statin in patients with T2DM.\[577\]

- Furthermore, in CHD/CHD risk-equivalent patients ezetimibe addition onto simvastatin, atorvastatin, or rosuvastatin provided greater LDL-C reductions and goal attainment than those who up-titrated these statin therapies.\[576\] The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study assessed the effect of fenofibrate on CV events in T2DM patients. Fenofibrate reduced total CV events, mainly due to fewer non-fatal MI and revascularizations but, did not significantly reduce the risk of coronary events such as CHD death or non-fatal MI.\[577\]

- Furthermore, USFDA states that the current evidence base is insufficient to support fibrates for CVD protection and that more trial evidence is needed.\[578\] Nonetheless, prescribing lipid-lowering agents in older people with T2DM (>85 years) requires special consideration because exposure to higher doses (or higher potency) might increase the risk of adverse effects instead of improving life expectancy.

- Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates degradation of LDL-receptors (LDLR). PCSK9 inhibitors, such as evolocumab and alirocumab, have been shown to enhance recirculation of LDLRs to the surface of hepatocyte cells and accelerate clearance of circulating LDL-C. PCSK9 inhibitors can prove to be a valuable treatment option for statin-intolerant patients.\[579\]

**Glucose lowering drugs**

- Intensive glycemic control with antidiabetic drugs [Table 1] reduces CV risk and complications in patients with T2DM. A meta-analysis including large, long-term prospective RCTs (such as the UKPDS, the prospective pioglitazone clinical trial in macrovascular events [PROActive], the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation [ADVANCE] trial, the Veterans Affairs Diabetes Trial [VADT] and the Action to Control Cardiovascular Risk in Diabetes [ACCORD] trial) report that intensive glycemic control was associated with 17% reduction in events of nonfatal MI (OR 0.83; 95% CI: 0.75–0.93), and a 15% reduction in events of CHD (OR, 0.85; 0.77–0.93); however the study did not find any significant effect on events of stroke (0.93, 0.81–1.06) or all-cause mortality (1.02, 0.87–1.19).\[275\]

- DPP4, dipeptidyl peptidase 4; GIP, gastric inhibitory polyepetide; GLP-1, glucagon-like peptide-1; SGLT2, sodium-glucose transport protein 2.

- In a meta-analysis of 301 clinical trials, the CVD risk of all glucose-lowering drugs including; metformin, sulphonylurea, thiazolidinedione, DPP4 inhibitor, AGI, SGLT2 inhibitors, GLP-1 analogue, meglitinides, and insulins, were evaluated. The results indicated that there were no significant differences in the association
between any of the nine glucose-lowering drugs alone or in combination and risk of CV mortality.\(^{[580]}\)

- Two SGLT2 inhibitors, empagliflozin and canagliflozin, were recently shown to provide CV benefits in patients with T2DM. Empagliflozin was reported to produce substantial reductions in CVD death (38%) and all-cause mortality (32%), as well as in hospitalization for HF (35%), as compared with standard-of-care in EMPA-REG OUTCOME trial.\(^{[205]}\) In the recently published CANVAS trial, canagliflozin significantly reduced the composite of death from CV causes, non-fatal MI, or nonfatal stroke (HR, 0.86; 95% CI, 0.75 to 0.97; \(p<0.001\) for non-inferiority; \(p=0.02\) for superiority) in T2DM patients with established CVD or at high risk for CV events.\(^{[207]}\)

- Similarly in LEADER trial, liraglutide 1.8 mg daily was associated with lower rates (patients of death from CV causes (4.7% vs. 6.0%), HR, 0.78; 95% CI: 0.66 to 0.93; \(p=0.007\) or any causes (8.2% vs 9.6%), HR, 0.85; 0.74 to 0.97; \(p=0.02\)) compared to placebo in patients with T2DM.\(^{[277]}\) Therefore, using these medications early in the course of management in high risk T2DM patients could provide potential benefits from looming CVDs.

- Furthermore, recently released top-line results from the, CAROLINA trial (NCT01243424) showed that linagliptin was comparable to glimepiride vis-à-vis their impact on CV morbidity and mortality in patients with T2DM, after a median follow-up of 6.3 years.\(^{[581]}\)

- In the SAVOR-TIMI 53 trial where patients were either randomized to saxagliptin or placebo, treatment with saxagliptin was associated with a 27% increased relative risk of hospitalization for heart failure in patients assigned to saxagliptin.\(^{[197]}\) The risk was highest in patients with elevated levels of natriuretic peptides, previous heart failure or chronic kidney disease.\(^{[582]}\)

- Except saxagliptin, other DPP-4 inhibitors are cardiovascular neutral and therefore safe for the heart.\(^{[583]}\)

- Major trials assessing the impact of glucose lowering agents in improving cardiovascular endpoints are schematically presented in Figure 14.

### Blood pressure lowering agents

- A tight control of BP with pharmacological therapy like ARBs, ACE inhibitors, or \(\beta\)-blockers, diuretics, and calcium channel blockers helps in minimizing CVD risks in patients with T2DM.\(^{[534]}\) Tight control of blood glucose decreases the risk of microvascular complications, whereas tight control of BP reduces both micro-and macrovascular complications.

- ADA, IDF and other organizations recommends a target BP of 130/80 mmHg in diabetes patients.\(^{[322,534]}\) Furthermore, patients with confirmed office-based BP \(>140/90\) mmHg in addition to lifestyle therapy should be initiated with pharmacological therapy to achieve BP goals.\(^{[534]}\)

- A meta-analysis including 147 RCTs involving 464,164 people report a significant reduction in risk of coronary events (20–25%) and stroke (30–45%) with all five BP lowering agents. However, calcium channel blockers had a greater preventive effect on stroke (RR 0.92, 95% CI: 0.85 to 0.98).\(^{[584]}\)

- Two meta-analyses and ACCORD study reported that intensive BP control was associated with a reduction of stroke event, albeit with greater adverse effects.\(^{[150,585,586]}\) In addition, in the ADVANCE trial, a fixed combination of perindopril and indapamide was associated with mean reduction in SBP of 5.6 mmHg and DBP of 2.2 mm of Hg after a mean of 4.3 years of follow-up in patients with T2DM. The relative risk of a major macrovascular or microvascular event was also reduced by 9%,\(^{[285]}\)

- Furthermore, some patients require a combination of two drugs in order to achieve a recommended BP target. Several Indian studies evaluated the efficacy of some FDCs: losartan 50 mg plus ramipril 2.5 mg vs each alone,\(^{[587]}\) metropolol extended release (XL) plus amlodipine vs losartan plus amlodipine,\(^{[588]}\) metropolol and amloidine,\(^{[689]}\) and reported that the FDCs were effective, safe and well-tolerated in patients with hypertension.

### Metabolic memory

Metabolic memory refers to the beneficial effects of early, intensive control of hyperglycemia, which can help reduce chronic complications of T2DM in later years. The STENO-2, EMPA-REG and LEADER trials have shown the positive effects of metabolic memory. Recent results of STENO-2 trial after 21 years follow-up reported that an intensive, multifactorial intervention including ACE inhibitors/ARBs demonstrated a median of 7.9 years of gain of life in patients with T2DM.\(^{[591,592]}\) The choice of individual agent for a person with diabetes may be influenced by a number of factors including their risk profile (CV, renal, end-organ damage), preferences, and previous experience of therapy, as well as costs.

### IMPLEMENTATION

Patients with diabetes and CVD risk should be assessed for complete lipid profile and BP measurement during their medical visits. Antiplatelet agents, lipid lowering therapies, and antihypertensive medications along with lifestyle interventions should be provided with individualization and preference of each patient. Structured annual assessment and record-keeping should be instituted.
Figure 14: Major trials assessing cardiovascular outcomes in patients with diabetes. 3-P: 3-point; 4-P: 4-point; 5-P: 5-point. DECLARE-TIMI 58: Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events; ESRD: End-stage renal disease; HARMONY Outcomes: Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus; PIONER 6: A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes; REWIND: Researching Cardiovascular Events With a Weekly Incretin in Diabetes; VERTIS CV: Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease. Adapted from Cefalu et al., 2018

Obesity and Type 2 Diabetes Mellitus

**Recommendations**

<table>
<thead>
<tr>
<th>Recommended Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>• The cut-off points for overweight and obesity in Indian T2DM patients are as follows:</td>
</tr>
<tr>
<td>† BMI 18-22.9 kg/m²: normal</td>
</tr>
<tr>
<td>† BMI 23-24.9 kg/m²: overweight</td>
</tr>
<tr>
<td>† BMI ≥25 kg/m²: generalized obesity</td>
</tr>
<tr>
<td>† Waist circumference (WC) ≥90 cm for men and ≥80 cm for women: abdominal obesity</td>
</tr>
<tr>
<td>• Criteria for metabolic syndrome is as follows:</td>
</tr>
<tr>
<td>† Abdominal or central obesity (WC ≥90 cm for men and ≥80 cm for women) plus</td>
</tr>
<tr>
<td>† Any 2 of the following four factors:</td>
</tr>
<tr>
<td>† Increased triglycerides (≥150 mg/dL or specific treatment)</td>
</tr>
<tr>
<td>† Reduced HDL cholesterol (men: &lt;40 mg/dL; Women: &lt;50 mg/dL or specific treatment)</td>
</tr>
<tr>
<td>† Increased blood pressure (systolic BP ≥130 or diastolic BP ≥85 mm Hg or treatment of previously diagnosed hypertension)</td>
</tr>
<tr>
<td>† Increased fasting plasma glucose (FPG ≥100 mg/dL or previously diagnosed T2DM)</td>
</tr>
<tr>
<td>• Maintaining healthy lifestyle is recommended for management of metabolic syndrome.</td>
</tr>
<tr>
<td>† Moderate calorie restriction (to achieve a 5%-10% loss in body weight)</td>
</tr>
<tr>
<td>† 150 mins/week of physical activity is recommended which includes aerobic activity, work related activity and muscle strengthening activity (to be increased to 300 mins/week if tolerated).</td>
</tr>
<tr>
<td>† Change in dietary composition (low-calorie diet)</td>
</tr>
<tr>
<td>† Combination of aerobic and resistance training exercise</td>
</tr>
<tr>
<td>† Change in behavioural pattern</td>
</tr>
<tr>
<td>• Pharmacotherapy for obese patients with T2DM should be considered in addition to lifestyle changes in those with BMI ≥25 kg/m²</td>
</tr>
<tr>
<td>† GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors may be preferred as add-ons to metformin in obese T2DM patients</td>
</tr>
</tbody>
</table>

Contd...
**Background**

Obesity is a highly prevalent metabolic disorder that is often associated with T2DM.\[^{134,593}\] For adults, WHO defines overweight as BMI of ≥25 kg/m² and obesity as BMI of ≥30 kg/m².\[^{594}\] However, WHO and International Obesity Task Force (IOTF) suggested BMI cut-offs of 23 and 25 kg/m² for Asian Indian adults for overweight and obesity, respectively.\[^{595,596}\] Furthermore, the World Health Organization Asia Pacific Guidelines defined generalized obesity (GO, BMI ≥25 kg/m²), AO (WC ≥90 cm for men and ≥80 cm for women) and combined obesity (CO, GO plus AO) for Asian population.\[^{595,597}\] In India, the prevalence of obesity is rising at an alarming rate, especially affecting urban population.\[^{134,598}\] The ICMR-INDIAB study currently report that 135, 153 and 107 million individuals in India will have GO, AO and CO, respectively in extrapolation to the whole country.\[^{597,599}\] Furthermore, female gender, hypertension, diabetes, higher socio-economic status, physical inactivity and urban residence were significantly associated with obesity in Indian populations. Indians are at increased predisposition to diabetes that has been attributed to the “Asian Indian Phenotype” characterized by lesser GO as measured by BMI and greater central body obesity and more truncal fat as shown by greater WC and WHR.\[^{44,134,600-603}\] Abdominal obesity contributes significantly to metabolic alterations such as IR, dysglycemia and dyslipidaemia.\[^{45,598,603-606}\] T2DM is closely linked to obesity, particularly adult weight gain, and is the main contributor to rising healthcare costs. Whilst it seldom develops with BMI <21 kg/m², most people with T2DM have a BMI ≥25 kg/m² and around 50% have a BMI ≥30 kg/m².\[^{607}\]

High consumption of sugars among children and adults in India may also have clinical significance in view of the high tendency for Indians to develop IR, abdominal adiposity, and hepatic steatosis, and the increasing “epidemic” of T2DM.\[^{107,132}\] Because Asians Indians tend to develop diabetes at a significantly lower BMI and WC than white Europeans, lower thresholds of BMI to define overweight (BMI: 23-24.9 kg/m²) and obesity (BMI ≥25 kg/m²) were proposed by IDF and National Institute of Health and Care Excellence (NICE).\[^{608,609}\]

In light of increasing prevalence of obesity in both developed and developing countries and a higher risk for developing IR, dyslipidemia, dysglycaemia and a higher CV risk at lower levels of BMI in Indians, a consensus meeting was convened in New Delhi in 2008\[^{610}\] to redefine the cut-offs for BMI and WC for diagnosing overweight and obesity in Indian population. According to this consensus statement, a BMI of 18-22.9 kg/m² should be considered as normal, a BMI of 23-24.9 kg/m² should be considered as overweight, and BMI ≥25 kg/m² indicates presence of obesity. The upper limit for WC for men and women was defined as 90 cm and 80 cm, respectively.\[^{598}\]

**Considerations**

The following local factors were considered when framing recommendations for obesity that were reviewed in Indian context: high prevalence of obesity, high abdominal adiposity, increased fasting insulin and IR, nutritional factors, atherogenic lipid profile [increased triglycerides and LDL and low HDL].\[^{610}\]

**Identification of obesity in type 2 diabetes mellitus**

- At first and each subsequent visit, patients with T2DM should be screened for presence of excess body weight using appropriate anthropometric measurements (BMI, WC, WHR) and should be classified as overweight or obese based on normal cut-off values recommended for Indian population.

- In Asian Indians, the BMI cut-off points to define overweight and obesity are lower than in other populations.\[^{610-612}\] Several investigators have shown that Asian Indians are more predisposed to develop insulin resistance and CVDs at lower levels of BMI as compared to other ethnic groups.\[^{613,614}\]

- Based on the current evidence, WC is preferred over WHR as a measure of abdominal obesity with Asian Indian specific cut-offs.\[^{610}\] Asian Indians appear to have higher morbidity at lower cut-offs for WC than the western population; ≥90 cm in men and ≥80 cm in women.\[^{604,610}\]

**Lifestyle intervention**

- Lifestyle interventions including diet therapy, physical activity, behavioural and psychosocial strategies have shown positive health outcomes in obese T2DM patients. The Diabetes Prevention Program (DPP)\[^{615}\] and the Look AHEAD (Action for Health in Diabetes) trial\[^{616}\] report clinically significant weight losses averaging 4-5% (or 4–5 kg) at 3–4 years with lifestyle intervention. Similarly, a RCT including Asian Indians report that lifestyle intervention with less education lost a model-predicted 3.30 kg more in weight and 4.95 cm
more in WC than those with more formal education.\[617]\n
- The lifestyle interventions for overweight or obese T2DM patients should be based on the principle of decreased energy intake and increased energy expenditure to produce the negative energy balance. This includes low-calorie diet with higher intake of fibre, lower intake of saturated fats, optimal ratio of essential fatty acids, reduction in trans fatty acids, slightly higher protein intake, lower intake of salt, and restricted intake of sugar.\[618]\n
  High-protein meal replacement diet-based intervention in overweight/obese Asian Indians has shown significant reduction in weight, abdominal obesity, blood pressure, lipids, glycaemic parameters and hepatic enzymes compared with a standard control diet in Indians.\[619]\n
  Although studies assessing the ideal amount of carbohydrate intake for people with diabetes are inconclusive, modifying carbohydrate intake considering the blood glucose response is of value, especially in the Indian context, where carbohydrate intakes across all regions of India could be very high.

- Behavioural therapy should address modifiable factors such as eating patterns and exercise habits that can have significant impact on the management of obesity. A review in Indian scenario suggested that slow eating techniques along with stimulus control (not distracted by television, books, or other materials) have positive effect on weight loss.\[619]\n
  In obese T2DM patients, IDF recommends not only moderate calorie restriction, but also moderate increase in physical activity as a part of behavioural therapy in order to promote weight loss (5–10% loss of body weight in the first year).\[620]\n
  Other important components of behavioural therapy embrace self-monitoring, goal setting and stimulus or cue control. Such strategies help in setting up realistic goals, guide patients in identifying stimulus that lead to excessive nutrient intake and eliminate them accordingly.\[621]\n
- Bodyweight has been shown to be inversely associated with physical activity.\[622]\n
  Patients with low physical activity have 3-fold greater risk of major weight gain in men and almost a 4-fold in women.\[623,624]\n
  Moreover, this association was stronger for women than for men and for obese compared to normal weight or overweight individuals.\[625]\n
  Furthermore, slow and prolonged exercise is associated with improved fat metabolism in muscle and better conservation of muscle mass during dietary restriction.\[626,627]\n
  An RCT comprising 262 sedentary men and women reported that combination of aerobic and resistance training exercise reduced WC from −1.9 to −2.8 cm and mean fat mass of −1.7 (−2.3 to −1.1 kg; p<0.05) compared with the non-exercise group.\[628]\n
  Physical activity, which includes aerobic activity, work-related activity and muscle strengthening activity should be prescribed at the individual, community and societal level to help Asian Indians become more physically active [Table 17]. As per the WHO, the recommended levels of physical activity for adults (18-64 years) for at least 150 minutes of moderate-intensity weekly or 75 minutes of vigorous-intensity aerobic physical activity weekly.\[629]\n
- In the Diabetes REmission Clinical Trial (DiRECT), 306 patients with T2DM, with BMI of 27-45 kg/m² and not receiving insulin were assessed for remission of T2DM during a primary care-led intensive weight management program. At 12 months, almost half of participants [68/149 (46%)] achieved remission versus 4% in the control group, to a non-diabetic state and were off antidiabetic drugs. At 24 months, 64% of those who had lost more than 10 kg, were still in remission \[630,631]\n
- The findings of the randomized controlled PREVIEW lifestyle intervention study reported that the total physical activity accounts for greater variance in IR and some related cardiometabolic risk factors as compared with moderate-to-vigorous physical activity. In adults with prediabetes, objectively measured physical activity and sedentary time have been found to have associated with cardiometabolic risk markers.\[632,633]\n
  Fixed low-energy diet has been shown to induce an overall 11% weight loss and showed significant improvements in insulin resistance; men appeared to benefit more than women.\[634]\n
  Therefore the panel suggests that prescribing a combination of aerobic and resistance training exercises in individuals with T2DM can improve metabolic control while reducing obesity and its related complications.

**Pharmacotherapy for obese type 2 diabetes mellitus**

- Though lifestyle modifications are effective in inducing weight loss and improving diabetic status, they often fail requiring initiation of pharmacotherapy. Metformin is the

---

**Table 17: Physical activity prescription for aerobic and muscle strengthening exercise**\[610]\n
<table>
<thead>
<tr>
<th>Type of physical activity</th>
<th>Moderate intensity modality</th>
<th>Duration</th>
<th>Frequency/ days per week</th>
<th>Vigorous intensity modality repetitions</th>
<th>Duration</th>
<th>Frequency/ days per week</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aerobic physical activity</td>
<td>Brisk walking, stair climbing, jogging (4-7 m/s), cycling, treadmill and swimming</td>
<td>30 min</td>
<td>5</td>
<td>Football, badminton, basketball, running, rope jumping, dancing</td>
<td>20 min</td>
<td>3</td>
</tr>
<tr>
<td>Muscle strengthening activity</td>
<td>Resistance weight training, curls, presses, anti-gravity exercise, isometric exercise, children-body weight activity (pull ups)</td>
<td>1-3 sets of 8-12 repetitions targeting major muscle groups</td>
<td>2-3</td>
<td>Resistance weight training, curls, presses, anti-gravity exercise, isometric exercise, children-body weight activity (pull ups)</td>
<td>&gt;3 sets of &gt;12 repetitions targeting major muscle groups</td>
<td>2-3</td>
</tr>
</tbody>
</table>
first choice drug with some evidence for weight loss.\textsuperscript{635,636} The DPP and Indian Diabetes Prevention Program (IDPP) trial report that metformin and lifestyle intervention greatly reduce the risk of T2DM in overweight or obese patients.\textsuperscript{637} Use of GLP-1receptor agonists,\textsuperscript{234} SGLT-2 inhibitors,\textsuperscript{255,638} and to some extents DPP-4 inhibitors\textsuperscript{257,258} have been shown to induce weight loss and should be considered as add-on to metformin in obese T2DM patients. Furthermore, GLOBE study report that fixed dose combination (FDC) of acarbose/metformin in Indian T2DM patients was associated with significant reduction in body weight (−1.7±2.2 kg compared to control (p<0.0001)).\textsuperscript{639} Current ADA recommendations suggest SGLT2 inhibitors and GLP-1 agonists as preferred add-on agents in addition to lifestyle interventions and metformin for diabetes patients with compelling indications for weight loss.\textsuperscript{231}

- Orlistat (tetrahydrolipstatin), a lipase inhibitor, is an approved agent for weight loss in India. It causes modest weight loss by blocking fat absorption from gut, and when used in combination with lifestyle changes was found to be effective in inducing weight loss as well as for prevention of diabetes.\textsuperscript{640} A recent systematic review and meta-analysis report that treatment with orlistat and lifestyle intervention resulted in significantly greater weight loss (p<0.001) and improved glycaemic control (p<0.001) in overweight and obese T2DM patients compared with lifestyle intervention alone.\textsuperscript{640}

- Lorcaserin, an FDA approved agent for weight loss, has been recently approved in India. Lorcaserin is a highly selective serotonin 2C receptor agonist and acts on proopiomelanocortin neurons to induce satiety. It has been shown to cause meaningful weight loss and prevent progression to T2DM in patients with obesity. In the BLOOM-DM study, treatment with lorcaserin was associated with significant weight loss (≥5% body weight) and improvement in glycaemic control in patients with T2DM.\textsuperscript{641} Results of the CAMELLIA-TIMI 61, CVOT with lorcaserin, suggested that durable weight loss observed with lorcaserin and lifestyle interventions was associated with significant reduction in the incidence of diabetes, improvement in the proportion of prediabetic patients not progressing to diabetes along with and significant reductions in the risk of a composite outcome for diabetic microvascular complications.\textsuperscript{642} There was no increase in 3 point MACE or extended MACE in patients treated with lorcaserin showing its CV safety. Lorcaserin facilitated the sustained weight loss without a higher rate of major cardiovascular events.\textsuperscript{643} However, the USFDA has issued a request to withdraw lorcaserin from the markets due to increased occurrence of cancer, based on a recent long-term safety study.\textsuperscript{644}

**Surgery**

- The surgical options for weight loss include LAGB and sleeve gastrectomy, RYGB, BPD, ileal interposition and duodenojejunal bypass, and various implantable pulse generators.\textsuperscript{640}

- Surgical treatment (bariatric surgery) is indicated in patients with BMI >32.5 kg/m\(^2\) with co-morbidity, or BMI >37.5 kg/m\(^2\) without co-morbidity; who fail to lose weight with medical management,\textsuperscript{640} although hard evidence for this is lacking. Evidence from several studies suggests that bariatric surgery provides durable glycaemic control compared with intensive medical therapy.\textsuperscript{645-648} Moreover, gastric bypass has been observed to uniquely restore the pancreatic β-cell function and reduce truncal fat, thus reversing the core defects in diabetes.\textsuperscript{645} In addition, a systematic review and meta-analysis of RCTs report that RYGB surgery is superior to medical treatment for short-to medium-term remission of T2DM, and improvement of metabolic condition and CV risk factors.\textsuperscript{649}

- Bariatric surgery is an effective option for severely obese patients with poorly controlled T2DM and weight loss due to gastric bypass surgery is associated with good glycaemic control. In patients who had undergone bariatric surgery, about 8% showed complete remission of diabetes while more than 90% showed a significant decrease in their insulin or OADs requirement.\textsuperscript{650}

- Laparoscopic sleeve surgery and RYBG was found to be safe and effective treatment option among obese Indian population with T2DM with significant remission rates (>95%, p<0.001), larger reductions in HbA1c, and diabetes medication usage.\textsuperscript{651-653}

**Medical devices for weight loss and weight management**

- Several minimally invasive medical devices have been recently approved by the FDA for short-term weight loss or management which can be used for obesity management in T2DM patients.\textsuperscript{654}

- At present, there are four types of FDA-regulated devices intended for weight-loss:
  - Gastric band which can be placed around the top portion of the stomach, thereby leaving a small portion available for food
  - Electrical stimulation systems block nerve activity between the brain and stomach using electrical stimulators which are placed in the abdomen
  - Gastric balloon systems act by delay gastric emptying using inflatable balloons which are placed in the stomach to utilize space.
  - Gastric emptying systems drain food after eating with the help of a tube that is inserted between the stomach and outside of abdomen.
There are two types of FDA-regulated devices intended for weight-loss:

- Oral removable palatal space occupying device which is worn during meals to limit bite size and the ingested, transient, space occupying device—an ingested material that transiently occupies space in the stomach
- However, high cost, extremely limited insurance coverage, and paucity of data limit their use.\(^{[655]}\)

**Obesity and type 2 diabetes mellitus: increased risk of cancer**

- Individuals with obesity and T2DM are at greater risk of developing multiple cancers including breast, prostate, colorectal, gastric, pancreatic, hepatic.\(^{[656]}\) There are multiple potential metabolic abnormalities that occur in obesity and T2DM that may explain the increased risk of cancer and cancer-related mortality in these patients.\(^{[657,659]}\)

- Currently, there are no specific guidelines for cancer screening in patients with obesity and T2DM, despite their higher risk of cancer. Further studies should be performed to determine whether specific screening strategies to target this population would lead to a decrease in their cancer mortality. Till further evidence, a high index of suspicion should be maintained.

### Infections and Vaccinations

#### Recommendations

<table>
<thead>
<tr>
<th>Recommended Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>• All diabetes subjects should be educated about administering at least pneumococcal and influenza vaccine.</td>
</tr>
<tr>
<td>• Vaccination against pneumococcal disease, including pneumococcal pneumonia, with 13-valent pneumococcal conjugate vaccine (PCV13) is recommended for children before age 2 years.</td>
</tr>
<tr>
<td>• People with diabetes aged 2 through 64 years should receive 23-valent pneumococcal polysaccharide vaccine (PPSV23). At age ≥65 years, regardless of vaccination history, additional PPSV23 vaccination is necessary.</td>
</tr>
<tr>
<td>• Annual vaccination against influenza is recommended for all people ≥6 months of age, especially those with diabetes.</td>
</tr>
<tr>
<td>- Quadrivalent influenza vaccine should be preferred.</td>
</tr>
<tr>
<td>• Vaccination is contraindicated/postponed in patients with:</td>
</tr>
<tr>
<td>- hypersensitivity to the active substances or to any of the excipients of the vaccine</td>
</tr>
<tr>
<td>- history of chicken egg allergy particularly when considering flu shot</td>
</tr>
<tr>
<td>- recent history of Guillain-Barre syndrome within six weeks of a previous influenza vaccination in the case of flu shot</td>
</tr>
<tr>
<td>- postponed in patients with febrile illness or any acute infection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Limited Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>The principles for infections and vaccinations during diabetes are as for recommended care subject to availability and affordability of pneumococcal and influenza vaccines.</td>
</tr>
</tbody>
</table>

#### Background

The risk of developing infectious diseases due to diabetes is now being considered an important complication of diabetes.\(^{[1,2]}\) Diabetes increases the risk of infection by two to three times in comparison to the non-diabetic population. The morbidity and mortality associated with infectious diseases such as influenza, pneumonia and hepatitis, which is usually preventable by appropriate vaccination, also appears to be very high in diabetes subjects.\(^{[3]}\) Patients with T2DM, especially those with PVD, are at high risk for many types of typical and atypical infections due to immune dysfunction, DN and poor circulation.\(^{[4]}\) Furthermore, skin breakdown in patients with advanced diabetes and PVD provides a portal of entry for bacteria. Longer duration of diabetes and poor glycaemic control causes increased risk of pneumonia related hospitalizations in diabetes subjects due to compromised immune system of the host.\(^{[5]}\) A recent study demonstrated that patients with high blood glucose level are at increased risk of community-acquired pneumonia.\(^{[6,7]}\) Even certain viral infections can lead to new onset of diabetes in the population who are genetically prone to develop diabetes.

#### Considerations

The decision about conducting a screening program should be based on local factors such as limited resources and high prevalence of diabetes related infections factors that were reviewed in Indian context.

#### Rationale and Evidence

**Infections in diabetes**

- Several factors have been implicated for infections in diabetes, of which, altered immunity is the most predominant one.\(^{[4,8]}\) Other predisposing factors
increasing susceptibility to infections include diabetes related complications, frequent catheterization and dialysis in chronic renal failure patients. Evidence that these immunological defects can be corrected through good glycaemic control support the importance of close monitoring of infectious diseases in subjects with diabetes.[9] • Urinary tract, respiratory tract, foot and deep soft infections are most common in T2DM occurring with increased incidence and resulting in high mortality.[10,11] • Following section deals with evidences from Indian and global studies on infections that commonly occur in patients with diabetes
  ▫ Influenza: Diabetes increases the risk of hospitalization after influenza infection and quadruples the risk of intensive care unit (ICU) admission after hospitalization.[12] Death rates among patients with diabetes during influenza epidemics may increase up to 5–15%.[13] Evidence that influenza can trigger coronary complications, when taken in the context of diabetes subjects, gains more significance since the risk for CVD is already 2-to 4-fold higher in this sub group.[11,14] • Retroviral infections: Cirrhosis of liver in diabetes patients results in higher incidence of glucose intolerance (60–96%) and overt diabetes (20–60%).[1] Elevated rates of inflammation and endothelial cell dysfunction are observed in human immuno-deficiency virus (HIV) infected patients with T2DM.[15] Moreover, in HIV patients undergoing active retroviral therapy, autoimmune diabetes may be caused due to protein inhibitors and nucleoside analogues. Therefore, in HIV patients with compensated cirrhosis and high IR, insulin should be the preferred choice of treatment.[1] • Malignant otitis externa: Commonly occurs in patients with diabetes and is mostly caused by Pseudomonas aeruginosa.[16] It can be prevented by creating proper awareness regarding healthy ear cleaning practices like, not using commercially available ear buds and other foreign objects or unsterilized cotton. Management protocol comprises of strict glycemic control, correction of electrolyte imbalance, improvement in immuno-competence, aural toileting, hyperbaric oxygen therapy and prolonged systemic and ototopic antimicrobial therapy (3–6 weeks) with agents such as piperacillin with tazobactam, ciprofloxacin and cefoperazone.[16] • Infections of hand and upper limb: Diabetes ulcers in the upper limb should be promptly treated with adequate surgical means in order to prevent spreading of infection. Creating awareness on healthy cleaning practices minimizes disability and result in better outcome.[17] • UTIs: These, mostly asymptomatic bacterial infections, occur more frequently in female diabetes patients. In all hospitalized diabetes patients it is recommended to perform urine culture to detect presence of bacteriuria, a condition leading to an unexplained worsening of the glycaemic control in some patients.[18] • Hepatitis: It has been observed that several patients with underlying diabetes suffer from prolonged or complicated course of acute viral hepatitis. It is possible that with impaired hepatocyte regenerating capacity, these patients run a more prolonged and complicated course. In diabetes population, hepatitis B and C produces more comorbidities and prolonged infections. • Even though hepatitis B virus (HBV) itself may not cause diabetes directly, cirrhosis derived from HBV infection poses two fold higher risk for T2DM.[19] Infection due to HBV may occur during monitoring of blood glucose and other procedures involving multi-patient use of finger stick devices designed for single-patient use and inadequate disinfection and cleaning of blood glucose monitors between patients.[20] • When hepatitis C virus (HCV) infection occurs in diabetes patients, the chronicity as well as risk of infections further increases. In a meta-analysis of 22 studies, it was found that patients with T2DM were at higher risk for acquiring HCV than non T2DM patients (OR: 53.50, 95% CI: 52.54, 54.82).[21] • Hepatitis A is the most common vaccine-preventable virus acquired during travel and it is highly prevalent in the Indian subcontinent. Protection with hepatitis A vaccination is proven to last at least 15 years.[22] • Tuberculosis: Because diabetes impairs host defense mechanism, it has long been known to be a risk factor for active tuberculosis (TB) and reactivation of latent TB.[23] Evidence suggests that the risk of developing TB is increased among patients with diabetes, particularly during the first year after diagnosis of diabetes.[24] Furthermore, it is associated with worse treatment outcomes, higher rates of relapse and higher mortality rates in patients affected by both diseases. It is estimated that 15% of TB cases globally could be attributed to diabetes and 40% of these cases are from India and China.[25] Moreover, in developing Asian countries prevalence of TB among diabetes patients was 1.8–9.5 times higher than in the general population.[25] The situation is particularly challenging in low-income and middle-income countries where TB is endemic.
Data from a systematic review of 13 observational studies indicate that efforts to diagnose, detect, and treat diabetes early may have a beneficial impact on TB control.[36]

**Types of vaccines**
Various types of vaccinations recommended to prevent these infections are:

- **Pneumococcal vaccination**: Two pneumococcal vaccines are available: PPSV23 and PCV13. Secondary immune response after PCV13 immunization is higher, whereas response is lower after immunization with PPSV23 vaccine.[37]
- **The panel recommends the use of PCV13 for adults’ ≥50 years followed by a dose of PPSV23 at least 1 year later (and at least 5 years after their previous PPSV23 dose) depending on the clinical judgement of the physician. These recommendations are in line with the guidelines from the ADA 2017, and are also in synergy with the guidelines released recently by the Indian Society of Nephrology 2016, Indian Academy of Allergy 2017, and the Geriatric Society of India 2015.[26-31]
- **PCV13 is available for vaccination of older adults and must be considered an important step for vaccinating older diabetes patients with age of ≥50 years. PPSV23 may be offered to immune-compromised patients with diabetes for additional coverage after PCV13. Repeated vaccination with PPSV23 must be avoided to prevent hypo-responsiveness. Clinical judgment in relation to individual subjects should be relied upon before these recommendations are put into practice.**
- **Influenza vaccination**: In all patients with T2DM with age ≥6 months, excluding those who are allergic to eggs, influenza vaccine is recommended.[32,33] Influenza vaccination among diabetes patients reduced hospital admissions by 79% in two influenza epidemics in England.[34]
- **HBV**: To all unvaccinated patients with diabetes of age 19–59 years, 3 dose series of HBV is recommended.[33] In unvaccinated patients with ≥60 years of age, three dose series vaccine could be considered.[33]
- **Apart from the vaccines mentioned above, other routinely recommended, age-related vaccines should also be provided to all diabetes patients.**
- **Annexure 7 provides brief information on recommended vaccines for patients with diabetes.**

**Methods to improve rate of vaccination**

- **Despite the importance of vaccination in diabetes patients, vaccination rates are low in them. In a survey on 307 diabetes patients in Singapore, only 30.6% of patients were found to be vaccinated with influenza vaccine.**[35] Another cross-sectional survey on 279 diabetes patients in Spain determined the vaccination rates for seasonal influenza, pneumococcus and hepatitis B as 40%, 2% and 2% respectively.[36] A survey on 274 elderly people in Turkey revealed that the proportion of diabetes patients vaccinated for influenza or pneumococcus or tetanus as 38.1%, 13.4% and 9.28% respectively.[37]
- **Perception, knowledge, and misconception that vaccines are infective and cause side effects are some of the barriers for avoiding vaccination.**[35,36]
- **Maintaining a diabetes registry, systemic tracking system, and reminder system serve as tools for improvising the acceptance to vaccination and communicating with the subjects for the need of vaccination which provides awareness on immunization.**[36,38] The combined used of patient outreach letters, special immunization clinics, standing orders, and practitioner reminders on medical records resulted in a remarkable 15 fold increase in pneumococcal vaccinations in diabetes patients in Guam, United States.[39] Similarly, a combination of strategies including dissemination of guidelines, advice on setting up disease and vaccine registers, call and recall systems and benchmarking of performance remarkably improved influenza and pneumococcal vaccination rates in high-risk individual groups including diabetes patients in the United Kingdom.[40] Periodic training of the staff accompanied by ongoing assessment of immunization rates and work flow and also a close follow up with the patient or his care giver by the treatment team is beneficial in minimizing the risk of inappropriate re-vaccinations.[41]
- **The protocols should also aim at implementing a quality assurance process so that the standards of care are maintained.**[42]

**IMPLEMENTATION**

Apart from the micro-and macro-vascular events in diabetes, infections due to influenza and pneumococci should be considered as significant public health concern. All clinics providing vaccinations shall maintain the records to assess the efficacy of vaccines regarding occurrence of various complications in vaccinated individuals compared to non-vaccinated subjects. Vaccination strategies in diabetes should evolve as part of routine care and a central registry need to be maintained.
Chawla, et al.: RSSDI-ESI clinical practice recommendations

**SEXUAL DYSFUNCTION**

### Recommendations

#### Recommended Care

- A detailed history and examination should be conducted in an unintimidating private setting with structured interviews by encouraging discussion regarding sexual concerns in both men and women with diabetes.
- Appropriate language considering the patient’s age and culture should be used to make the patient comfortable.
- Psychological and social disturbances if any, should be discussed in an empathetic manner.
- Promotion of lifestyle changes to reduce the associated risk factors should be encouraged in patients with diabetes of both sexes.

**Men**

- Adult men with diabetes should be screened with a detailed sexual function history for ED as early as when they are diagnosed with diabetes.
- Detection of ED and evaluation of the response to treatment should be performed by validated questionnaires such as IIEF or Sexual Health Inventory for men.
- PDE-5 inhibitors may be offered as a first-line therapy for the treatment of ED in men with diabetes as they improve the quality of life of the patients and are associated with low side-effects.
- Symptoms of hypogonadism including lack of interest in sex and ED should be investigated further with a screening for serum testosterone concentration in the morning. Testosterone replacement may be beneficial in men with diabetes with symptomatic hypogonadism.

**Women**

- To identify whether a diabetic woman has sexual dysfunction, eliciting a detailed history in a compassionate manner and examination is the first step.
- Several self-reported validated questionnaires such as Female Sexual Function Index, the Female Sexual Distress Scale, the Brief Index of Sexual Functioning for Women, and the Derogatis Interview for Sexual Function have been developed to assess FSD.
- Currently, the therapeutic recommendations for FSD include maintaining a healthy lifestyle, achieving an optimal glycemic control, genitourinary infection control, resolving psychosocial issues.
- Treatment with water-based vaginal lubricants, hormone replacement therapy, clitoral therapy device, genital infection control therapy are recommended.
- Treatment strategies with dehydroepiandrosterone supplementation, estrogen or androgen replacement, flibanserin (serotonin 2A receptor antagonist) and PDE-5 inhibitors are investigated, however, currently there is limited evidence for their use.

#### Limited Care

- Adult men with diabetes should be screened with a detailed sexual function history for ED, as early as when they are diagnosed with diabetes.
- Symptoms of hypogonadism including lack of interest in sex and ED should be investigated further with a screening for serum testosterone concentration in the morning.
- Promotion of lifestyle changes to reduce the associated risk factors should be encouraged in men with diabetes and SD
- To identify whether a woman with diabetes has sexual dysfunction, a detailed history and examination is the first step.
- Currently, the therapeutic recommendations for FSD include maintaining a healthy lifestyle, achieving an optimal glycemic control, genitourinary infection control, resolving psychosocial issues.

### Background

Diabetes ensued vasculopathy and neuropathy has been associated with dysfunction of normal sexual function leading to psychosocial disruption and decreased quality of life in both men and women. Sexual dysfunction (SD) in diabetics is a neglected aspect in India, primarily due to minimal communication time between physician and patient, lack of privacy during doctor visits and the taboo factor. In men with diabetes, erectile dysfunction (ED) as a result of autonomic neuropathy is commonly observed and the prevalence odds as compared with controls is more than 3.5 times. In a study conducted in a hospital in New Delhi, Sondhi et al. observed the prevalence of ED to be 78.7% in men with T2DM versus 46% in non-diabetics and a significant correlation between duration of diabetes and ED. Furthermore, the Massachusetts male aging study demonstrated that the risk of ED is double in aged diabetics versus the general population. Diabetic neuropathy, impaired relaxation of cavernosal smooth muscle due to altered cyclic guanosine monophosphate/nitric oxide pathway and risk of decreased testosterone levels resulting from hypogonadism can constitute the underlying pathology of ED. Other sexual complications in men with diabetes include ejaculatory dysfunction and hypogonadism. The recent ADA guideline recommends testing for serum testosterone concentration in men with diabetes who have symptoms of hypogonadism.

Compared with men, SD in women with diabetes is rarely investigated and most often untreated. Particularly in countries like India where gender inequality and cultural disparity is high, management strategies for tackling such health concerns are almost nonexistent. However, the findings of a meta-analysis showed that the risk of female sexual dysfunction (FSD) was two times higher (OR [95%CI], 2.02 [1.49, 2.72]) and correlated with a low Female Sexual Function Index (FSFI) score in women with diabetes as compared with nondiabetics. FSD is an intricate condition...
involving both physiological and psychosocial changes and includes hypoactive sexual desire disorder, arousal and lubrication disorder, pain during sexual intercourse, and loss of ability to achieve orgasm. Hypoglycemia decreases the hydration of the vaginal mucosa and lubrication of the vagina, and is the cause of genitourinary infections and dyspareunia. The vascular complications and endothelial dysfunction may impact blood supply to clitoris and lead to poor lubrication of the vagina, and reduced arousal and dyspareunia. Diabetic neuropathy may cause structural and functional changes in the female genitalia and can disrupt the balance between receiving sexual stimuli and sexual response triggers. Hormonal imbalances in levels of estrogen and androgens can lead to FSD in women with diabetes. In a study from North India conducted in women with diabetes it was observed that 45.19% complained of desire disorder, 62.71% of arousal disorder, 84.75% of orgasmic disorder and 20.38% experienced pain disorder; the incidence of these disorder was higher in older women.

**Considerations**

Gender, glycaemic control, comorbidities, lifestyle management and knowledge of sexual disorders and its management, cultural environment, psychological disorders and counselling should be considered when framing these recommendation for sexual dysfunction in patients with diabetes.

**Rationale and Evidence**

**Men**

- Longer duration of diabetes is considered a risk for ED.
- Commonly associated comorbidities of diabetes including metabolic syndrome, obesity, hyperlipidemia, hypertension and autonomic neuropathy are also considered as risk factors of ED.
- Anti-hypertensives, anti-depressants and fibrates are frequent concomitant medications consumed by diabetics and these are associated with increased risks of ED.
- A significant association between ED and cardiovascular events, all-cause mortality, CHD and stroke has been reported in several studies. Meena et al. observed an increased cardiovascular risk in patients with T2DM and ED without overt cardiovascular disease (CVD) in comparison to patients without ED (34.87 ± 18.82 vs 20.91 ± 11.03 p = 0.002).
- Below normal testosterone concentrations and higher rates of hypogonadism has been reported in men with diabetes as compared with the general population. Testosterone regulates the normal erectile functioning and evidence from studies suggests use of testosterone replacement in patients with diabetes and symptomatic hypogonadism. In a cross-sectional study conducted in India, the prevalence of hypogonadism was found to be 20.7% in T2DM patients.
- Men with hypogonadism do not respond optimally to phosphodiesterase type (PDE)-5 inhibitors and in such patients testosterone replacement was observed to be effective in 50% patients.
- Whether glicemic control has any effect on reduction of ED risk is unclear as studies have shown contrasting results. However, intensive lifestyle changes ameliorated worsening of ED and has shown an improvement in the overall International Index of Erectile Function (IIEF) score in overweight men with diabetes as compared with controls in the LOOK AHEAD study.
- Men with T2DM and severe ED were found to have poor glicemic control, longer duration of untreated diabetes, later age of onset and poor quality of life.

**Women**

- Diabetes-induced neuropathy and vascular dysfunction may be mainly responsible for the FSD and the low Female Sexual Function Index may be associated with BMI.
- Higher risk of FSD was observed in premenopausal as compared with postmenopausal women with diabetes.
- The risk factors associated with FSD include age, obesity, dyslipidemia, CVD, complications of diabetes, depression and marital status.
- Based on the current evidence a clear correlation between FSD and CVD has not been established unlike in men with diabetes.
- In women, psychological and psychosocial factors contribute to FSD more than in men.

**Implementation**

- Normal sexual function is essential for the holistic well-being of an individual. Diabetes with its ever increasing prevalence is a cause of sexual dysfunction in both men and women. The vascular and neurological complications induced by diabetes constitute the underlying pathogenesis of these sexual dysfunctions. Association of diabetes with obesity, metabolic syndrome, hypertension, dyslipidemia and CVD are considered as risk factors for ED. The diagnosis of ED predicts further investigation of CV events in men with diabetes. Furthermore, symptoms of hypogonadism should be investigated by assessing the serum testosterone concentrations. A detailed history of FSD obtained in a compassionate and structured method is essential in women with diabetes. Although, limited evidence exists to show correlation between FSD and CV events, lifestyle modifications, glicemic control, care of genetic infections and resolution of psychosocial factors should be discussed and emphasized.
**RECOMMENDATIONS**

**Recommended Care**

- Monitor blood glucose control by measuring HbA1c using high-precision methods standardized and aligned to the international reference values.
- Advise individuals with diabetes that maintaining an HbA1c <7.0% minimizes the risk of developing complications.
- A lower HbA1c target may be considered if it is easily and safely achieved without hypoglycaemia.
- A higher HbA1c target may be considered for individuals where previous attempts to optimize control were associated with unacceptable hypoglycaemia.
- Treatment should be reviewed and modified if HbA1c level is above the agreed target on two consecutive occasions.
- Advice those in whom target HbA1c levels cannot be reached that any improvement is beneficial.
- SMBG enables patients to detect and prevent asymptomatic hyperglycaemia and glucose variability and to make appropriate adjustments in treatment medications and nutrition therapy to achieve HbA1c targets.
- In patients on insulin, a combination of HbA1c and SMBG is useful in achieving glycaemic control.
- Measure HbA1c every three to six months depending on level, stability of blood glucose control and changes in therapy and report HbA1c results in percentages.
- Anaemia must be excluded before a proper diagnosis based on HbA1c values is made. Anaemia and abnormal haemoglobin may affect the values obtained for HbA1c in some assays. To determine whether abnormal haemoglobin is present, use high-performance liquid chromatography or mass spectrometry.
- Point-of-care capillary blood glucose meters should be used to measure blood glucose when patients are hospitalized. Blood glucose meters conforming to the latest ISO standards should be used.
- When prescribing CGM, robust diabetes education, training, and support are required for optimal continuous glucose monitor implementation and ongoing use.

**Limited Care**

- If HbA1c measurement is not available, blood glucose should be measured either at point-of-care or in the laboratory.
- In very limited settings, diabetes control may need to be based on measurement of plasma glucose levels alone.

**BACKGROUND**

Monitoring blood glucose levels is critical to ensure optimum glycaemic control. It is a corner stone of diabetes care that may help physicians to adjust the treatment regime according to patient’s need and help patients to follow the prescribed diabetes care. Glycated haemoglobin (HbA1c), which assesses the average level of blood glucose over 3 months, and self-monitoring of blood glucose (SMBG), which records the day-to-day blood glucose levels, are the two important tools for monitoring of glycaemic control. Measurement of HbA1c is known as a gold standard approach for monitoring diabetes in both research and in clinical settings. Most guidelines recommend clinicians must perform HbA1c measurements routinely in all patients with T2DM as a part of continuing care. Long-term hyperglycaemia as measured by HbA1c is associated with secondary macro-and micro-vascular complications due to diabetes. Therefore, patients with diabetes who do not reach appropriate glycaemic targets or are at an increased risk of developing complications require more intensive monitoring. Further, in Asian countries like India, religious aspects of weekly fasts, festivals, standard Indian diet rich in carbohydrates and reluctance to change the dietary habits, further support the need of regular glucose monitoring. Frequent SMBG, continuous glucose monitoring (CGM) assessing impending glucose excursions (both hypoglycaemia and hyperglycaemia) and glycaemic variability are some of the methods of intensive glucose monitoring.

CGM fulfilled an unmet need in diabetes care by providing an option of automated glucose monitoring which may help improve glucose control in patients with uncontrolled T2DM and in patients on acute and intensive glucose lowering regimen. In special cases such as pregnant women, children and adolescents group, CGM may help monitor prandial insulin doses and other dietary decisions. The current recommendations provide an insight on the importance and frequency of monitoring to be performed in order to facilitate medication and lifestyle changes when average HbA1c values remain above targets levels. HbA1c level monitoring is a convenient and reliable alternative to plasma glucose tests to diagnose diabetes.

SMBG is an essential component of the modern diabetes treatment, it is the simplest and possibly most practical tool to assess efficacy and safety of glycaemic control. SMBG facilitates patients and healthcare providers to adjust their therapeutic regimen in response to blood glucose values and regulate the dietary intake, physical activity, and insulin doses to improve glycaemic control on a regular basis. Established advantages with SMBG include, achieving target HbA1c, reducing glucose variability and prediction of severe hypoglycaemia. SMBG complements HbA1c testing as it can differentiate the fasting, pre-prandial, and
post-prandial hyperglycaemic levels, detect the glycaemic excursions, recognize and contribute in monitoring resolution of hypoglycaemia, and provide immediate feedback to patients about the effects of food choices, activity, and medication on glycaemic control.\[700\]

The International Diabetes Federation (IDF) and American Diabetes Association (ADA) recommend SMBG as an integral component of effective T2DM management.\[4,690\]

Despite substantial evidence of the benefits of SMBG, compliance to self-monitoring is reported “low” globally,\[701\] particularly in developing countries like India, where patients usually seek treatment after complications have set in. This may be attributed to various factors such as lack of awareness, literacy levels, and the perception that SMBG is painful and costly.\[702\]

Target values for glucose control for HbA1c and capillary plasma glucose for prediabetes and diabetes as described by the IDF 2017 are as follows\[703\] [Table 18].

**Recommendations for self-monitoring of blood glucose [Tables 19-22]**

Selecting a structured, flexible SMBG pattern that can be tailored to the clinical, educational, behavioural, and financial requirements of individuals with diabetes is recommended.\[698\] As it is important to determine the frequency and intensity of SMBG needed to support the chosen treatment regimen, one should also consider practical obstacles to monitoring, such as affordability or access and individualize glycaemic target and modify monitoring patterns accordingly.\[704,705\]

- In patients with pre-existing diabetes or GDM, target blood glucose levels should be 70 to 90 mg/dL fasting, <140 mg/dL 1-h post-prandial, and <120 mg/dL 2-h post-prandial.
- Individuals with insulin-treated diabetes should be advised to perform SMBG on a daily basis, failing which, at least weekly monitoring should be encouraged. Ideal SMBG: seven tests/day i.e. three before and three after each meal and one test at 3 am.\[684\]
- Pregnant women on lifestyle modifications should have a day profile once a week. This should include one fasting and three post-prandial values at least once a week or staggered over a week.\[684\]

**Considerations**

The decisions on clinical monitoring of glycaemic levels in T2DM patients was based on the local factors such as availability of newer technologies and cost of monitoring that were reviewed in Indian context [Table 23].

**Rationale and Evidence**

**Glycosylated haemoglobin for monitoring blood glucose**

- Regular monitoring of HbA1c will facilitate identification of patients with poor glycaemic control and help both physicians and patients to take necessary steps to achieve desired glycaemic targets.\[708,709\] Though frequent monitoring of HbA1c is associated with reduced diabetes-related complications and improved metabolic control,\[295,709\] most patients do not understand or are unaware of the importance of glycaemic monitoring. Therefore, educating patients and improving understanding on HbA1c levels for optimal glycaemic control is vital.\[709,710\]
- The concept of estimated average glucose (eAG) was introduced following introduction of continuous ambulatory blood glucose monitoring.\[711\] The eAG may help people with diabetes, relate their HbA1c to daily glucose monitoring and highlight any inaccuracies in HbA1c measurement relative to glucose levels.\[712\] Calculators are available for converting HbA1c to eAG in both mmol/L and mg/dL. Measurement of glucose levels, before meals, after meals and fasted state are often recommended as a substitute for HbA1c when the latter is either unavailable or inappropriate.
- Abnormal haemoglobin levels are known to affect HbA1c values in a way that can significantly alter the results with regard to diabetes control.\[713\] Therefore, it is important to consider haematological factors that can confound HbA1c levels in people with diabetes; best detected using HPLC-based assays.
- Anaemia significantly impacts HbA1c levels. In a cross-sectional study, the mean HbA1c in patients with controlled diabetes with iron deficiency anaemia (IDA) was significantly higher than those without IDA (7.86 ± 0.11% vs 5.45 ± 0.038% \(p<0.05\)) and the HbA1c values were inversely proportional to total haemoglobin \(p<0.05\).\[714\]
- Further, significantly higher HbA1c levels are observed in patients with IDA than healthy individuals \(5.51 ± 0.696\) vs \(4.85 ± 0.461\%\), \(p<0.001\) and the HbA1c levels significantly decline following iron supplementation \(p<0.001\).\[35\] Therefore, HbA1c results in diabetes patients

### Table 18: Target values for glucose control for glycosylated haemoglobin

<table>
<thead>
<tr>
<th>Normal</th>
<th>Prediabetes (IGT)</th>
<th>T2DM</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c (%)</td>
<td>&lt;5.7</td>
<td>5.7-6.4</td>
<td>&gt;7.0</td>
</tr>
<tr>
<td>FPG (mg/dL)</td>
<td>&lt;110</td>
<td>&gt;110 and &lt;126</td>
<td>≥126</td>
</tr>
<tr>
<td>PPG (mg/dL)</td>
<td>&lt;140</td>
<td>≥140 and &lt;200</td>
<td>≥200</td>
</tr>
</tbody>
</table>

DM: Diabetes mellitus; FPG: Fasting plasma glucose; HbA1c: Glycosylated haemoglobin, IGT: Impaired glucose tolerance, PPG: Postprandial glucose, T2DM: Type 2 DM
Glucose measurement

- Plasma glucose is the most preferred measure in most modern laboratories. Readings based on whole blood measurements are lower, due to the volume occupied by haemoglobin. Capillary blood glucose strips measure the glucose in the plasma of the capillary blood sample, but may be calibrated to give results either as plasma or sometimes whole blood glucose (check meter instructions).

Continuous glucose monitoring

- Garg et al. have demonstrated an improvement on glycaemic excursion in insulin-treated T2DM patients using Real time-CGM, showing a significant reduction of the time spent in hypo- and hyper-glycaemia range with an increased time spent in the target glucose range as well as a significant reduction of nocturnal hypoglycaemia in the Real time-CGM group.\[721\]
- Mohan et al. evaluating the use of retrospective CGM concluded that it can effectively help healthcare professionals with insights for initiating changes to treatment regimens, diet and exercise behaviours and provided patients with improved knowledge of the importance of therapy compliance by demonstrable reductions in HbA1c.\[722\]
- A retrospective analysis based on a blinded study of glycaemic control in 296 T2DM adults using masked professional CGM (P-CGM) revealed that the predominant pattern of hyperglycaemia was postprandial while previously unknown hypoglycaemia was found in 38% of the patients; over half of the cases were nocturnal. The mean HbA1c of the P-CGM group significantly dropped at 6 months from baseline (P < 0.0001). The frequency of performing SMBG was also found to be significantly increased. P-CGM motivated the patients for diabetes self-care practices, resulting in an improvement in glycaemic control over a wide range of baseline therapies.\[536\]

Implementation

There should be access to a laboratory or site-of-care test monitored by certified quality assurance schemes for measurement of HbA1c. In instances where HbA1c measurement is inappropriate, such individuals must be identified by careful review of haematological parameters and other factors that can affect HbA1c values. Provision of capillary blood glucose meters and strips need to be assured in hospitals and clinics. It is important to ascertain whether there are contraindications for use of a particular type of glucose meter in a particular patient. It is essential to establish whether glucose meters report values for plasma or blood and to ensure that schemes for monitoring the quality of their output are in place. Blood glucose meters should be calibrated on regular basis and their use in hospitals should be restricted to trained personnel.

### Table 19: Recommended care for frequency/timing of SMBG[688]

<table>
<thead>
<tr>
<th>T2DM on OADs</th>
<th>T2DM on insulin or insulin + OADs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>New onset/uncontrolled/ during acute illness</strong></td>
<td><strong>Stable/well-controlled</strong></td>
</tr>
<tr>
<td>Patients on SU or meglitinides:</td>
<td>At least 4 tests in a week on 4 consecutive days or on alternate days (including an FBG and 3 postprandial values)</td>
</tr>
<tr>
<td>At least 4 times/day and should include preprandial and bedtime levels.</td>
<td></td>
</tr>
<tr>
<td>Patients on other OADs:</td>
<td></td>
</tr>
<tr>
<td>At least FBG on alternate days</td>
<td></td>
</tr>
<tr>
<td><strong>New onset/uncontrolled/ during acute illness</strong></td>
<td><strong>Stable/well-controlled</strong></td>
</tr>
<tr>
<td>At least 4 times/day and should include preprandial and bedtime levels</td>
<td>Paired testing at least 3-4 days in a week (1 day/week pre- and post-breakfast, 1 day/week pre- and post-lunch, and 1 day/week pre- and post-dinner) or as frequently as possible</td>
</tr>
<tr>
<td>Must check whenever hypoglycaemia is suspected</td>
<td>Must check whenever hypoglycaemia is suspected</td>
</tr>
</tbody>
</table>

FBG: Fasting plasma glucose, OADs: Oral antidiabetics, SU: Sulphonylureas, DM: Diabetes mellitus, T2DM: Type 2 DM

### Table 20: Recommended care for frequency/timing of self-monitoring of blood glucose for diabetes in pregnancy[684]

<table>
<thead>
<tr>
<th>Patients on lifestyle modifications</th>
<th>Patients on OADs or insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>A day profile once a week-FBG and 3 postprandial values at least once a week or staggered over the week</td>
<td>At least 4 times/day (FBG and 3 postprandial values)</td>
</tr>
</tbody>
</table>

FBG: Fasting plasma glucose, OADs: Oral antidiabetics

with IDA should be interpreted carefully. IDA has to be corrected before a proper diagnosis is made.

- Measurement of blood glucose using blood glucose meters on admission to hospital wards helps to identify patients with hypoglycaemia or hyperglycaemia. Considering that in developing nations like India, where cost is major barrier for monitoring, these devices should be accurate, cost effective and field testing specifically tailored for Asian and Indian needs is imperative.\[715\]
- A study that assessed knowledge and attitude towards self-monitoring and the impact of SMBG on glycaemic control revealed that patients who monitored ≥3 times had significantly better glycaemic control of HbA1c (7.1–8%) than those who monitored <3 times (p=0.021).\[716\] Insulin self-titration interventions based on structured SMBG are associated with significant reduction in HbA1c during a follow-up of 12 weeks with a trend towards greater effectiveness in improving glycaemic control than conventional treatment, with no increase in incidence of hypoglycaemia or body weight gain.\[717\] Comparative studies in patients with T2DM on insulin across cohorts of regular SMBG users versus SMBG non-users have demonstrated that HbA1c levels in regular SMBG users were lower by 0.7-1.1%.\[718-720\]
### Table 21: Recommendations for glycaemic targets in the elderly

<table>
<thead>
<tr>
<th>Target glycaemic levels</th>
<th>Healthy elderly</th>
<th>Elderly with intermediate health status</th>
<th>Elderly with poor health status</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c (%)</td>
<td>&lt;7.5</td>
<td>&lt;8.0</td>
<td>&lt;8.0</td>
</tr>
<tr>
<td>Fasting or preprandial glucose (mg/dL)</td>
<td>90-130</td>
<td>90-150</td>
<td>100-180</td>
</tr>
<tr>
<td>Bedtime glucose (mg/dL)</td>
<td>90-150</td>
<td>100-180</td>
<td>110-200</td>
</tr>
</tbody>
</table>

HbA1c: Glycosylated haemoglobin

### Table 22: Limited care for frequency/timing of self-monitoring of blood glucose

<table>
<thead>
<tr>
<th>Type of monitoring</th>
<th>New onset/uncontrolled/DM during acute illness</th>
<th>Stable/well-controlled</th>
</tr>
</thead>
<tbody>
<tr>
<td>T2DM on OADs</td>
<td>Patients on SU or meglitinides: At least FBG alternate days</td>
<td>At least 4 tests in a month-at least 1 test/week (including a FBG and 3 postprandial values in a month)</td>
</tr>
<tr>
<td></td>
<td>Patients on other: At least FBG once a week</td>
<td></td>
</tr>
<tr>
<td>T2DM on insulin or insulin + OADs</td>
<td>At least FBG and one more preprandial value every day</td>
<td>At least one value on alternate days at different times of the day, with at least one FBG every week</td>
</tr>
<tr>
<td></td>
<td>Must check whenever hypoglycaemia is suspected</td>
<td>Must check whenever hypoglycaemia is suspected</td>
</tr>
</tbody>
</table>

### Table 23: Other methods of clinical monitoring

<table>
<thead>
<tr>
<th>Type of monitoring</th>
<th>Recommended care</th>
<th>Limited care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete history and physical examination</td>
<td>A complete history and physical examination is recommended</td>
<td>As for recommended care</td>
</tr>
<tr>
<td>Ophthalmic</td>
<td>Detailed exam by qualified ophthalmologist</td>
<td>Patients to be referred to ophthalmologists if retinopathy is suspected</td>
</tr>
<tr>
<td></td>
<td>Dilated</td>
<td></td>
</tr>
<tr>
<td>Smoking cessation</td>
<td>Counselling by physician at every visit</td>
<td>As for recommended care</td>
</tr>
<tr>
<td>BP measurement</td>
<td>BP measurement at each visit</td>
<td>As for recommended care</td>
</tr>
<tr>
<td>Measurement of lipids</td>
<td>At diagnosis or at age 40 years and periodically (6 monthly) thereafter</td>
<td>At diagnosis or at age 40 years at least</td>
</tr>
<tr>
<td>Screening for CVD</td>
<td>A resting ECG may provide useful information on baseline cardiac status and for future reference</td>
<td>As for recommended care</td>
</tr>
<tr>
<td></td>
<td>2d ECHO when required</td>
<td></td>
</tr>
<tr>
<td>Microalbuminuria</td>
<td>At diagnosis and annually thereafter</td>
<td></td>
</tr>
<tr>
<td>Distal peripheral neuropathy</td>
<td>At diagnosis and at least annually</td>
<td>As recommended by IDF</td>
</tr>
<tr>
<td></td>
<td>Test for vibration with 128 Hz tuning fork or a 10 g monofilament, pinprick sensation ankle jerk</td>
<td>Additional training required</td>
</tr>
<tr>
<td>Peripheral arterial disease</td>
<td>At diagnosis</td>
<td>As for recommended care</td>
</tr>
<tr>
<td>Comprehensive foot care</td>
<td>History of claudication, distal pulses and ABI</td>
<td>Additional training required</td>
</tr>
<tr>
<td></td>
<td>At diagnosis and annually</td>
<td>As for recommended care</td>
</tr>
<tr>
<td></td>
<td>Assessment of foot pulses, and testing for loss of protective sensation (10 g monofilament plus testing any one of: Vibration using 128 Hz tuning fork, pinprick sensation, ankle reflexes, or vibration perception threshold)</td>
<td>Additional training required</td>
</tr>
</tbody>
</table>

TECHNOLOGIES

RECOMMENDATIONS

**Recommended Care**

Continuous glucose monitoring (CGM)
- CGM (includes AGP) should be considered in conjunction with SMBG and HbA1C for glycaemic status assessment in those T2DM individuals treated with intensive insulin therapy who are not achieving glucose targets.
- CGM may be considered in women with GDM or pregnant women with T2DM and as a supplemental tool to SMBG in individuals with hypoglycaemia unawareness and/or frequent hypoglycaemic episodes.
- CGMs should preferably be used daily to gain maximal benefit.
- CGMs can be a helpful tool in diabetes education by facilitating effective communication between clinicians and patients. All users should get trained on how to interpret and respond to their glucose data.
- Only CGM systems with an acceptable level of sensor accuracy should be used and when assessing hypoglycaemia the accuracy of the CGM data in the lower glycaemic range should be considered.

Continuous subcutaneous insulin infusion (CSII) or insulin pump therapy
- CSII or insulin pump therapy may be considered in paediatric patients or in adults on ≥4 insulin injections per day (intensively managed insulin-dependent T2DM).
  - Common indications being:
    - High HbA1C levels on injection therapy
    - Recurrent episodes of hypoglycaemia or hypoglycaemia unawareness
    - Patients on high doses of insulin or poor glycaemic control despite intensive therapy
    - Presence of or a future risk of diabetes-related complications, or recurrent DKA/recurrent hospitalizations
    - Dawn phenomenon
    - Glycaemic variability causing challenges in diabetes management
    - Unpredictable food or meal intake patterns
    - Patients seeking improved quality of life
- In hospital admissions, CSII is not recommended in critically ill patients if the hospital/ICU staff is not familiar with the device.
- In non-critically ill patients, continued use of CSII is recommended if the patient can manage the use of the device himself or has trained assistance for the same.
- CSII should be prescribed to only those eligible patients who are willing and motivated to monitor glucose levels at least four times a day, quantify food intake, and comply with follow-up. Patients must be psychologically stable and in the case of young candidates, they should have adequate support from motivated caregivers who can learn and can commit to the different aspects of diabetes management.
- CSII should only be initiated at a well-equipped centre that has trained resources to initiate and follow-up the patients on CSII.
- Continuous training and retraining would be required to learn the techniques and excel in CSII management.

Clinical decision support tools and diabetes management platforms
- Technologies that aid patients and/or healthcare providers in the diagnosis and management of diabetes, can improve both the short-term and long-term disease outcomes.
- Adequate training need to be provided to the healthcare professionals in using the clinical decision support tools and diabetes management platforms.
- From among the various diabetes self-management tools and platforms available, patients must be encouraged to adopt the most appropriate tool that would best suit their disease needs and lifestyle.
- Patients must be encouraged to seek timely guidance and frequent reassessment from a trained healthcare team and must be made aware that the adoption of various diabetes self-management tools does not diminish the importance of the former.

<table>
<thead>
<tr>
<th>Technology</th>
<th>Recommended Care</th>
<th>Limited Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucometer</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Diabetes Apps</td>
<td>Yes</td>
<td>Can be discussed when there is a compelling indication</td>
</tr>
<tr>
<td>Insulin pump</td>
<td>Yes; indications should be discussed and apart from usual indications, CSII as an option to improve quality of life of the individual should be discussed.</td>
<td>Can be discussed when there is a compelling indication</td>
</tr>
<tr>
<td>CGM</td>
<td>Yes; indications should be discussed</td>
<td>Can be discussed when there is a compelling indication</td>
</tr>
</tbody>
</table>
BACKGROUND

Technologies have gradually become indispensable in the management of diabetes. Technologies such as insulin pump, artificial pancreas, CGM are relatively expensive. However, connected glucose meters, telemedicine and mobile apps for enhancing adherence to therapies and to enable coaching could be cheaper options even for limited care in the absence of which it is difficult to reach the goals of management. There have been a few guidelines available both internationally as well as specific to the Indian scenario, regarding the use of various diabetes technologies.[698,723-732] The current RSSDI guidelines are aimed at preventive technologies which are directed at saving the cost and future complications. Most of the technologies discussed are those which can be used by any modern medicine physician with appropriate training.

RATIONALE AND EVIDENCE

Blood glucose meters
SMBG with a quality glucose meter has been proven to be useful at any stage of diabetes provided a structured SMBG protocol is implemented with patient centred approach. Glucose monitoring, particularly SMBG is considered as an integral part of diabetes care[698,726,733,734] since achieving optimal glycaemic control has been proven to be associated with reductions in both macro-and microvascular complications of the disease.[169,295,735] SMBG has been demonstrated to be helpful or to correlate with effective management in both insulin-treated and noninsulin-treated diabetes.[295,333,334,726,736-738] Many different models of glucometers are available to suit the needs of the patients and differ in terms of their accuracy, amount of blood needed for each test, ease of use, pain associated with using it, testing speed, overall size, memory functions to store the test results, likelihood of interferences, ability of transferring data, procurement costs of the meter and accessories, special features such as automatic timing, error codes, large display screen etc.[739] Regarding the accuracy of the glucometers, though there are several current standards, the most commonly followed are those of the International Organization for Standardization (ISO 15197:2013)[740] and the U. S. Food and Drug Administration (USFDA).[741-743] The marketing strategies in India are highly influenced by the cost of meter and strips and quite often the quality is compromised. The CONTOUR® PLUS ONE smart meter The OneTouch Verio Flex® meter, Accu Chek Instant etc. are some among the globally popular glucose meters available in India. Currently connected glucose meters provide a patient friendly visualisation of blood glucose trends, time spent in range, time spent in hypoglycaemia, cloud storage, ability to email the digital blood glucose diary to the physician’s office along with storing the entire information. These glucose meters also provide options for users to enter data on insulin and other medications, calculate insulin carb ratio, insulin correction factor etc. thereby providing a comprehensive digital solution to a motivated patient.

Continuous glucose monitoring systems
HbA1C, the traditional metric for assessing glycaemic control in prognosis of diabetes, fails to capture intra- and interday glycaemic excursions which have been identified as risk factors for micro-and macrovascular complications. Therefore frequent glucose monitoring should be performed to reveal the underlying glycaemic variability in order to complement HbA1C.[744,745] A structured SMBG cannot predict impending hypoglycaemia or alert for hypoglycaemia.[746,747] Thus SMBG and HbA1C monitoring though an integral component of diabetes management, CGM is now considered as a complementary method for the assessment of glycaemic control.[743,748,749] CGM devices are comprised of a transcutaneous probe (sensor) that procures interstitial fluid glucose readings every 5-15 minutes depending on the make. CGM sensors can stay in place from 6 to 14 days or even 6 months at a time, depending on the model used. They fetch information regarding hourly, daily, and weekly glucose trends and patterns and thus offer opportunities for detailed analyses of the patient data. A variety of metrics have been proposed including average glucose, percentage of time in hypoglycaemic, hyperglycaemic and target ranges. This has been further endorsed by the fact that CE (Conformite Europeenne) and US FDA have approved some CGM devices for adjustment of insulin dosages [Figure 15].[750-752] CGMs broadly fall into two categories. The ‘Professional CGM’ (P-CGM), meant for the healthcare professionals to record the patient’s ambulatory glucose values, which are then downloaded and used for retrospective review and analysis. The ‘Personal CGMs’ are patient-owned devices where the sensor glucose values are sent wirelessly to a separate receiver device where they can be viewed in real-time (RT CGM).

Continuous subcutaneous insulin infusion
CSII or insulin pump therapy [Figure 16] is an alternative insulin delivery method and is superior in many aspects to ordinary syringes and insulin pens. An insulin pump is a small computerised device that can be worn externally, delivers a continuous infusion of rapid-acting insulin and attempts to mimic the function of a normal pancreas. It delivers insulin in two ways: a continuous, small dose of insulin to maintain glucose levels stable between meals and overnight (basal rate); and a much higher rate of insulin taken before meals to “cover” the food one plans to eat (bolus rate).

In India, insulin pumps were introduced in 2004. No definite reimbursement policies exist in the country and hence this life-saving technology is still not available to the most deserving candidates except on charity.[760] Five different types of insulin pump models currently available in India include Medtronic’s (MiniMed, Inc., Northridge, CA) Minimed 715, Minimed 722, Minimed 620G and Minimed 640G. The MiniMed
Chawla, et al.: RSSDI-ESI clinical practice recommendations

Figure 15: Currently available continuous glucose monitoring models [336,744,753-757]

Figure 16: Types of insulin pumps [758-760]

640G is the first-generation artificial pancreas available in India since 2015 indicated for both T1DM and T2DM. It has built-in intelligent features for increased protection including the SmartGuard™ technology, active insulin tracking, bolus progress bar, and predictive battery life. The SmartGuard technology predicts hypoglycemic events up to 30 minutes in advance and automatically stops insulin delivery (Suspend before low option), and automatically resumes insulin delivery when the glucose levels recover. Multiple low limits can be set throughout the day to give increased protection in times of need. A completely Closed Loop system enable complete automation of insulin delivery with minimal patient interaction. [761-763]

The latest development, MiniMed™ 670G insulin pump, is based on Hybrid Closed Loop Technology and has an auto mode feature that automatically adjusts basal insulin delivery every 5min based on sensor glucose to maintain blood glucose levels as close to a specific target as possible. Patients receive prandial insulin by entering carbohydrate amount into the bolus calculator. The device is expected to be available in India in the near future. [764] The Micro Solo Patch Pump, Medtrum insulin pump with sensor, etc. are also expected to be soon available in India. [765-767]

Even though CSII being the most physiological mode of insulin delivery and has several advantages over conventional insulin delivery modes, [768-771] it is not meant for everyone. The diabetes care provider and the patient need to make choices based on the pros and cons of the treatment option. [772-779]

Technologies to improve clinical decision support and treatment compliance

The overall quality of diabetes care still remains suboptimal due to various patient and provider related factors. An organized, systematic approach in diabetes self-management and a continued support from a trained multidisciplinary diabetes care team are thus highly crucial for achieving optimal outcomes. [780,781] Many solutions have been identified or are being employed to achieve this such as redesigning the organization of the care process, empowering and educating patients, implementing clinical decision support systems such as electronic health record tools, using diabetes detection or management apps and platforms for patients and healthcare professionals etc. [780,782,783]

Clinical decision support systems (CDSS) are applications that can analyse data and aid healthcare providers to make clinical decisions and improve patient care. Classic CDSSs may include various features like alerts, reminders, order
sets, drug-dose calculators etc. that automatically remind the doctors of a specific action, or care summary dashboards that provide performance feedback on quality indicators thereby ensuring patient safety and improved health outcomes. Both commercially and locally developed CDSSs have been found to be effective at improving healthcare process measures across diverse settings.[784,785]

Telemedicine is a disease management strategy whose basic concept matches with that of a CDSS. With the aid of telecommunications, telemedicine facilitates remote delivery of health-related services and clinical information.[786] Various telemedicine modalities have been proven to be effective and safe across various patient populations irrespective of their type of diabetes. They have been also associated with time savings, cost savings, high appointment adherence rates, and high patient satisfaction. In populations with limited access to care, telemedicine effectively improves the overall disease outcomes.[787-791] Diabetes Tele Management System, DTMS®, a telemedicine-based diabetes care implemented at a diabetes care hospital in South India since the 1990s, is now well proven and accepted as a simple and cost-effective tool for comprehensive diabetes management.[791-793]

**IMPLEMENTATION**

Almost ninety percent of the world’s population is estimated to be within the reach of a mobile network[794] and the number of smartphone users also seems to be on the rise. Therefore, the feasibility of mobile apps to empower patients and healthcare providers is now a step higher than other approaches. Numerous mobile apps for diabetes management are nowadays available to help clinicians and/or the patients themselves to track and manage diet, physical activity, blood glucose target and medications. Examples include Life in Control, Medios Technologies AI assistant to detect diabetic retinopathy, mySugr etc.[95,795-797] Diabetes technologies are meant for saving the time and better short term and long term outcomes. Choice should depend on the knowledge, infrastructure and the need.

## Special Situations

### Type 2 Diabetes Mellitus and Surgery

#### Recommendations

<table>
<thead>
<tr>
<th>Recommended Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Conduct preoperative assessments: baseline history of diabetes, symptoms of microvascular and macrovascular complications, physical examination HbA1c, blood glucose level, serum electrolytes and creatinine level, and current treatment regimen</td>
</tr>
<tr>
<td>• Maintain post prandial glucose of 140-180 mg/dL in-hospital ICU and 100-180 mg/dL as a guideline for general care medical and surgical wards</td>
</tr>
<tr>
<td>• Anti-diabetic agents like sulfonylureas, meglitinides, TZDs, SGLT-2 inhibitors, GLP-1 agonists must be discontinued on the day of surgery and metformin should be discontinued a night before surgery.</td>
</tr>
<tr>
<td>• In patients undergoing surgery, insulin basal-bolus regimen should be preferred</td>
</tr>
<tr>
<td>• For longer and complex surgeries IV insulin infusion is recommended</td>
</tr>
<tr>
<td>• Monitor blood glucose more frequently ranging from 0.5-2h</td>
</tr>
<tr>
<td>• On the day of surgery, avoid alterations in long acting basal insulin unless there is a tendency of hypoglycaemia or if patient is on diet restriction preoperatively. 75-100% of long acting insulin daily dose may be used on the day of surgery</td>
</tr>
<tr>
<td>• Patient should be provided with clear instructions about the return to their preoperative OADs and management of hypoglycaemia</td>
</tr>
<tr>
<td>• Resume the regular OAD medications only after the patient is medically stable and retaining oral meals regularly. Do not resume metformin in patient with renal dysfunction.</td>
</tr>
<tr>
<td>• Non-emergency procedures should be cancelled if patients have metabolic abnormalities (DKA, HHS, etc.) or glucose level &gt;400-500 mg/dL</td>
</tr>
<tr>
<td>• Multidisciplinary care team within an institution should formulate appropriate protocol to be followed during the hospital/surgical course for hyperglycaemia screening, monitoring, and treatment to reduce errors and improve postoperative outcomes.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Limited Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Delay surgery until fluid volume status (BUN, creatinine and urine output) are stable and metabolic (pH, plasma glucose, creatinine, BUN, electrolytes) control is achieved</td>
</tr>
<tr>
<td>• Tailor the post prandial insulin requirements according to the nutritional mode of patient</td>
</tr>
<tr>
<td>• Avoid respective doses of subcutaneous insulin to prevent “stacking” of insulin</td>
</tr>
</tbody>
</table>
**Background**

Patients with diabetes experience higher number of hospitalisation and surgeries with longer hospital stays, higher treatment costs and greater risks of morbidity and mortality than non-diabetics.\(^\text{[798-800]}\) Surgeries in patients with diabetes can be categorized as major or minor. Major impatient surgeries are defined as procedures requiring general, epidural, or spinal anaesthesia for \( \geq 1 \) h as well as hospitalization for \( > 1 \) day while all other outpatient procedures may be defined as minor surgeries.\(^\text{[801,802]}\)

Surgical procedures may result in a number of metabolic perturbations that can alter normal glucose homeostasis. Persistent hyperglycaemia prior to and during surgical procedures may lead to postoperative complications like cerebral ischemia, endothelial dysfunction, postoperative sepsis, acute renal failure and surgical site infection (most common complication) and may also impair wound healing in patients with diabetes.\(^\text{[803,804]}\) Surgical stress may lead to hyperglycaemic hyperosmolar syndrome (HHS), the most common postoperative complication associated with 42% mortality rate along with diabetic ketoacidosis (DKA) during or after surgery.\(^\text{[802,803,805]}\) Furthermore, increased stress leads to increase in the counter regulatory hormones causing insulin resistance and the resulting hyperglycaemia impairs neutrophil function and trigger overproduction of inflammatory cytokines and reactive oxygen species which causes vascular and immune dysfunction, and cellular damage.\(^\text{[804]}\) Therefore, to minimize these negative consequences and improve the postoperative outcomes it is important to carefully manage the glycaemic level in diabetic patients undergoing major surgeries including orthopaedic and cardiac.\(^\text{[805]}\) The treatment recommendations for patients with T2DM should be individualized-based on the severity of diabetes, usual their standard diabetes regimen, level of glycemic control, types of surgical procedures (major/minor).\(^\text{[802]}\) Overall, the management goal in diabetic patients undergoing surgery should be optimization of metabolic control, adequate fluid repletion and postoperative care management with or without insulin to improve surgical outcomes.\(^\text{[798,804,805]}\)

**Preoperative assessment**

Early risk assessments can minimize the incidence of perioperative and postoperative morbidities and reduce mortality rates as it provides an opportunity for planned intervention, proper arrangement and long-term follow-up.\(^\text{[799]}\) Physicians and multidisciplinary care teams must comprehend strategic plan to optimize glycaemia management in diabetic patients undergoing surgery.\(^\text{[806]}\)

**Perioperative glycaemic targets and assessment**

Preoperatively, the ADA recommends a perioperative glucose target of 80 to 180mg/dL as reasonable blood glucose maintenance. It is mandatory that the preoperative evaluation for surgical procedures must be conducted and must include assessment of glycaemic control and presence of any diabetes-related complications. Measurement of serum creatinine level to assess DKD, haemoglobin HbA1c, and blood glucose level are the critical baseline laboratory data that must be assessed.\(^\text{[806]}\) Other critical assessments that must be considered are enumerated below [Table 24].

**Preoperative management**

**Patients treated with oral medications and/or noninsulin injectable**

Metformin should be discontinued a day before surgery due to the high risk of lactic acidosis with mortality rate of approx. 50%.\(^\text{[807]}\) OADs mainly sulfonylureas and meglitinides, in fasting state have potential to cause hypoglycaemia and trigger endogenous secretion of insulin, independent of the glucose level, hence should be discontinued 1 day before surgery. Further, sulfonylureas and meglitinides increase the risk of myocardial ischemic injury and may be associated with increased risk of cardiovascular events and mortality.\(^\text{[808]}\) SGLT-2 inhibitors are associated with high risks for DKA and volume depletion. There have been a number of case reports of euglycemic ketoacidosis in the perioperative setting and hence SGLT-2 inhibitors should be stopped a day prior to surgery.\(^\text{[809,811]}\) DPP-4 inhibitors may be discontinued before surgery; however, in a recent study establishing the safety and efficacy of sitagliptin alone or sitagliptin in combination with basal insulin in hospitalized medical and surgical patients demonstrated good tolerability and low risk of hypoglycaemia and can be considered as a viable option in the perioperative setting.\(^\text{[806,812]}\) Due to slow gastric motility GLP-1 agonists (exenatide, liraglutide) are usually withheld the day before surgery.\(^\text{[809,813]}\) However, in cardiac and noncardiac surgical patients addition of a GLP-1 agonists to insulin therapy has demonstrated improved perioperative glycaemic control.\(^\text{[814,815]}\) AGIs (acarbose, miglitol) lower the absorption of glucose after meals, but these agents do not have any effect in the perioperative fasting states, and hence should be discontinued until the patient resumes eating.\(^\text{[816]}\) TZDs should be avoided due to risks like congestive heart failure, fluid retention and peripheral oedema.\(^\text{[812]}\)

**Patients treated with insulin**

Insulin being the most preferred choice of drug for patients undergoing surgery the basal-bolus regimen is the best protocol as it is associated with improved glycaemic control and lower perioperative complications.\(^\text{[807]}\) Continuing at least part of the basal insulin is the reasonable, physiologic approach to controlling glucose levels before surgery in patients with diabetes. Basal bolus regimens are also associated with reduced postoperative complications and reduced inpatient costs per day. The dose of usual basal insulin can be reduced by 20-30% if patient reports nocturnal or fasting hypoglycaemic history.\(^\text{[877]}\) Long-acting insulins demonstrate lesser peaks and hence do not result in hypoglycaemia during fasting states. It is advised that long-acting insulins must be taken as close as possible to the usual time of injection, preoperatively. The intermediate-acting insulin neutral protamine Hagedorn (NPH) is usually given 2 times daily. Premixed insulins
Chawla, et al.: RSSDI-ESI clinical practice recommendations

Table 24: Preoperative assessments

<table>
<thead>
<tr>
<th>History</th>
<th>Physical assessment</th>
<th>Baseline assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asses for symptoms of neurologic, cardiac, retinal, renal and PVD</td>
<td>Examine BP, feet, skin (insulin-injection site), thyroid palpation</td>
<td>Assessment of serum electrolytes and creatinine level, HbA1c (if not assessed since last 3 months) and BG level</td>
</tr>
<tr>
<td>Family history of diabetes, nutritional status, eating pattern, weight history, previous or current infection, use of alcohol, tobacco etc.</td>
<td>Cardiac examination including resting tachycardia, orthostatic hypotension, stress test or angiography as indicated</td>
<td>Identification of comorbidities and optimize wherever required with the help of a multidisciplinary team</td>
</tr>
<tr>
<td>Endocrine disorders, history of acute hypoglycaemia, ketoacidosis</td>
<td>Airway, neurologic and abdominal examinations</td>
<td></td>
</tr>
<tr>
<td>Type and duration of diabetes, current treatment regimen along with diet and results of glucose monitoring</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

BP: Blood pressure, HbA1c: Glycosylated haemoglobin, PVD: Peripheral vascular disease, BG: Blood glucose

(combinations of basal and prandial insulin) are not prior to the surgery. Patients on insulin pumps subjected to longer surgical procedures should be shifted to the IV insulin infusion. Patient on basal-bolus insulin regimen should calculate the total daily insulin dose [Table 25].

Intraoperative management

Endocrine Society and Society for Ambulatory Anesthesia (SAMA) recommend that intraoperative glucose levels be maintained less than 180 mg/dL. Glucose levels should be monitored hourly intraoperatively and immediately after surgery. For patients with T2DM undergoing major or minor surgery IV infusion of insulin, glucose and potassium is recommended to maintain the glycaemic targets [Table 26]. To maintain the glucose targets intraoperatively, IV insulin infusion regimen-a protocol-driven algorithm is recommended.

Postoperative management

Glucose control in noncritically-ill, non-ICU surgical patients is managed with subcutaneous insulin. During recovery, the glucose levels must be monitored for at least every 2-h for all diabetic patients and for nondiabetics treated in the operating room. Correctional subcutaneous rapid-acting insulin doses are provided for BG greater than 180mg/dL. Patient should be transitioned to subcutaneous basal/bolus insulin regimen as soon as the patient is able to consume solid food. To prevent the insulin coverage gap while transitioning from IV infusion to subcutaneous, after the administration of first subcutaneous insulin dose there should be infusion overlap for at least 1-2-h. Patients previously on insulin regimen can continue their regular dose provided they are good with eating patterns. For patients not on insulin treatment previously, depending on patient’s sensitivity to insulin calculate a subcutaneous regimen by totalling 0.2-0.5 U/kg of body weight. The total calculated daily insulin dose is to be divided as 50% basal component (long-acting insulin) + 50% prandial boluses (rapid-acting insulin) and split between breakfast, lunch and dinner. In patients treated with oral/non-insulin injectable initiate their regular home regimen provided they are eating regularly and are medically stable. Do not resume metformin for at least 2-3 days, especially in patients with renal dysfunction, hepatic impairment or heart failure because of potential risk of metabolic acidosis.

<table>
<thead>
<tr>
<th>Table 25: Supplemental insulin dose adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>BG (mg/dL)</td>
</tr>
<tr>
<td>-----------------</td>
</tr>
<tr>
<td>&gt;141-180</td>
</tr>
<tr>
<td>181-220</td>
</tr>
<tr>
<td>221-260</td>
</tr>
<tr>
<td>261-300</td>
</tr>
<tr>
<td>301-350</td>
</tr>
<tr>
<td>351-400</td>
</tr>
<tr>
<td>&gt;400</td>
</tr>
</tbody>
</table>

Numbers in each column represent the number of regular or rapid-acting insulin analogs per dose. Add the “supplemental” dose to the scheduled insulin dose. Given before each meal and at bed-time for the patients able to take all or most of his meals. Start regular insulin every 6 h or rapid acting insulin every 4-6 h for the patients who are elderly, not eating and with impaired renal function, In patients receiving more than 80 U/day before admission and those who were receiving corticosteroids. BG: Blood glucose

<table>
<thead>
<tr>
<th>Table 26: Intravenous insulin infusion protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initiate insulin infusion by mixing 100 U short-acting insulin + 100 mL normal saline at the rate of 0.5-1 U/h (0.5-1 mL/h). Initiate separate infusion of 5% dextrose + water at the rate of 100-125 mL/h. Monitor BG every hour (every 2 h when stable) and according to the following algorithm adjust the insulin infusion rate</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BG level (mg/dL)</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;70</td>
<td>Recheck BG after turning off infusion for 30 min. If reading still shows &lt;70 mg/dL, give 10 g glucose and keep checking BG every 30 min until the level rises to 100 mg/dL, resume the infusion and reduce rate by 1 U/h</td>
</tr>
<tr>
<td>70-120</td>
<td>Reduce insulin infusion rate by 1 U/h</td>
</tr>
<tr>
<td>120-180</td>
<td>Continue the regular insulin infusion</td>
</tr>
<tr>
<td>181-250</td>
<td>Increase rate of insulin infusion by 2 U/h</td>
</tr>
<tr>
<td>251-300</td>
<td>Increase rate of insulin infusion by 3 U/h</td>
</tr>
<tr>
<td>301-350</td>
<td>Increase rate of insulin infusion by 4 U/h</td>
</tr>
<tr>
<td>351-400</td>
<td>Increase rate of insulin infusion by 5 U/h</td>
</tr>
<tr>
<td>&gt;400</td>
<td>Increase rate of insulin infusion by 6 U/h</td>
</tr>
</tbody>
</table>

| If hypoglycaemic condition persists rate of glucose infusion can also be increased, 120-180 mg/dL is the target BG range. BG: Blood glucose |

renal dysfunction, hepatic impairment or heart failure because of potential risk of metabolic acidosis.
**Type 2 Diabetes Mellitus and Pregnancy**

### Recommendations

**Recommended Care**

- Preconception care should be introduced in the routine diabetes care and maternal complications should be addressed.
- All diabetic women of child bearing potential should be educated about risks of unplanned pregnancy and its outcomes, use of contraceptives and family planning.
- Need for strict glycaemic control, use of insulin, maintenance of safe levels of HbA1c, i.e. 6.5%-7.0% to minimize risk of neonatal complications must be explained.
- Insulin is the first line therapy to treat hyperglycaemia in pregnant women with pre-existing diabetes. Replace all the other anti-glycaemic medication with insulin treatment.
  - If adequate blood glucose levels not achieved during pregnancy with multiple daily insulin infusions, insulin pump therapy for safe treatment should be advised.
  - Educate about teratogenic effects of ACEi, ARBs, atenolol and statins.
- A dose of 400 µg/day of folic acid should be recommended to avoid neural tube defects.
- Antepartum care:
  - During first 10 weeks of pregnancy, offer retinal and renal assessment if not assessed.
  - Offer ultrasound monitoring during week 16-32 to detect foetal growth and to detect structural abnormalities, if any.
- Intrapartum care:
  - Capillary blood glucose level should be within the optimum level of 70-110 mg/dL during labour.
  - Appropriate dose of regular insulin with dextrose infusion must be preferred to achieve target glycaemic levels during labour.
- Postpartum care:
  - Monitor blood glucose level, consider insulin dose reduction/stoppage to avoid hypoglycaemia. Reassessment of glycaemic status at 6 weeks postpartum with a 75 gm OGTT.
  - Reminder about importance of contraceptives in women with pre-existing diabetes and pre-conception care and planning for pregnancies in future

**Limited Care**

- Multi-disciplinary clinic constituting perinatologist, dietician, endocrinologist, obstetrician, diabetes counsellor should be developed for ideal management of diabetes.
- Monthly assessments of HbA1c level should be carried out. SMBG level at fasting, pre and post-prandial intervals to attain optimum glycaemic control.

### Background

Poorly controlled diabetes in women before conception can lead to severe birth defects in 5%-10% of pregnancies, and can lead to spontaneous abortion in 15%-20% of pregnancies.\(^{[820]}\) Despite the alarmingly high prevalence of diabetes in India, studies on the effects of T2DM in pregnancy and its outcomes are limited. The overall prevalence of pre-gestational diabetes has been recorded to be doubled from 1999-2005.\(^{[821]}\) Recent studies have revealed that the prevalence of diabetes in pregnant women with pre-existing diabetes as 3.4%-3.8%, of which the majority were suffering from T2DM.\(^{[822,823]}\) Pre-existing diabetes can have deleterious effects on pregnancy as it leads to complications for both mother and the foetus. These complications are associated with hazardous pregnancy outcomes including still-birth, spontaneous abortion, pre-eclampsia, perinatal mortality, low birth weight, respiratory distress, neonatal death, neonatal hypoglycaemia etc.\(^{[824-826]}\)

Though there are several management protocols available for GDM, limited resources for the management of pregnancy in patients with pre-existing T2DM is available. Since it involves various stages of pregnancy, a multidisciplinary approach must be adopted.

### Preconception planning and care [Table 27]

Before conception, a set of treatment regimens that aim at optimization of social, biomedical and psychological aspects in a woman with pre-gestational diabetes (T1DM and T2DM) is referred to as pre-conception management.\(^{[827]}\) In order to minimize the diabetic pregnancy complications and to control congenital malformation it is essential to introduce preconception care in primary care plan for women with child bearing potential.\(^{[828]}\)

Along with early diagnosis and glycaemic controls, proper nutritional diet, and regular follow-up of metabolic stress and complications can help in a successful pregnancy in patients with diabetes. Introduction of multidisciplinary clinics in management of diabetic pregnancy can reduce the rate of perinatal mortality and can also improve neonatal care.\(^{[829]}\)

**Counselling**

The pre-conception counselling process should be discrete, concise and considerate and must provide clear explanation about sensitivity to social and moral conventions. Women with pre-existing diabetes should be counselled about the need for contraception while on treatment with insulin. Educate diabetic women in their reproductive age about the...
issues associated with unplanned pregnancy. Patients must be counselled and prescribed appropriate contraceptive measures that must be adapted until the metabolic parameters are appropriate to conceive. Since the primary goal for glycemic management in the preconception period and during the first trimester is to obtain the lowest HbA1c levels possible without hypoglycaemia, women should be made aware that they can have a planned conception only with HbA1c less than 6.5-7.0% to lower the risk of congenital anomalies.\cite{827,829}

Critical complications with T2DM such as hypertension, intra uterine growth retardation and risk of obesity along with their prevention and management should be explained to the patients during pre-conception counselling.\cite{827} Muslim pregnant women with pre-existing T2DM must be advised to avoid fasting during the month of Ramadan. However, religious fasting are personal decisions, and a practical approach should be explained with emphasis on the risks to the mother and the foetus.\cite{609} Pre-conception counselling must aim at minimizing the risk of pregnancy complications in girls and women in their reproductive age with diabetes. Such counselling can improve the health of the mother and reduce cost burdens for the mother and the child.\cite{830}

**Glycaemic target-preconception and antepartum**

[Tables 28 and 29]

It is recommended that women with T2DM who are actively trying to become pregnant should be switched from oral or noninsulin injectable hypoglycemic agents to insulin prior to conception if possible during preconception and the first trimester of women with pre-gestational diabetes the primary goal is to maintain optimum glycaemic level. Effective measures must be taken to maintain the ideal glycaemic value while minimizing the risk of hypoglycaemia. The IDF and ADA recommend a pre-conception HbA1c level of <7%, whereas as per the National Institute for Health and Clinical Excellence (NICE) recommendation, the HbA1c level can be lower i.e. <6.5%, provided it is safely achieved.\cite{831} In order to prevent chances of spontaneous abortions and major congenital malformations, target HbA1c must be as close to normal as possible without significant hypoglycaemia.\cite{832} HbA1c should be assessed monthly due to the changing kinetics of RBCs and physiological alterations in glycomic aspects during preconception and in pregnant women with diabetes as it proves to be helpful in planning therapy.\cite{827,830} The ADA recommends HbA1c testing to be done at the time of fasting, pre-parandial and post-parandially in pregnant women with diabetes.\cite{830} In women with pre-existing diabetes, provision of basal and prandial insulin needs with intensified insulin regimens (multiple dose regimens of subcutaneous long-and short-acting insulins) are known to give best results. Rapid acting insulin dosage (pre meal) can be adjusted using insulin pumps or basal-bolus therapy for which preprandial glucose monitoring is essential. Monitoring of postprandial blood glucose aids in lowering the risk of preeclampsia.

**Optimization of antidiabetic regimes**

No oral OADs are approved for pre-existing diabetes in pregnancy although glyburide and metformin have been used in multiple RCTs for GDM. Minimal data on thiazolidinediones or metiglinides and no data on incretin-based DPP-4 inhibitors and GLP-1 analogues are available.\cite{833} Metformin and glyburide may be used during pregnancy but these drugs cross the placental barrier and hence should be replaced with insulin therapy at the earliest.\cite{827,831,833} Potential concerns for SGLT2 inhibitors in pregnancy due to profound polyuria in a pregnant patient with familial renal glycosuria have been reported and since pregnancy causes polyuria and glycosuria normally due to increased glomerular filtration rate so SGLT2-inhibitors are not expected to be beneficial.\cite{833} Insulin, does not cross the placenta, and hence is the first choice to attain targeted glycaemic goal in pregnant women with pre-existing diabetes.\cite{827,830} Insulin requirements may increase as the pregnancy progresses, and the requirement peaks between 28 weeks and 32 weeks of gestation.\cite{834} Considering alteration in physiology of pregnant women, daily SMBG is required more frequently and insulin dose must be optimized at different stages of pregnancy as per requirement.\cite{830} Compared to T1DM, management of glucose level is easier in T2DM, however there might be requirement of higher dose of insulin as >150 units/day i.e. approximately 50% elevation.\cite{801} Insulin pump therapy is also considered to be beneficial in maintaining HbA1c level in pregnant women with pre-gestational diabetes, without any increase in risk of hypoglycaemia. However, cost and the risk for marked hyperglycaemia or DKA as a consequence of insulin delivery failure from could be an issue.\cite{833}

Pre-gestational diabetics are at a high risk of preeclampsia, hence the American College of Obstetricians and Gynecologists recommends use of low-dose aspirin (81 mg/day) prophylaxis to be initiated between 12 weeks and 28 weeks of gestation (ideally before 16 weeks of gestation) and continued until delivery to

---

### Table 27: Elements of preconception plan

<table>
<thead>
<tr>
<th>Counselling</th>
<th>Assessment of medication</th>
<th>Glycemic control</th>
<th>Supportive investigation and management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Need for contraception and effective measures</td>
<td>Potentially teratogenic drugs</td>
<td>Risk of hypoglycaemia</td>
<td>Optimum HbA1c level</td>
</tr>
<tr>
<td>Risk associated with unplanned pregnancy</td>
<td>Use of oral hypoglycaemic agents</td>
<td>Risk of maternal and foetal complications due to</td>
<td>Urine albumin: Creatinine ratio</td>
</tr>
<tr>
<td>Financial/family planning</td>
<td>Insulin therapy</td>
<td>hyperglycaemic condition</td>
<td>Test for HIV, HBV, HCV, VDRL, pap smear, rubella, TSH and fundus</td>
</tr>
<tr>
<td>Need for strict glycaemic control and insulin</td>
<td>Use of insulin analogs</td>
<td>Educate on self-monitoring of BG</td>
<td></td>
</tr>
</tbody>
</table>

prevent preeclampsia. Such preventive action can lower the rates of morbidity and health care costs of the neonate.

Screening and management for diabetes complications [Table 30]
Early screening of diabetes complications like retinopathy, neuropathy, heart failure, chronic kidney disease in pre-conception period is essential as they can be life-threatening and associated with lower quality of life for both the mother and the foetus if not diagnosed or treated at an early stage. Poorly controlled pre-gestational diabetes may lead to serious end-organ damage that may result into life threatening conditions. These complications can be controlled or prevented with appropriate diabetes management. Diabetic retinopathy is the leading cause of blindness, and women with diabetes who become pregnant should have a comprehensive eye examination in the first trimester and should be monitored closely throughout pregnancy. Diabetic nephropathy is estimated to be present in 5–10% of diabetic pregnancies ad progression to end stage renal disease have been reported in several women. Also, women with pre-existing diabetic nephropathy are at significantly higher risk for obstetric complications, such as hypertension, uteroplacental insufficiency, and iatrogenic preterm birth because of worsening renal function. Hyperension, especially in the presence of nephropathy, increases the risk of preeclampsia, uteroplacental insufficiency, and stillbirth.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Glycaemic target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting</td>
<td>95 mg/dL (5.3 mmol/L)</td>
</tr>
<tr>
<td>1-h postprandial</td>
<td>140 mg/dL (7.8 mmol/L)</td>
</tr>
<tr>
<td>2-h postprandial</td>
<td>120 mg/dL (6.7 mmol/L)</td>
</tr>
</tbody>
</table>

Noninsulin glucose-lowering agents

<table>
<thead>
<tr>
<th>Compound</th>
<th>Effects on pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>SU</td>
<td></td>
</tr>
<tr>
<td>Gliptins</td>
<td>Intrauterine death, skeletal deformities and foetal growth retardation</td>
</tr>
<tr>
<td>Glimepiride</td>
<td>Crosses placental barrier</td>
</tr>
<tr>
<td>Glipizide</td>
<td>Small amount may cross placental barrier, may reduce rate of morbidity and mortality in foetus and infant</td>
</tr>
<tr>
<td>GLIsensamide</td>
<td>Crosses placental barrier and shows congenital malformation however lower in rate than those not on metformin medication</td>
</tr>
<tr>
<td>Biguanide</td>
<td></td>
</tr>
<tr>
<td>Metformin</td>
<td>Crosses placental barrier</td>
</tr>
<tr>
<td>α-glucosidase inhibitors</td>
<td>Study depicted few babies with congenital malformation</td>
</tr>
<tr>
<td>Meeglitinides</td>
<td>Transfusion through placental barrier is unknown yet suggested that may produce risk of developmental toxicity in foetus at a lower risk</td>
</tr>
<tr>
<td>TZDs</td>
<td>Crosses placenta, delayed foetal development, reduced foetal weight and postimplantation losses</td>
</tr>
<tr>
<td>Insulins</td>
<td>Crosses placenta, causes foetal growth retardation, foetal death and also placental toxicity</td>
</tr>
<tr>
<td>Rapid acting analog</td>
<td>Insulin aspart known be most effective in management of glycemic control without causing the risk of hypoglycemia during preconception and throughout pregnancy</td>
</tr>
<tr>
<td>Lispro</td>
<td>No safety and efficacy data available on use of detemir or glargine and glulins in pregnancy</td>
</tr>
</tbody>
</table>

Optimization of anti-hypertensive medications [Table 31]
Anti-hypertensive medication therapy with ACE inhibitors and angiotensin receptor blockers (ARBs) are contraindicated in women with pre-existing diabetes and planning for pregnancy as these medications are teratogenic and can cause intra-uterine growth retardation, foetal renal dysplasia and oligohydramnios. A large randomized controlled trial in pregnant women with pre-existing or gestational hypertension showed that targeting a diastolic blood pressure (BP) of 85 mmHg vs. 100 mmHg reduced neonatal respiratory complications and rates of severe maternal hypertension (i.e. >160/110 mmHg). Labetalol, methylplda, dipatiazem, nilfiedpine, clonidine and prazosin are considered to be safe anti-hypertensives during pregnancy. Use of atenolol is not recommended in pregnancy. Use of chronic diuretics as anti-hypertensives are also not recommended as they are associated with restriction of maternal plasma volume that leads to
Screening of BP at every visit is essential to avoid any maternal or foetal complications. Guidance on arterial blood gases to ascertain degree of acidosis must be conducted. Glucose must be continuously monitored.

Diagnosis of BP at every visit should be monitored as perinatal complications like preeclampsia, intra-uterine growth retardation and preterm birth in diabetic nephropathy are very common.

Patient with preexisting nephropathy should be monitored closely to maintain the albuminuria and medication started to decrease the renin-angiotensin-aldosterone-system activity as varying renal function deterioration is expected during pregnancy.

Referral to nephrologist should be considered if there is abnormal serum creatinine level i.e., ≥120 µmol/L, albumin: Creatinine ratio being >30 mg/mmol of or eGFR <45 mL/min/1.73m²

As complication risks are comparatively high in diabetic patients who undergo kidney transplantation, patient counselling and clinical decision making of conception are to be considered.

Screening of BP at every visit is essential to avoid any maternal or foetal complications. Guidance on self-monitoring of BP should be provided.

During preconception counselling, patient with preexisting diabetes and hypertension should be made aware of the teratogenic anti-hypertensive medications to avoid during pregnancy. ACEIs, ARBs and spironolactone are contraindicated and hence should be discontinued before pregnancy as these anti-hypertensive drugs are teratogenic.

In patients with preexisting hypertension and on anti-hypertensive medication, in order to optimize long-term health of the mother and reduce risk of foetal complications ADA suggests the target BP to be 120-160 (systolic) and 80-105 mmHg (diastolic).

Educate patient with preexisting diabetes and planning for pregnancy, about the diabetic foot hygiene, nail cutting, appropriate footwear to prevent the risk of diabetic foot.

Feet inspection in every month is recommended for patients with preexisting diabetes but at every visit for patients at high ulceration risk

Maintaining optimum HbA1c level <7% can lead to reduction in risk of neuropathy by 35%

Arterial blood gases to ascertain degree of acidosis must be conducted. Glucose must be continuously monitored along with capillary BG ketones, and serum ketones.

Aggressive hydration and IV insulin and the most important treatment regimes

IV fluids: Isotonic sodium chloride may be used, with total replacement of 4-6 L

Bicarbonates may be used based on the pH levels


reduction in utero-placental perfusion. Severe preeclampsia and acute-hypertension management may be treated with vasodilator like hydralazine during pregnancy.

Management of dyslipidaemia

Dyslipidaemia identified during pregnancy should be treated with diet and exercise intervention, as well as glycaemic control if indicated. A lipid profile at preconception in women with familial hypercholesterolemia (FH) must be conducted and a target level of LDL cholesterol, HDL cholesterol and triglycerides as <100 mg/dL. (2.6 mmol/L), >35 mg/dL. (0.905 mmol/L) and <105 mg/dL (1.7 mmol/L), respectively must be established for each patients. The use of statins is contraindicated during pregnancy due to teratogenicity. There is limited data on the teratogenicity of lipid-lowering agents, ezetimibe, nicotinic acid, and fibrates in humans. Bile acid binding resins, cholestyramine and colsevelam, are the only medications currently acceptable to use during pregnancy as they do not pass into the systemic circulation. Fenofibrate and gemfibrozil are pregnancy category C drugs and should only be used if the potential benefit justifies the potential risk to the fetus. Initiate treatment with fibrate if the triglyceride level is more than the optimum level of >400 mg/ml (fasting condition) so as to minimize the occurrence of pancreatitis.

Antepartum care

Folic acid supplementation

Periconceptional folic acid supplementation decreases the occurrence and recurrence of neural tube defects (NTDs). Hence, in the preconception counselling, patients should

Table 30: Screenings and management for diabetes complication

<table>
<thead>
<tr>
<th>Complication</th>
<th>Screening and management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic retinopathy</td>
<td>Screening of retina during preconception and more frequently during pregnancy and up to 1 year postpartum is essential for early detection and implementation of preventive measure</td>
</tr>
<tr>
<td></td>
<td>In patients with preexisting retinopathy ensure appropriate treatment to avoid disease progression</td>
</tr>
<tr>
<td></td>
<td>Tight glycemic control is the primary measure to prevent retinopathy other measures to treat retinopathy are laser coagulation treatment, vitrectomy, VEGF drugs and intravitreal steroid injections</td>
</tr>
<tr>
<td></td>
<td>Counsel women who are planning pregnancy about the risk of diabetic retinopathy and if existing then prevention of its progression</td>
</tr>
<tr>
<td>Nephropathy</td>
<td>Diagnosis of BP at every visit should be monitored as perinatal complications like preeclampsia, intra-uterine growth retardation and preterm birth in diabetic nephropathy are very common</td>
</tr>
<tr>
<td></td>
<td>Patient with preexisting nephropathy should be monitored closely to maintain the albuminuria and medication started to decrease the renin-angiotensin-aldosterone-system activity as varying renal function deterioration is expected during pregnancy</td>
</tr>
<tr>
<td></td>
<td>Referral to nephrologist should be considered if there is abnormal serum creatinine level i.e., ≥120 µmol/L, albumin: Creatinine ratio being &gt;30 mg/mmol of or eGFR &lt;45 mL/min/1.73m²</td>
</tr>
<tr>
<td></td>
<td>As complication risks are comparatively high in diabetic patients who undergo kidney transplantation, patient counselling and clinical decision making of conception are to be considered</td>
</tr>
<tr>
<td>Chronic hypertension</td>
<td>Screening of BP at every visit is essential to avoid any maternal or foetal complications. Guidance on self-monitoring of BP should be provided</td>
</tr>
<tr>
<td></td>
<td>During preconception counselling, patient with preexisting diabetes and hypertension should be made aware of the teratogenic anti-hypertensive medications to avoid during pregnancy</td>
</tr>
<tr>
<td></td>
<td>ACEIs, ARBs and spironolactone are contraindicated and hence should be discontinued before pregnancy as these anti-hypertensive drugs are teratogenic</td>
</tr>
<tr>
<td></td>
<td>In patients with preexisting hypertension and on anti-hypertensive medication, in order to optimize long-term health of the mother and reduce risk of foetal complications ADA suggests the target BP to be 120-160 (systolic) and 80-105 mmHg (diastolic)</td>
</tr>
<tr>
<td>Neuropathy</td>
<td>Educate patient with preexisting diabetes and planning for pregnancy, about the diabetic foot hygiene, nail cutting, appropriate footwear to prevent the risk of diabetic foot</td>
</tr>
<tr>
<td></td>
<td>Feet inspection in every month is recommended for patients with preexisting diabetes but at every visit for patients at high ulceration risk</td>
</tr>
<tr>
<td></td>
<td>Maintaining optimum HbA1c level &lt;7% can lead to reduction in risk of neuropathy by 35%</td>
</tr>
<tr>
<td>Diabetic ketoacidosis</td>
<td>Arterial blood gases to ascertain degree of acidosis must be conducted. Glucose must be continuously monitored along with capillary BG ketones, and serum ketones</td>
</tr>
<tr>
<td></td>
<td>Aggressive hydration and IV insulin and the most important treatment regimes</td>
</tr>
<tr>
<td></td>
<td>IV fluids: Isotonic sodium chloride may be used, with total replacement of 4-6 L</td>
</tr>
<tr>
<td></td>
<td>Bicarbonates may be used based on the pH levels</td>
</tr>
</tbody>
</table>


---

Chawla, et al.: RSSDI-ESI clinical practice recommendations

Int J Diabetes Dev Ctries (Jan-March 2020) 40 (Suppl 1):S1-S122
be educated on folic acid requirement. Women with pre-existing diabetes who are planning to become pregnant must be advised to take folic acid (5 mg/day) until 12 weeks of gestation to reduce the risk of having a baby with a neural tube defect.

**Nutrition therapy and weight gain targets**

The primary aim of nutritional therapy in pregnancy is to provide calories to maintain optimum glycaemic control for normal growth and development of the foetus with normalizing dyslipidaemia. As a consequence of physiologic changes that follow pregnancy, caloric requirements are increased during the second and third trimesters. Wholesome food choices with 40–50% calories from complex, high-fibre carbohydrates, 15–30% calories from protein, and 20–35% calories from primarily unsaturated fats) are commonly advised. To fulfil the additional dietary needs, diets often altered or modified for the amount and type of carbohydrates to be consumed during pregnancy. It is advisable to include diet rich in omega-3 fatty acids and non-starch polysaccharides with low glycemic index, and avoid excess intake of saturated fats and TFAs that can lead to increased risk of complications. High-carbohydrate low-fat diet such as legumes, unprocessed fruits and vegetables should be included in the diet. Vitamin D supplementation (10 μg/day) are prescribed in women with risk of vitamin D deficiency during pregnancy. Folic acid supplementation with a recommended dose of 400 μg/day is prescribed until 12 weeks of pregnancy to prevent risk of neural tube defects. Vitamin A supplementation, liver and liver products rich in vitamin A should be avoided as they may be teratogenic. Iron supplements are not often prescribed in pregnancy as they might be associated with unpleasant maternal side-effects. ADA suggests the Dietary Reference Intakes (DRI) to be >175 g of carbohydrate, >71 g of protein and about 28 g fiber in all pregnant women.

**Weight management**

Obesity is the major complication in women with pre-existing T2DM and hence, monitoring and weight management is important to avoid CV risk in pregnancy. ADA recommends the weight gain of overweight women during pregnancy should be 15–25 lb whereas for obese women it should be 10–20 lb. Maintenance of weight gain targets during pregnancy can be easily done with the help of appropriate dietary plan along with life-style interventions. Yoga either individually or combined physical activity has been remarkably helpful in weight management. Orlistat a lipase inhibitor shows low risk to foetal development and hence obesity treatment in pregnancy with orlistat shows low risk to foetus and hence should be used with caution during pregnancy.

<table>
<thead>
<tr>
<th>Class</th>
<th>Compound</th>
<th>Effects on pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACEIs</td>
<td>Lisinopril, perindopril, enalapril, moexipril, trandolapril and quinapril</td>
<td>Usage of ACEI and ARBs to treat hypertension should be avoided during pregnancy as they severely affect the control over renal function and also foetal and neonatal BP. They may also cause oligohydramnios and skull defects</td>
</tr>
<tr>
<td>ARBs</td>
<td>Losartan, telmisartan</td>
<td>Usage of statins in reduction of elevated levels of cholesterol should be avoided in pregnancy as well as in lactation as they may cause congenital malformation</td>
</tr>
<tr>
<td>Statins</td>
<td>Atorvastatin, rosuvastatin, fluvastatin</td>
<td></td>
</tr>
<tr>
<td>Lipase inhibitor</td>
<td>Orlistat</td>
<td>Obesity treatment in pregnancy with orlistat shows low risk to foetus and hence should be used with caution during pregnancy</td>
</tr>
</tbody>
</table>

ACEIs: Angiotensin converting enzymes, ARBs: Angiotensin receptor blockers, BP: Blood pressure
maintained between 70-110 mg/dL may be considered. Rapid acting insulin analog like aspart or lispro are the preferred choice in achieving target glyceamic value as they minimize the risk of hypoglycaemia. Use of oral anti-diabetics during intrapartum is not permitted as patients are on insulin or glucose infusion during that phase. Also FDA does not approve use of oral anti-diabetics during pregnancy.\[^{830}\]

**Postpartum management**

**Care of newborn**

Neonates born to women with pre-existing T2DM are at a higher risk of morbidities like macrosomia, hypoglycaemia, respiratory distress, cardiomyopathy, hematologic disorders and hypocalcaemia.\[^{848}\] It is recommended to admit babies showing signs of above morbidities to the NCU immediately postpartum for proper care and management.\[^{834}\] To minimize neonatal complication, proper diabetic management in the antenatal period is required and delivery should be accompanied by experienced paediatricians.\[^{827}\]

**Glycaemic control**

Insulin requirement falls in the postpartum period by 34% than that required in preconception period. Over the next 1-2 weeks of postpartum the insulin requirement returns back to that required during pre-conception period. Women on insulin should be closely monitored to avoid the risk of hypoglycaemia. Monitor maintenance of pre-feed capillary plasma glucose level of the neonate and assure it to be minimum 2 mmol/L.

**Lactation**

Breastfeeding should be encouraged in women with pre-gestational diabetes. There is a sharp decline in the insulin requirement after delivery and hence the dose of insulin needs to be adjusted accordingly.\[^{827}\] Dietary care to prevent risk of obesity and neonatal care is prime concern during lactation. Strict control over blood glucose level for women with pre-existing diabetes who underwent caesarean section is important to avoid infection injuries. During lactation, women with pre-existing diabetes can resume or continue to take metformin and glibenclamide immediately after birth, however should avoid use of medicines that were contraindicated during pregnancy, for treatment of diabetes and its complication, due to safety considerations. ACE inhibitors, ARBs, oral hypoglycemic agents, obesity medicines and statins should be avoided during breastfeeding.\[^{831}\]

**Postpartum contraception**

One of the major barriers to effective preconception care is unplanned pregnancy. To minimize the risk of congenital malformation due pre-existing diabetes and its complications it is important to remind women in postpartum period about use of effective contraception and family planning. For women who do not choose permanent contraception with tubal ligation, long-acting reversible contraception with an intrauterine device or implantable progestin are the most effective forms of contraception and should be recommended.\[^{849}\]

---

**TYPE 2 DIABETES MELLITUS AND CRITICAL ILLNESS**

**Recommendations**

<table>
<thead>
<tr>
<th>Recommended Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Maintain glycaemic target of 140-180 mg/dL in medically morbid patients and a target of 110-140 mg/dL in surgically morbid patients</td>
</tr>
<tr>
<td>• Intensive insulin therapy should be initiated when the blood glucose level is more than 180 mg/dL</td>
</tr>
<tr>
<td>• Patients on continuous IV insulin infusion should be monitored frequently to avoid the risk of hypoglycaemia</td>
</tr>
<tr>
<td>• Monitor blood glucose on hourly basis and then every 2 h once blood glucose level is stable or 3 consecutive readings fall near the target glycaemic range</td>
</tr>
<tr>
<td>• Insulin in the form of continuous IV infusion is the only recommended route of administration in the critical care setting.</td>
</tr>
<tr>
<td>• Use of SSI, long or intermediate acting insulin regimens and premixed insulin, subcutaneously are not recommended</td>
</tr>
<tr>
<td>• On admission in the hospital, there should be mandatory testing of blood glucose, in 24 h at least two readings should be obtained</td>
</tr>
<tr>
<td>• CGMS should be preferred for glucose monitoring in critically ill patients</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Limited Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Use validated written or computerized protocols for predefined insulin dosage based on glycemic fluctuations</td>
</tr>
<tr>
<td>• Hospitals should have a record of hypoglycaemic episodes and should be evaluated for root cause</td>
</tr>
</tbody>
</table>
BACKGROUND

Risk of longer hospital stay, morbidity and mortality increases with the risk of hyperglycaemia in the ICU. There have been several discussions on the ideal glycaemic control in surgical, medical or cardiac ICUs but the results are controversial and the final outcome has not been attained.\(^\text{[850]}\) Hospitalization of the diabetic patient interrupts the outpatient balance of medications, diet, and exercise, and may lead to hyperglycaemia or hypoglycaemia.\(^\text{[851]}\) Conversely, hyperglycaemia as a co-morbid condition increases the level of severity of primary illness and complicates the patient management.\(^\text{[852]}\) There have been many published guidelines on management of hyperglycaemia in hospitalized patients but with unclear biases involving nutritional, sociobehavioral, economic and cultural factors. Further, differences in racial, genetic and ethnic conditions impact insulin resistance, glucose and lipid metabolism which makes it difficult to apply western guidelines to Indian population. Hence in India there is an acute need to formulate relevant guidelines, friendly to both patient and physician to control hyperglycaemia in hospitalized diabetic patients.\(^\text{[853]}\)

Glycaemic targets in critically ill patients

For the majority of critically ill patients with medical morbidity, ADA and AACE recommends the premeal glycaemic target to be between 110-130 mg/dL and the post meal 140-180 mg/dL (7.8–10.0 mmol/L).\(^\text{[854]}\) For patients with surgical morbidity, a goal of 110-40 mg/dL (6.1-7.8 mmol/L) is recommended if achievable without causing hypoglycaemia.\(^\text{[855]}\) The American College of Physicians recommends avoiding blood sugar levels below 140 mg/dL, due to the associated risks of hypoglycaemia and glycaemic variability, in ICU patients and glycaemic target of >180 mg/dL and less than 110 mg/dL are not recommended.\(^\text{[856]}\)

Moderate versus tight glycemic control in intensive care unit

In critically ill patients, controlling blood glucose to the normal range as of healthy adult i. e 4.4–6.1 mmol/L with an aim to avoid hypoglycaemia is called tight glycemic control (TGC). The Leuven trials and the normoglycaemia in intensive care evaluation-survival using glucose algorithm regulation (NICE-SUGAR) trial were conducted based on the TGC. Intensive insulin therapy to maintain blood glucose at or below 110 mg/dL is known to reduce morbidity and mortality among critically ill patients in the surgical intensive care unit.\(^\text{[856]}\) To maintain the patient in normoglycaemic range, the intensive insulin therapy was initiated when the blood glucose level reached renal threshold value usually \(\geq 12 \text{ mmol/L}\) in Leuven trial. Conversely in the NICE-SUGAR trial, intensive glucose control increased mortality among adults in the ICU: a blood glucose target of \(<180 \text{ mg/dL}\) resulted in lower mortality than a target of 81 to 108 mg/dL [Table 32].\(^\text{[857]}\) Although the Leuven trial was associated with lower mortality rates, overall the TGC does not show any additional benefit.

Glycaemic variability in critically unwell

Glycaemic variability (GV) in critically ill patients have a negative impact and increased rate of mortality along with severe hyperglycaemia. Risk of hypoglycaemia increases with the GV. Hence, clear understanding of GV is required to maintain glycaemic targets in the critically ill patients. It has been noted that there is an increase in insulin sensitivity over the duration of stay in ICU. During the first 24h to 48h the insulin requirement rapidly increases. At the onset of critical illness, patient being initially non-responsive to low intrinsic insulin sensitivity can lead to over administration of insulin. Thus, change in hormonal regulation increases risk of hypoglycaemia if TGC protocols are not taken into consideration.\(^\text{[856]}\)

During the length of stay in ICU, patient’s clinical assessment that includes fluctuation in glucose level, illness severity, concomitant medication that brings about GV (e. g glucocorticoids) and nutritional status should be carried out on daily basis to calculate insulin dosing [ADA 2019].

Insulin therapy in critically ill and route of administration

OADs should be discontinued and their use avoided in the critical care setting. A continuous insulin infusion in the critically ill patient with T2DM may provide optimal glycaemic management.\(^\text{[851]}\) Insulin regimens should provide basal insulin and short-acting insulin to cover meal-related glucose excursions and to improve glycaemic control acutely. Unless the hyperglycaemia is mild and expected to be transient, regular insulin sliding scales should not be used alone in hospitalized patients. The IV infusion of insulin is initiated when the blood glucose level is \(>180 \text{ mg/dL}\). Insulin analogs like insulin aspart and insulin lispro as IV have less variability in pharmacokinetic properties and it is also easier to predict their absorption and duration of action, hence are more preferable than normal neutral protamine Hagedorn (NPH). Regular preprandial and postprandial insulins when replaced with these rapid-acting insulin analogs can reduce the risk of hypoglycaemia.\(^\text{[856]}\)

Glucose monitoring in critically ill [Figure 17]

Glucose measurement should be performed every 2 to 4 h. If the serum glucose concentration are constantly fluctuating, it may be necessary to measure glucose every 30 or 60 min. Approaches like venous, or whole blood, capillary blood and/ or plasma have been practiced for the accurate blood glucose monitoring. In India, capillary blood glucose assessment is the only approach followed till date.\(^\text{[858]}\) For patients who
Figure 17: Point-of-care meters based monitoring of blood glucose in critically ill patients

are not on meals, the glucose monitoring is performed every 4-6 h whereas for those who take meals, preprandial glucose monitoring is preferred. Patients receiving intravenous insulin infusions require monitoring every 30 minutes to every 2-h. Point-of-care meters (POC) should be checked for its accuracy and approval status before use, to measure blood glucose in hospital settings.

Continuous Glucose Monitoring (CGM) helps to maintain the glycaemic target goals as they provide measurement of intermediate glucose levels frequently. CGM is advantageous over POC testing as they measure both magnitude as well as the direction of glucose trends which helps in minimizing the risk of hypoglycaemia. Compared to intermittent monitoring systems, CGM can offer benefit in the prevention of severe hyperglycaemia and hypoglycaemia by enabling insulin infusions to be adjusted more rapidly and potentially more accurately.\(^{[859]}\) A sensor based CGMS, which is placed subcutaneously is a preferred method to monitor blood glucose in critically ill patient.\(^{[853]}\)

Hypoglycaemia in critical care

Validated protocols to prevent and treat hypoglycaemia for inpatients should be adopted by each hospital. Blood glucose levels ≤70 mg/dL (3.9 mmol/L) should immediately be addressed in the nurse-initiated, standardised-hospital-wise protocols and also patient individual plans to prevent and treat hypoglycaemia.\(^{[854,860]}\) Information from patients with hypoglycaemic episodes should be recorded in the hospital records and tracked. Patient undergoing sudden dose reduction of corticosteroids, emesis, decreased oral intake, short/rapid-acting insulin showing inappropriate timings with regard to meals, interruption in oral, enteral or parenteral feedings and decreased rate of IV dextrose infusion may trigger iatrogenic hypoglycaemia. Prescribing appropriate medication for hypoglycaemia, proper treatment of first hypoglycaemic episode, suitable nutritional management and maintaining nutrition-insulin match throughout the hospital stay can help preventing iatrogenic hypoglycaemia.\(^{[860]}\) Proactive monitoring of glycaemic levels and data-driven glycaemic management approaches can serve as preventive measures for hypoglycaemia in the hospital.\(^{[867]}\)
**Type 2 Diabetes Mellitus in Young and Adolescents**

**Recommendations**

<table>
<thead>
<tr>
<th>Recommended Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Risk-based screening for prediabetes and/or T2DM should be considered in asymptomatic children and adolescents, performed after the onset of puberty or after 10 years of age, whichever occurs earlier.</td>
</tr>
<tr>
<td>• If tests are normal, repeat testing at a minimum of 3-year intervals, or more frequently if BMI is increasing.</td>
</tr>
<tr>
<td>• Fasting plasma glucose, 2-h plasma glucose during a 75-g oral glucose tolerance test, and HbA1c can be used to test for prediabetes or diabetes in children and adolescents.</td>
</tr>
<tr>
<td>• Panel of pancreatic autoantibodies tested to exclude the possibility of autoimmune T1DM.</td>
</tr>
<tr>
<td>• Treatment of youth-onset T2DM should include lifestyle management (long-term weight management, vigorous physical activity, healthy eating patterns), diabetes self-management education, self-monitoring of blood glucose, and pharmacologic treatment.</td>
</tr>
<tr>
<td>• A family-centred approach to nutrition and lifestyle modification is essential and nutrition recommendations should be culturally appropriate and sensitive to family resources.</td>
</tr>
<tr>
<td>• Bariatric surgery may be considered in adolescents with marked obesity (BMI: &gt;35 kg/m²) and uncontrolled glycaemia and/or serious comorbidities despite lifestyle and pharmacologic intervention.</td>
</tr>
<tr>
<td>• Blood pressure should be measured and optimized to reduce risk and/or slow the progression of diabetic kidney disease.</td>
</tr>
<tr>
<td>• Youth with T2DM should be screened for the symptoms of other comorbidities including laboratory studies when indicated for neuropathy, retinopathy, non-alcoholic fatty liver disease, obstructive sleep apnoea, polycystic ovary syndrome (in female adolescents), cardiovascular disease, and dyslipidaemia.</td>
</tr>
<tr>
<td>• Starting at puberty, preconception counselling should be incorporated into routine diabetes clinic visits for all females of childbearing potential.</td>
</tr>
<tr>
<td>• Patients should be screened for smoking and alcohol use at diagnosis and regularly thereafter.</td>
</tr>
</tbody>
</table>

**Background**

Until recently most children with diabetes had type 1 disease, however, prevalence of T2DM in children and adolescents is dramatically increasing.[861] Onset of diabetes at a younger age is associated with longer disease exposure and increased risk for chronic complications. This young-onset T2DM essentially affects individuals of working age, further accentuating the adverse societal effects of the disease. Several studies have demonstrated that there has been a shift in the age (<30 years) at onset of T2DM in India.[862-867] The major predisposing diabetes risk factors in children and young adults include obesity, decrease in physical activity, family history, and sedentary lifestyle. In addition, other factors including prenatal factors (e.g., low birth weight, maternal under-nutrition), biological propensity to central obesity and insulin resistance, low lean mass, diabetes during pregnancy, impaired glucose tolerance, and urban stress are associated with high prevalence of T2DM in Indian children and young adults.[864,867-872]

More recently, up to 1 in 3 new cases of diabetes mellitus in USA diagnosed in youth younger than 18 years is T2DM and is common among youth between 10 and 19 years of age.[863]

**Pathophysiology of type 2 diabetes mellitus in young versus adults**

The mechanism of development of T2DM in young people are similar to those in older patients; however, the speed of onset, severity, and interplay of reduced insulin sensitivity and defective insulin secretion might be different in patients who develop the disease at a younger age.[873] Studies suggest that loss of β-cell function is accelerated in young-onset type 2 diabetes to 20–35% annual decline as compared to 7% decline in adults.[874] This suggest that T2DM in adolescents and children might have a more aggressive course along with loss of β-cell function as compared with adult later onset T2DM.[873]

**Screening and diagnosis**

The diagnosis criteria for children and adolescents are symptoms of diabetes mellitus such as polydipsia, polyuria, and unexplained weight loss plus casual glucose concentration ≥200 mg/dL (11.1 mmol/L) in venous plasma, fasting glucose ≥126 mg/dL (7.0 mmol/L) in venous or capillary plasma, or 2-h glucose during OGTT ≥200 mg/dL (11.1 mmol/L) in venous plasma or capillary whole blood or HbA1c ≥6.5%.[875] Children at substantial risk for the presence or the development of type 2 diabetes mellitus should be tested. Children and adolescents who are overweight (BMI ≥90 percentile) and have family history T2DM in first- or second-degree relative must be screened. Children with certain signs of insulin resistance or conditions associated with insulin resistance such as acanthosis nigricans, hypertension, dyslipidaemia, polycystic ovarian syndrome, must also be screened regularly.[876]

**Management of type 2 diabetes mellitus in children and adolescents**

The ideal goal of treatment is normalization of blood glucose values and HbA1c. Weight control is essential for reaching treatment goals and are effective to treat type 2 diabetes mellitus in adolescents. Although lifestyle modification is the most commonly used intervention in adolescents with type 2 diabetes, less than 20% achieve or maintain adequate glycaemic control with lifestyle intervention alone.[877] Aerobic activity, alone or in combination with diet, can reduce systolic blood pressure, reduce total cholesterol, raise HDL cholesterol, and improve endothelial function in overweight children with T2DM.[878] Metformin, is the most appropriate starting point for pharmacological treatment in children with T2DM. Results of the TODAY study suggest that monotherapy with metformin was associated with durable glycaemic control in children and adolescents.[879] Bariatric surgery has emerged as a viable treatment option in young individuals with type 2 diabetes and evidence has shown that it is safe and effective in obese adolescents.[880] However clinical data to support this are limited.
**Recommendations**

### Recommended Care

- **Fasting to be avoided in individuals with T2DM especially if they also have:**
  - Uncontrolled or unstable glycaemia history of recurrent diabetic ketoacidosis (DKA), significant macrovascular/microvascular complications or hypoglycaemic unawareness
  - Individuals with T2DM should abstain from fasting if they are:
    - On intensive insulin therapy or experience frequent hypoglycaemic episodes
    - Non-adherent to advice on diet, drug regimens, and daily activities
    - Antenatal or nursing or elderly or children
  - Diabetic individuals who wish to fast must:
    - Consult a physician prior to fasting
    - Should be encouraged to participate in pre fast counselling/assessment to optimize monitoring/therapeutic strategies for optimal glycaemic control
  - During fasting, patients with diabetes should always:
    - Carry some sweets/glucose source to be used in case of hypoglycaemia
    - Carry identification card displaying diabetic status and current medication
    - Test blood glucose levels regularly (especially, if unwell during fasting)
    - Treat promptly if glucose levels are deranged
    - In case of dehydration or hypoglycaemic episode-end the fasting immediately
    - Discuss with the physician regarding change in dose, and timing of insulin injections
  - Hypoglycaemia may be prevented in four levels including primordial, primary, secondary and tertiary, using ASAP (Anticipate, Suspect, Act to treat, Prevent) strategy
  - Metformin, incretin based therapies (sitagliptin, vildagliptin and lixisendal) and pioglitazone, glinides, AGIs, newer sulfonylureas like gliclazide MR and glimepiride are the preferable agents to be used during fasting that is spread over a number of days or weeks. In patients on insulin therapy analogues may be preferred over conventional insulins. Since prolonged fasting may involve significant reduction in fluid intake so SGLT-2 Inhibitors may be avoided.
  - To minimize T2DM-related AEs during fasting, patient centred diabetes education, fasting nutrition plan with regular glucose monitoring and adjustment of treatment regimens is recommended.

### Background

Fasting is just not merely abstaining from food or ‘starving’, it is defined as the ability to meet the body’s requirements for vital nutrients during either shortage or absence of food, by utilizing the body’s energy reserves without jeopardising health and wellbeing. Periodic voluntary fasting, is a common religio-cultural practice adopted by individuals from various religions across the world for centuries as a crucial pathway of spiritual purification. Fasting or food abstinence, initiates metabolic and psychological changes and adaptations which need close monitoring, primarily in patients with derailed metabolism. Therefore, individuals with diabetes, or pre-diabetes must fast only after appropriate risk assessment and counselling with healthcare practitioners (HCPs) and religious leaders and make an informed decision. In diabetic individuals, insulin resistance and/or deficiency can lead to excessive glycogen breakdown and a surge in gluconeogenesis or ketogenesis leading to sudden hyperglycaemia, diabetic ketoacidosis, dehydration and thrombosis. Furthermore, in special populations like pregnant individuals, geriatric patients, individuals with comorbidities such as cardiac, renal or hepatic impairment, the risk of complications may increase if appropriate care is not taken. Therefore, a patient-centric approach with diet plan, and dose modification/omission with careful monitoring during fasting period may reduce the complications in patients with diabetes. Depending on the degree of abstinence from food, fasts may be classified as follows [Table 33].

### Religious fasts

Although, religious fasts seldom exceed 24 h, the variability of the duration of every phase may lead to different physiological responses to fasting particularly in patients with diabetes. Though several guidelines are available for different aspects of diabetes care, fasting in diabetes poses a unique challenge. Additionally, designing randomized controlled studies to address fasting related issues in patients with diabetes is particularly difficult. Therefore, understanding the physiology of fasting [Figure 18] and linking it to pathophysiology and clinical manifestation

<table>
<thead>
<tr>
<th><strong>Table 33: Types of fast</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete fasting: Giving up food and water completely for a period</td>
</tr>
<tr>
<td>Partial fasting: Eating less than you need to avoid hunger</td>
</tr>
<tr>
<td>Limiting the number of food items eaten</td>
</tr>
<tr>
<td>Giving up favourite foods</td>
</tr>
</tbody>
</table>
of diabetes is required to design strategies for glycaemic management during fasting.\textsuperscript{[883]}

The different religious fasts commonly observed in India that can have significant impact on metabolic and glycaemic health in diabetics are:

- Ramadan fasting: It is a principle ritual followed by Muslims during the sacred month of Ramadan (the ninth lunar month of Islamic/Hijri calendar).\textsuperscript{[886]} During this month, all healthy adult Muslims abstain from food, drinks and medication from dawn to dusk (sunset). Believers usually eat two meals, one before dawn (Suhur) and one after sunset (Iftar). Hypoglycaemia and dehydration are major complications associated with fasting though hyperglycaemia may occur, due to over indulgence in food during the two main meals of Suhur and Iftar.\textsuperscript{[886,887]} Therefore, pre fast risk stratification, followed by a treatment tailored to individual needs appears to be the best management strategy. In addition, structured education enables patients to self-manage their condition better.\textsuperscript{[885-887]}

### Table 34: Factors to be modified

<table>
<thead>
<tr>
<th>Fasting</th>
<th>Antidiabetic agents</th>
<th>Individual phenotype</th>
<th>Patient characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of fast</td>
<td>Potential for hypoglycaemia</td>
<td>Risk of hypoglycaemia</td>
<td>Pregnancy</td>
</tr>
<tr>
<td>Restriction of fluids/solids: absolute/partial</td>
<td>Potential for dehydration</td>
<td>Risk of hypoglycaemia unawareness</td>
<td>Elderly</td>
</tr>
<tr>
<td>Frequency of fast (once weekly/once monthly/once yearly/others)</td>
<td>Potential for gastrointestinal upset</td>
<td>Ability to self-monitor BG</td>
<td>Concomitant diseases</td>
</tr>
<tr>
<td>Duration of action</td>
<td></td>
<td></td>
<td>Adolescent and children</td>
</tr>
</tbody>
</table>

BG: Blood glucose
• Hindu fasts: Though not mandatory, most Hindus observe day-long and week-long fasts. KarvaChauth, Guru Purnima, Ekadashi, Makar Sakranti and Holi Ashami are some of the annual, monthly and weekly fasts observed as part of various vows. During Navratri, which occurs twice a year, Hindus observe fast for 9 days usually from dawn to moonrise/star-rise. The day-long nature of Hindu fasts however makes it distinct from the month-long fasts of Ramadan and Buddhist Lent. Unlike Islam, there are no universal rules laid down for Hindu fasts, and therefore data on metabolic effect of these fasts are scanty thus far.[888,889]

• Jain fasts: During the pious month of Paryushana (eight days for the Shwetamber sect, ten days for the Digamber sect), Jains usually fast from dusk to dawn unlike Hindu fasting which extends from dawn to moonrise.[882]

**Considerations**

Based on the following factors the glucose lowering therapy/strategy during fasting period may be modified/altered [Table 34].

**Rationale and Evidence**

Complete abstinence from food and drink between sunrise and sunset can lead to disruption of homeoeostasis. Since the majority of diabetic individuals are asymptomatic, they are unaware of the potential deleterious effects of diabetes, particularly during religious fasts. Additionally, conditions of complete abstinence from food and/or water during religious fast leads to skipping medications, culminating in to derailed metabolism and worsening of their condition.

• An observational study in Muslim patients with diabetes fasting during Ramadan reports that 59% patients had substantial knowledge of diabetes, 37% patients did not monitor their blood glucose levels in the previous Ramadan and 47% had hypoglycaemic episodes.[890]

• In a prospective clinical study conducted in Iran the glycaemic control deteriorated significantly among T2DM patients who opted to fast during Ramadan and however the, HbA1c levels reduced significantly following the month after Ramadan.[891]

**Recommendations on management of diabetes during fasting**

Concerned physicians and the HCPs may play a critical role in educating the patients with diabetes during fasting [Figure 19]. Patients and their families should be included in a structured diabetes educational programme, which gives information on risk quantification, physical activity, glucose monitoring, diet, hypoglycaemia, dosage and timing of medications, and identification of the symptoms of complications.[892]

• Implementation of the Ramadan Education and Awareness in Diabetes (READ) programme led to significantly lower weight gain (p<0.001) and hypoglycaemic episodes (p<0.001) with reduced risk of acute complications compared to those who were not educated during fasting.[158]

• Self-monitoring of blood glucose (SMBG) should be considered as an important tool that helps both patients and physicians to practice safe decision making regarding drug dosage and other aspects of management.[193]

• Patients who received individualized education are more likely to modify their diabetes treatment plan during Ramadan, perform self-monitoring of blood glucose at least twice daily during Ramadan and to have improved knowledge about hypoglycaemic signs and symptoms as compared to patients who followed the standard diabetes management protocol.[194]

**Lifestyle modification and nutrition**

• Fasting or healthy abstinence from food, is a form of lifestyle modification for T2DM patients and if utilized appropriately, may result in several health benefits to these patients.[195]

• Pre-fasting diet should include slow release foods and patients with T2DM should not indulge in over-eating in the post-fasting period in order to avoid postprandial hyperglycaemia.[195] Therefore, complex carbohydrates like whole grains, potato, berries, citrus fruits, apple, nuts and legumes at pre-fasting, and simple carbohydrates like bread, cereals, rice, and pasta at post-fasting may be more appropriate to reduce complications.[886]

• During prolonged fasting periods like Ramadan or Navaratri, physical activity should be restricted. While routine exercise can be continued, elective moderate to highly vigorous exercise should be rescheduled.[888]

**Pharmacological management**

• Individualized or bespoke treatment choices must be made for oral agents during fasting period.[896] Antidiabetic agents that improve the insulin sensitivity must be chosen as the risk of hypoglycaemia is significantly lower.[885]

• Biguanides (Metformin) are generally considered safe in patients with diabetes during fasts due to minimal incidences of hypoglycaemia, however, once daily dosing need to be adjusted or modified to avoid complications.[897] Slow-release formulations of metformin must be taken once daily following the sunset meal.[898]

• Sulphonylureas (new generation: gliclazide MR and glimepiride) should be preferred over older, long acting sulphonylureas like glibenclamide and chlorpropamide during Ramadan fasting, as they are relatively more safe and economical.[171,884,878,899] Glibenclamide may be associated with a higher risk of hypoglycaemia than other second generation sulphonylureas like gliclazide, glipezide, and glimepiride.[884] Therefore use of sulfonylurea should be individualized.
Recommended Care

- A patient-centred, structured diabetes self-management education (DSME) is an integral part of the care of all people with T2DM.
- The diabetes self-management education and support (DSMES) program should be conducted at four critical times: at diagnosis, annually, when complicating factors arise, and when transitions in care occur.
- Education programs can be conducted by medical professionals, certified diabetes educators who are quality assured to provide education (Certified Diabetes Educators) either in groups or individual settings. If needed, any family member, friend or a caretaker should be involved.
- The education program should focus more on rural or poorly educated patients as they have less knowledge and awareness regarding diabetes. Different education material may be needed for such patients.
- Switching anti-hyperglycaemic treatment to sitagliptin from a sulfonylurea reduced the risk of symptomatic hypoglycaemia by approximately 50% in patients who fasted during Ramadan.
- In Treat 4 Ramadan trial, liraglutide compared with sulfonylurea was well tolerated with more patients achieving target HbA1c, lose or maintain weight with no severe hypoglycaemia and with high level of treatment satisfaction.
- Contrary to the Treat 4 Ramadan trial, no significant difference between liraglutide and sulfonylureas in terms of severe hypoglycaemia. However, significant, weight loss and HbA1c reduction (p<0.0001) were observed in liraglutide group suggesting that liraglutide may be considered an effective therapy in combination with metformin during Ramadan.
- Sodium-glucose cotransporter 2 inhibitors may be used during fasting, in view of their low risk of hypoglycaemia. However, the potential risk of dehydration must be considered.
- Treatment with dapagliflozin was associated with fewer incidences of hypoglycaemia than sulfonylureas (p=0.002).
- A recent survey report conducted in physicians highlights that SGLT2 inhibitors are safe and effective for T2DM management during Ramadan and (92.2%) physicians suggested prescribing SGLT2 inhibitor with the first evening meal (iftar).
- Use of a rapid acting insulin analogue instead of regular human insulin before meals in patients with T2DM who fast during Ramadan was associated with less hypoglycaemia and less PPG excursions.
- Use of sodium-glucose cotransporter 2 inhibitors may be used during fasting, in view of their low risk of hypoglycaemia. However, the potential risk of dehydration must be considered.
- Treatment with dapagliflozin was associated with fewer incidences of hypoglycaemia than sulfonylureas (p=0.002).
- Use of a rapid acting insulin analogue instead of regular human insulin before meals in patients with T2DM who fast during Ramadan was associated with less hypoglycaemia and less PPG excursions.
- A recent survey report conducted in physicians highlights that SGLT2 inhibitors are safe and effective for T2DM management during Ramadan and (92.2%) physicians suggested prescribing SGLT2 inhibitor with the first evening meal (iftar).

Detailed information on categories of risk in patients with T2DM who fast during Ramadan can be found in Annexure 8.

Detailed information on recommended changes in treatment regimens of OADs and insulin in patients with T2DM who fast during Ramadan and other religious fasts can be found from in the Annexure 9.

Education

Thiazolidinedione (pioglitazone and rosiglitazone) are generally regarded as safe and in patients who fast during Ramadan, however, it may lead to an increase in body weight.

Incretin based treatments may maintain adequate glycaemic control in a glucose-dependent manner, thus providing a safe alternative therapeutic option during Ramadan.

Vildagliptin was found to be effective, safe, and well tolerated in T2DM patients fasting during Ramadan, with a consistently low incidence of hypoglycaemia across studies, accompanied by good glycaemic and weight control.

Switching anti-hyperglycaemic treatment to sitagliptin from a sulfonylurea reduced the risk of symptomatic hypoglycaemia by approximately 50% in patients who fasted during Ramadan.

In Treat 4 Ramadan trial, liraglutide compared with sulfonylurea was well tolerated with more patients achieving target HbA1c, lose or maintain weight with no severe hypoglycaemia and with high level of treatment satisfaction.

Contrary to the Treat 4 Ramadan trial, no significant difference between liraglutide and sulfonylureas in terms of severe hypoglycaemia. However, significant, weight loss and HbA1c reduction (p<0.0001) were observed in liraglutide group suggesting that liraglutide may be considered an effective therapy in combination with metformin during Ramadan.

Sodium-glucose cotransporter 2 inhibitors may be used during fasting, in view of their low risk of hypoglycaemia. However, the potential risk of dehydration must be considered.

Treatment with dapagliflozin was associated with fewer incidences of hypoglycaemia than sulfonylureas (p=0.002).

A recent survey report conducted in physicians highlights that SGLT2 inhibitors are safe and effective for T2DM management during Ramadan and (92.2%) physicians suggested prescribing SGLT2 inhibitor with the first evening meal (iftar).

Use of a rapid acting insulin analogue instead of regular human insulin before meals in patients with T2DM who fast during Ramadan was associated with less hypoglycaemia and less PPG excursions.

Use of sodium-glucose cotransporter 2 inhibitors may be used during fasting, in view of their low risk of hypoglycaemia. However, the potential risk of dehydration must be considered.

Use of a rapid acting insulin analogue instead of regular human insulin before meals in patients with T2DM who fast during Ramadan was associated with less hypoglycaemia and less PPG excursions.

A recent survey report conducted in physicians highlights that SGLT2 inhibitors are safe and effective for T2DM management during Ramadan and (92.2%) physicians suggested prescribing SGLT2 inhibitor with the first evening meal (iftar).

Use of sodium-glucose cotransporter 2 inhibitors may be used during fasting, in view of their low risk of hypoglycaemia. However, the potential risk of dehydration must be considered.

Use of a rapid acting insulin analogue instead of regular human insulin before meals in patients with T2DM who fast during Ramadan was associated with less hypoglycaemia and less PPG excursions.

A recent survey report conducted in physicians highlights that SGLT2 inhibitors are safe and effective for T2DM management during Ramadan and (92.2%) physicians suggested prescribing SGLT2 inhibitor with the first evening meal (iftar).
BACKGROUND

Diabetes self-management education (DSME) is a key component of management of T2DM, facilitating the knowledge and skills required to improve self-care practices to prevent or delay progression and development of diabetes. Numerous studies report that DSME is associated with improved metabolic control, reduced glycaemic levels, fewer complications, and improved quality of life (QoL). DSME program is aimed to improve diabetic knowledge and empower people to make informed choices to self-manage their condition more effectively. It is guided by evidence-based standards while incorporating needs, goals and life-experiences of the patients with diabetes. The 2019 Standards of Medical Care in Diabetes recommends that people living with diabetes should be actively engaged in education, self-management, and treatment planning with their health care team, including the collaborative development of an individualized eating plan. The 2019 consensus report by ADA and EASD on management of hyperglycaemia in T2DM recommends that all people with T2DM should be offered access to ongoing DSMES (Diabetes self-management education and support) programs.

India represents a country with diversity in social, economic, cultural, and educational patterns. Majority of Indian population resides in rural areas, where there is lack of knowledge and awareness on diabetes than urban population. No or low literacy in India is the key deterrent to poor level of awareness of diabetes. Effective patient education is an essential tool in resource poor settings like India, where prevalence of T2DM has escalated to epidemic proportions over past 2 decades.

CONSIDERATIONS

The panel endorsed the IDF recommendations on education as such. However, evidence from India together with local factors such as cost, literacy, malnutrition, body weight, and BMI were reviewed in the Indian context and are reflected in the recommendations.

RATIONAL AND EVIDENCE

Educational programs and their outcomes

- In management of T2DM patients, structured diabetes care program (Freedom 365*) of ongoing diabetes education on diet and lifestyle correction, biochemical investigations, clinical monitoring, and treatment at regular intervals was associated with better clinical outcomes compared to routine medical care. The program played a pivotal role in improving the patient’s quality of care by overcoming clinical inertia, improving adherence to therapy, while preventing the occurrence/progression of diabetes associated complications.
- Organized diabetes education, that involves improving knowledge on better control of disease symptoms, disease regimens, and risks in practice was found to have a positive impact on lifestyle changes, self-control abilities, and improving the QoL in T2DM patients.
- A recent systematic review including 118 unique interventions reported that DSME was associated with a statistically significant mean reduction in HbA1c levels (-0.74 for intervention and -0.17 for control groups).
- A case control study conducted in the department of medicine of a tertiary care teaching hospital in north-west India demonstrated that effective health education improves knowledge, attitude, and practices leading to better glycaemic control that can slow down the progression of diabetes and prevent downstream complications.
- To minimize the increasing burden of NCDs, ministry of health and family welfare, Government of India, has launched the National Programme on Prevention and Control of Diabetes, Cardiovascular diseases and Stroke (NPDCS) on 8th January 2008 with several objectives including health promotion and health education for the community.
- Besides diabetes, educational intervention was also successful in reducing some of the obesity parameters and improving dietary patterns in individuals with pre-diabetes and diabetes. Initiation of primary prevention strategies through education right from elementary schools could reduce IFG by 17% suggesting such interventions may delay T2DM or even change the course of disease for improved outcomes among vulnerable population groups.
- Awareness about early detection and treatment of hyperglycaemia in pregnancy is also important, as it will not only offer better fetal outcome, but a good glycaemic control during pregnancy will provide better intrauterine metabolic environment, which may help to prevent the development of diabetes, obesity, and metabolic syndrome in these offspring of diabetic mother in their later life.
- India held the world’s first national GDM (NGDM) Awareness Day on March 10, 2019 for raising awareness about the link between maternal health and diabetes nationwide, and invited pregnant women to hospitals and clinics for free screening. The program included training for healthcare professionals, press conferences, awareness raising events, seminars for women’s group, and widespread screening.

Knowledge and awareness

- The ICMR-INDIAB study reported that the awareness of diabetes in urban India was significantly higher than rural residents (58.4% vs 36.8%, p<0.001). Furthermore, participants from Tamil Nadu had the highest (31.7) and Jharkhand the lowest (16.3) knowledge score, and among self-reported patients with diabetes, Maharashtra had the highest (70.1) and Tamil Nadu, the lowest score (56.5).
- Similarly another ICMR-INDIAB study including 14,277

...
participants revealed that only 480 patients were with self-reported diabetes (254 urban and 226 rural) and the level of glycaemic control among patients with self-reported diabetes in India was poor.\[36\]

- A population-based study from a south Indian state reported that among 6211 participants, good knowledge and positive attitude were observed in 3457 (55.6%) and 3280 (52.8%) people, respectively. Furthermore, literacy had a significant association with good knowledge, attitude, and practice in general and T2DM population. Overall, women had significantly better knowledge (p<0.001).\[97\]

- A recent study from east Delhi, India reported that self-learning module (SLM) was significantly associated with increasing knowledge on aspects of effect of diabetes on foot (p<0.05), foot care and its steps (p<0.05) than control group in T2DM patients\[918\]

- Though general practitioners in India are aware and updated about symptoms and screening of T2DM, there is a dearth of effective approaches towards screening and treatment of complications. Most patients are usually not advised on non-pharmacological measures and diabetes education, while interpretation of test results for screening of disease and its complications appear to be a major flaw in general practice.\[55\]

- Evidence from several studies determining the level of knowledge and awareness on diabetes across India suggests that most of the patients had poor knowledge and awareness about their condition.\[912,919-925\] Low socio-economic status, old age, cultural factors, lack of access to healthcare, family history of diabetes, and importantly low literacy levels were the major predictors of poor glycaemic control among patients with T2DM.

- A cross-sectional, questionnaire-based survey was conducted in 100 patients attending the diabetic unit of a tertiary care teaching hospital in central India. Majority of patients were found to be aware about hypoglycaemic symptoms and its treatment and development of complications. Regular check-up was done by 70% of patients, while 73% were adhered to treatment.\[926\]

- A cross-sectional survey was carried out among participants aged ≥18 years, visiting tertiary care eye institute in north India to assess awareness of people about various aspects of diabetes. Of 530 participants interviewed, only 40 (25.6%) diabetic, and 45 (13.8%) non-diabetic participants were aware about diabetic retinopathy. Their knowledge about its risk factors, complications, prevention, and management was poor.\[927\]

- In a study conducted on 400 diabetic patients (out-patient or admitted), awareness of diabetic nephropathy was marginally higher in patients staying in urban areas (vs rural areas, p=0.120) and among the literate (vs uneducated, p=0.567) patients. Awareness of diabetic nephropathy was higher in older patients (p=0.004) and in patients with chronic diabetes (p<0.0001), controlled diabetes (p=0.026), and diabetic nephropathy (p<0.0001).\[928\]

### Challenges in diabetes management in India\[702,929-931\]

- The awareness about the disease and its complications is less than satisfactory.
- There is lack of knowledge, attitude, and practice studies to determine the gaps in knowledge among people living with diabetes and physicians in the areas of individual diabetes care in India. Physician-related issues including inadequate knowledge, delay in clinical response, poor control need to be addressed through diabetes education.
- Lack of knowledge among people living with diabetes is a significant barrier to their ability to self-manage the disease. Hence, there is an imperative need for more structured diabetes education programs in India.
- Lack of strong referral system to provide quality care i.e. early diagnosis, prevention and control of chronic complications in diabetes. Specialist referral for diabetes management is a major challenge in remote and rural primary care facilities, often lacking trained diabetes specialists.\[932\]
- Indian studies have also shown that barriers to insulin therapy are due to lack of awareness, causing wrong perception, and false beliefs. People with ongoing insulin therapy had better understanding and acceptability towards insulin therapy than those not on insulin; besides intensification remains a challenge in these patients.\[933\]
- Implementing efficacious health service intervention like patient education in a real-world resource-constrained setting is challenging and may not prove effective in improving patient outcomes. Therefore, interventions need to consider patients’ and healthcare providers’ experiences and perceptions and how macro-level policies translate into practice within local health systems.\[934\]
- In India, counselling of young unmarried women with diabetes eroding familial support and marital prospects is particularly challenging due to disease-related stigma.\[935\]

### Assessing the need for evidence-based education\[936-940\]

- Diabetes educator (nurse, dietician, social worker, or qualified diabetes educator) can play a major role in raising diabetes awareness and optimal diabetes care.
- Continuous medical education and periodic trainings are needed to help health professionals integrate new knowledge and transform old practices.
- Need to assess the impact of existing education and training programs in diabetes.
- Investment must be made to ensure that specialized diabetes education is accessible to healthcare personnel and people with diabetes.
- General practitioners and physicians should be periodically updated on recent guidelines on diagnosis, treatment as well as management goals.
- Key aim of diabetes education is to change behaviour of people and promote self-management.
- Steps to improve awareness in diabetes care in India:
  - Physician and family physician education
Need for continuing medical education
- Education for patients with diabetes
- Diabetes education programs in India.

- Study has shown that pharmacist may also be involved with clinicians as a part of collaborative diabetes care and has documented positive clinical, humanistic, and economic outcomes, which emphasized the value of multidisciplinary collaborative care for Asian diabetes patients and supported the effectiveness of this approach in managing chronic diseases,[1040]
- Counselling is the most important strategy capable of bringing about sustained lifestyle changes.

IMPLEMENTATION
- Major components of implementing these recommendations are the recruitment of personnel and their training in the principles of both diabetes education and behaviour change strategies. The staff are required to develop theoretically-based, patient-centred, and ongoing and follow-up education programs for people with diabetes. Educational strategies and materials aligned with the needs and culture of the community served with attention to health literacy are necessary. Institutional support at the practice, community, and health care system levels is critically important [Figure 20].
- Diabetes discrimination at education institutes and workplaces is often the result of a lack of knowledge about diabetes. Since diabetes is usually a “hidden” disability, many patients do not understand the gravity of the condition and what it is like to have diabetes. By educating such authorities about diabetes and their needs and abilities, they may be able to get fair treatment.
- Mass awareness campaign through various print and electronic media will also be an effective model of education.

PSYCHOSOCIAL ISSUES

RECOMMENDATIONS

Recommended Care

<table>
<thead>
<tr>
<th>Approach to care</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Diabetes management should be carried out within a framework of informed and shared decision making, following the philosophy of responsible patient-centred care.</td>
</tr>
<tr>
<td>- Psychosocial care should be provided to all individuals with T2DM using a collaborative, patient-centred care approach with referral to mental health care professional where needed.</td>
</tr>
<tr>
<td>- Family members and other close ones in the management of diabetes must be involved</td>
</tr>
<tr>
<td>- Self-disclosure of diabetes, as opposed to maintenance of confidentiality, should be decided on a case-to-case basis, keeping the sociocultural environment in mind</td>
</tr>
<tr>
<td>- HCPs should take care of their own psychosocial health, as compassion fatigue is a common professional hazard.</td>
</tr>
</tbody>
</table>

Assessment
- Periodic assessment of psychosocial well-being should be done using questionnaires or validated tools (e.g. WHO-5, PAID, Whooley’s 2-item questionnaire)
Patients' psychosocial conditions have been highlighted as crucial in the multidisciplinary team and have been recommended by the AAACE, the Chawla, et al.: RSSDI-ESI clinical practice recommendations. The IDF 2018 guideline has suggested the inclusion of a mental health professional with effective coping strategies. The World Health Organization (WHO) has proposed reducing depression in diabetes management. The American Diabetes Association (ADA) and the American Association of Diabetes Educators (AADE) have focused on the Role of Diabetes Self-management Education and Support (DSMES) on improving psychosocial benefits, including the role of diabetes self-management education and support. The ADA and the American Association of Diabetes Educators (AADE) have focused on the role of diabetes self-management education and support (DSMES) on improving psychosocial benefits, including the reduction of depression. In addition, integrating mental health services in diabetes management can help with effective coping strategies. The IDF 2018 guideline has suggested the inclusion of a mental health professional in the multidisciplinary team and highlighted the need for counseling a patient in the setting of ongoing diabetes education and care. The AAACE has recommended, cultural and faith-based aspects of therapy during counseling.

In India, heterogeneity in linguistic, cultural, religious, socioeconomic, educational, regional, and familial factors affects the clinical progression, treatment, and outcome of diabetes management. While family and community support medically-impaired persons as a part of our ethos, societal insensitivity often exhibits itself, as culinary cruelty in many ways for example: Indian patients with T2DM showed a significantly higher perception of burden of social and personal stress associated with the disease, and have been reported to have one of the lowest levels of psychological well-being based on the World Health Organization-5 (WHO-5) Well-being Index. These challenges and strengths warrant the development of India-specific recommendations for psychosocial management of diabetes, sensitive to and appropriate for the Indian context.

**Background**

Complex environmental, social, behavioural, and emotional factors, together known as psychosocial factors, play a crucial role in optimum diabetes management and achieving satisfactory medical outcomes. The daily demands of the disease course and management interrupts the psychological well-being of people with diabetes. The prevalence of comorbid psychosocial problems is greater in patients with diabetes than in the general population. The psychological and social issues such as stress, anxiety, depression, eating disorders, cognitive dysfunction, or other psychological disorders are associated with poor self-care, increased mortality, functional impairment, increased healthcare cost, loss of productivity, and reduced quality of life. Patient’s psychosocial conditions have significant impact on the overall outcomes of diabetic care process.

Euthymia is a target, as well as a tool, for diabetes management. Psychosocial well-being comprehends both physical and mental health, and is integral to diabetes care and self-management. The ADA and the American Association of Diabetes Educators (AADE) have focussed on the role of diabetes self-management education and support (DSMES) on improving psychosocial benefits, including the reduction of depression. In addition, integrating mental health services in diabetes management can help with effective coping strategies. The IDF 2018 guideline has suggested the inclusion of a mental health professional in the multidisciplinary team and highlighted the need for counseling a patient in the setting of ongoing diabetes education and care. The AAACE has recommended, cultural and faith-based aspects of therapy during counseling.

**Considerations**

Diabetes care and self-management is likely to be affected in presence of a mental health disorder that notifies patient’s psychosocial condition. Detection of such disorders in relatively brief consultations with diabetes professionals is challenging. There is a need for some basic training to diabetes professionals in management of psychosocial issues, and for...
Chawla, et al.: RSSDI-ESI clinical practice recommendations

appropriate referral approach to mental health professionals with a knowledge of diabetes, especially for seriously affected patients.

**RATIONAL AND EVIDENCE**

**Challenge**

- Being diagnosed with diabetes imposes a life-long psychological burden on the patient and his/her family. Prevalence of clinically significant depression, anxiety, eating behaviour disorder are considerably more common in patients with diabetes than in those without the disease. [958-960]
- The findings from a systematic review and meta-analysis conducted on 248 observational studies demonstrated that almost one in four adults with T2DM experienced depression; while depression was more common in patients with <65 years of age compared with elderly. [964]
- Poor psychological functioning can seriously interfere with daily diabetes self-management, with subsequent poor medical outcomes and high costs [962,963]

**Solution**

- Collaborative care interventions and a team approach for diabetes management have demonstrated efficacy in self-management with improved psychosocial outcomes,[964,965]
- A systematic review and meta-analysis has shown that, overall, psychological interventions are effective in improving glycaemic control in T2DM.[966]
- A randomized-controlled study showed that web-based guided self-help centred on cognitive behaviour therapy for people with diabetes with mild-to-moderately severe depression is effective.[967]
- Psychological counselling can contribute to improved adherence and psychological outcomes in people with diabetes [Figure 21].[968]

**Implementation**

- Major components of implementing these recommendations is the involvement of HCPs and their training on principles of both diabetes education and psychosocial interventions.
- HCPs are required to develop collaborative, patient-centred medical care strategy for all patients with diabetes to improve health outcomes and quality of life.
- HCPs must be trained in applying psychological assessment tools and monitoring procedures, for diagnosis and periodic evaluation.
- Collaboration with mental health specialists who have knowledge in diabetes can help extend the education and training of other mental health specialists in relation to diabetes.

**COMPLEMENTARY AND ALTERNATE THERAPY**

**RECOMMENDATIONS**

**Recommended Care**

- Physicians, diabetologists and registered dieticians who are trained to practice modern system of medicine are advised not to prescribe complementary and alternative medicine to treat T2DM.
- Complementary and alternative medicine therapies should not replace conventional modalities of T2DM management.
BACKGROUND

The chronic nature of T2DM and its course of treatment often intimidates patients with the possibility of a lifetime treatment with conventional allopathic medications. Complementary medicine refers to interventions used in conjunction with conventional pharmacological treatment while alternative medicine are treatments that replace modern medicines.\cite{969} Complementary and alternative medicine (CAM) comprise mind-body practices (e.g. yoga, pranayama, meditation, tai chi, massage therapy, acupuncture etc.), natural remedies (usually herbal dietary supplements) or treatments from a traditional system of medicine.\cite{755,969} The use of CAM in India has been quite popular especially with the use of traditional Indian practices-Ayurveda, Yoga, Naturopathy, Unani, Siddha and Homeopathy. Studies exploring the use of CAM in India reported a prevalence of 68% in Uttar Pradesh, 63% in Maharashtra and almost 39% in rural Kerala among T2DM patients.\cite{970-972} It was also observed that the level of physician consultation among CAM users was generally low\cite{970,972} (Table 35).

Medicinal herbs with potential anti-diabetic effects have been extensively studied in India. Most of these are indigenous to the Indian diet and are consumed as a part of everyday meals. However, studies investigating the glycemic effects of these herbs (methi, vijaysar, gurmar, neem, amla, ghritkumari, turmeric, black pepper, ginger, cinnamon, dates, onion, and karela) have shown inconsistent findings.\cite{755,757,973-976} Supplementation with chromium, alpha-lipoic acid, omega-3 fatty acids, magnesium, and zinc have also shown minimal antidiabetic effects, however, the long-term use and interactions between herbs and medications are known to cause some serious side effects.\cite{977} The safety of these agents for T2DM is greatly challenged due to the lack of stringent regulations for their approval, manufacturing and marketing.\cite{975-979} Also there is a serious lack of high-level evidence from adequately powered randomized controlled studies to validate the clinical efficacy and safety of these preparations.\cite{980} Several Ayurveda and herbal Indian medicines have been found to be contaminated with heavy metals (lead, arsenic and mercury) and known to have serious health consequences.\cite{69,981} There is a general trend of increased consumption of herbal remedies in patients—alone or concomitantly with prescribed medicine. A study conducted in patients with T2DM in a tertiary care teaching hospital of North India reported that 45% patients were taking herbal remedies along with the prescribed drugs for diabetes and a majority (36/45) were taking these on their own or after advice from family members or friends; only 5% patients consulted an herbal specialist/ayurvedic doctor before starting these and 98% of cases the treating physicians were unaware of this fact.\cite{982} However, yoga, pranayama, meditation, acupuncture, massage therapy, aromatherapy and many relaxation techniques are being practiced in India, for prevention and management of diabetes.\cite{555,976,983}

| Table 35: Complementary and alternative medicine |
|---|---|
| Mind-body practices | Traditional system of medicine |
| Yoga | Ayurveda |
| Pranayama | Yoga |
| Meditation | Naturopathy |
| Tai chi | Unani |
| Massage therapy | Siddha |
| Acupuncture | Homeopathy |

Yoga

Mind-body techniques utilize the influence of mind on the physical body and in the recent times, these have been popularly adapted into mainstream management of T2DM. Yoga, which is native to India, involves coordinated physical body movements, meditation, breathing exercises and chanting. The intensity of yoga activities can be adjusted based on the patients’ needs and capabilities and used more effectively as a form of exercise for patients with diabetes. However, there is inadequate clinical evidence showing the benefits of yoga for glycemic control and therefore, it cannot substitute physical activity completely.\cite{969,984,985} A randomized controlled study conducted in North India showed a significant improvement in the quality of life in the intervention group practicing the comprehensive yogic breathing program in addition to standard treatment of diabetes. Additionally, a nonsignificant trend towards improvement in glycaemic control was observed.\cite{986} In a prospective case-control study conducted in 30 men with T2DM on diabetic diet and oral hypoglycaemic agents, initiation of yoga as an adjuvant treatment was associated with significant improvement in fasting and post meal glucose levels.\cite{555} Since the risks associated with practicing yoga and meditation are minimal and it is known to have a favourable impact on sleep and overall well-being, it should be encouraged among patients with T2DM as a part of lifestyle management.\cite{984,985} Refer to the “Lifestyle changes and medical nutrition therapy section for additional information.

Acknowledgements

The authors thank Shweta Pitre, CMPP for writing support and Sangita Patil, PhD for editorial support (SIRO Clinpharm Pvt. Ltd, Maharashtra, India). This RSSDI clinical practice recommendations for management of type 2 diabetes mellitus is a revision of RSSDI clinical practice guideline for management of type 2 diabetes mellitus published in 2017.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
REFERENCES


7. Guo F, Moellerling DR, Garvey WT. Use of HbA1c for diagnoses of diabetes and prediabetes: Comparison with diagnoses based on fasting and 2-hr glucose values and effects of gender, race, and age. Metab Syndr Relat Disord 2014;12:238-68.


125. Liu AG, Most MM, Brashier MM, Johnson WD, Cefalu WT, Greenway FL. Reducing the glycemic index or carbohydrate content of mixed meals reduces postprandial glycemia and insulinaemia over the entire day but does not affect satiety. Diabetes Care 2012;35:1633-7.


using vildagliptin add-on or lone therapy (INTERVAL): A 24 week, randomised, double-blind, placebo-controlled study. Lancet 2013;382:409-16.


Cerielio A. Postprandial Hyperglycemia and Cardiovascular Disease: Is the HEART2D Study the Answer? American Diabetes Association; 2009.


328. Reynolds AN, Mant J, Williams S, Venn BJ. Advice to walk after meals is more effective for lowering postprandial glycaemia in type 2 diabetes mellitus than advice that does not specify timing: A randomised crossover study. Diabetologia 2016;59:2572-8.
Preoperative Diabetic retinopathy screening using telemedicine tools: Pilot study.


Meijer JW, Smit AJ, Sonderen EV, Groothoff JW, Eisma WH,
Chawla, et al.: RSSDI-ESI clinical practice recommendations


582. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA,


611. Misra A. Revisions of cutoffs of body mass index to define overweight and obesity are needed for the Asian-ethnic groups. Int J Obes Relat Metab Disord 2003;27:1294-6.


624. Williamson DF, Madans J, Anda RF, Kleinman JC, Kahn HS, Byers T. Recreational physical activity and ten-year weight change in a US


708. Larsen ML, Horder M, Mogensen EE. Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes
746. Boli GB. Hypoglycaemia unawareness. Diabetes Metab
Chawla, et al.: RSSDI-ESI clinical practice recommendations


Managing preexisting diabetes for pregnancy:


et al et al et al et al et al.


Blumer I, Hadar E, Hadden DR, Jovanović L, Mestman JH, Murad MH,
Knowledge and awareness about diabetes mellitus
Chawla, et al.: RSSDIESI clinical practice recommendations

Efficacy and safety of liraglutide compared to sulphonylurea


Liraglutide improves metabolic control in patients with type 2 diabetes:

Diabetes Care 2018;41:S4-6.

Deepa M, Bhanasali A, Anjana RM, Pradeepa R, Joshi SR, Joshi PP, et al. Knowledge and awareness of diabetes in urban and rural India:
The Indian Council of Medical Research India Diabetes Study (Phase I): Indian Council of Medical Research India Diabetes 4. Indian J Endocrinol Metab 2014;18:379-85.

glucose tolerance associated with lifestyle transition occurring in the rural population in India. Diabetologia 2004;47:860-5.

Singh DK, Tari V. Structured diabetes care (Freedom 365*) provides
better glycemic control than routine medical care in type 2 diabetes:

Jankowska-Polanska B, Fal AM, Uchmanowicz I. Influence of

Verma R, Khanna P, Mehta B. National programme on prevention and

Kide S, Rangari A, Shiral R. Knowledge and awareness of diabetes

Limaye TY, Wagle SS, Kumaran K. Lack of knowledge about diabetes

Long P, Long KN, Kedia A. A cross-sectional study of diabetic
knowledge in West Bengal, India: An analysis based on access to

Mathew AC, Jacob N, Jose S. Knowledge about risk factors, symptoms
and complications of diabetes among adults in South India. Int J Med

Munirayana C, Balachandra G, Hiremath SG, Iyengar K, Anil NS.
Prevalence and awareness regarding diabetes mellitus in rural Tumakuru,

Saurabh S, Sarkar S, Selvaraj K, Kar SS, Kumar SG, Roy G. Effectiveness

Singh AK, Mani K, Krishnan A, Aggarwal P, Gupta SK. Prevalence,
awareness, treatment and control of diabetes amongst elderly persons in

of type II diabetes mellitus patients in a tertiary care teaching institute

Sharma S, Jha J, Varshney A, et al. Awareness of various aspects of
diabetes among people visiting tertiary eye care institute in north India.

Bansal C, Kasuihk R. Awareness of diabetic nephropathy in patients


Chawla, et al.: RSSDIESI clinical practice recommendations

Indian J Diabetes Dev Ctries (Jan-March 2020) 40 (Supp 1):S1-S122


ANNEXURES

Screening/Early detection of diabetes

Annexure 1: The Indian Diabetes Risk Score (IDRS)\textsuperscript{[1-6]}

- The tool encompasses four parameters: age, abdominal obesity, family history of diabetes, and physical activity to detect T2DM and also helps to distinguish T2DM from non-T2DM.
- A maximum score of 100 is given for these categories combined as shown in the Table.
- Subjects with an IDRS of < 30 are categorized under low risk, 30–50 as medium risk and those with > 60 as high risk for diabetes.
- Similarly WC ≥ 90 cm, sedentary lifestyle and family history of diabetes are indicators for high risk of diabetes.
- Limiting the blood sugar testing to those with an IDRS score of 50 and above could identify more than 90% of Indians with diabetes and prediabetes.

Indian Diabetes Risk Score

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
</tr>
<tr>
<td>&lt;35</td>
<td>0</td>
</tr>
<tr>
<td>35-49</td>
<td>20</td>
</tr>
<tr>
<td>≥50</td>
<td>30</td>
</tr>
<tr>
<td>WC</td>
<td></td>
</tr>
<tr>
<td>Waist &lt;80 cm (female), &lt;90 cm (male)</td>
<td>0</td>
</tr>
<tr>
<td>Waist ≥80-89 cm (female), ≥90-99 cm (male)</td>
<td>10</td>
</tr>
<tr>
<td>Waist ≥90 cm (female), ≥100 cm (male)</td>
<td>20</td>
</tr>
<tr>
<td>Physical activity</td>
<td></td>
</tr>
<tr>
<td>Regular vigorous exercise or strenuous (manual) activity at home/work</td>
<td>0</td>
</tr>
<tr>
<td>Regular moderate exercise or moderate physical activity at home/work</td>
<td>10</td>
</tr>
<tr>
<td>Regular mild exercise or mild physical activity at home/work</td>
<td>20</td>
</tr>
<tr>
<td>No exercise and/or sedentary activities at home/work</td>
<td>30</td>
</tr>
<tr>
<td>Family history of diabetes</td>
<td></td>
</tr>
<tr>
<td>No diabetes in parents</td>
<td>0</td>
</tr>
<tr>
<td>One parent is diabetic</td>
<td>10</td>
</tr>
<tr>
<td>Both parents are diabetic</td>
<td>20</td>
</tr>
</tbody>
</table>

Minimum score=0; Maximum score=100; Positive score ≥60/100

REFERENCES

Annexure 2: Dr. A. Ramachandran’s Diabetes Risk Score for Indians can be used to identify people having undetected diabetes. The likelihood of detecting diabetes in people with a score of 21 or more is high and require testing with an oral glucose tolerance test[1]

<table>
<thead>
<tr>
<th>Variables</th>
<th>Risk score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
</tr>
<tr>
<td>30-44</td>
<td>10</td>
</tr>
<tr>
<td>45-59</td>
<td>18</td>
</tr>
<tr>
<td>&gt;59</td>
<td>19</td>
</tr>
<tr>
<td>Family history of diabetes</td>
<td>7</td>
</tr>
<tr>
<td>BMI (≥ 25) kg/m²</td>
<td>7</td>
</tr>
<tr>
<td>Waist (M ≥85, W ≥80) cm</td>
<td>5</td>
</tr>
<tr>
<td>Sedentary physical activity</td>
<td>4</td>
</tr>
<tr>
<td>Maximum score</td>
<td>42</td>
</tr>
</tbody>
</table>

BMI: Body mass index

REFERENCE

Annexure 3: Diabetic neuropathy symptom score (DNS)[1]

DNS questionnaire
1. Are you suffering of unsteadiness in walking?
   Need for visual control, increase in dark, walk like a drunken man, and lack of contact with floor
2. Do you have a burning, aching pain or tenderness at your legs or feet?
   Occurring at rest or at night, not related to exercise, exclude intermittent claudication
3. Do you have pricking sensations at your legs and feet
   Occurring at rest or at night, distal > proximal, stocking glove distribution
4. Do you have places of numbness on your legs or feet?
   Distal > proximal, stocking glove distribution

The questions were answered either “Yes” (positive: 1 point) if symptom has occurred during the last 2 weeks or ‘No’ (negative: 0 point) if it did not.
Maximum score is 4 and minimum 0. DNS: Diabetic neuropathy symptom

REFERENCE

Annexure 4: Modified Neuropathy Disability Score (NDS)[1]

<table>
<thead>
<tr>
<th>NDS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vibration perception threshold</td>
</tr>
<tr>
<td>128-Hz tuning fork; apex of big toe: Normal=Can distinguish vibrating/not vibrating Abnormal=1</td>
</tr>
<tr>
<td>Temperature perception on dorsum of the foot Use tuning fork with beaker of ice/warm water Pin-prick Apply pin proximal to big toe nail just enough to deform the skin: trial pair=Sharp blunt: Normal=Can distinguish sharp/not sharp Present=0 Present with reinforcement=1 Absent=2 NDS total out of 10</td>
</tr>
</tbody>
</table>

NDS: Neuropathy disability score

REFERENCE
Annexure 5: Diabetic foot care

**Diabetic neuropathy examination**

<table>
<thead>
<tr>
<th>Muscle strength</th>
<th>Reflex</th>
<th>Sensation:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Quadriceps femoris: Extension of the knee</td>
<td>3. Triceps surae</td>
<td>Index finger</td>
</tr>
<tr>
<td>2. Tibialis anterior: Dorsiflexion of the foot</td>
<td>4. Sensitivity to pinpricks</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sensation:</th>
<th>Monofilament and vibration perception threshold</th>
</tr>
</thead>
<tbody>
<tr>
<td>5. Big toe</td>
<td></td>
</tr>
</tbody>
</table>

Only the right leg and foot are tested
Scoring from 0 to 2
0=Normal
1=Mild/moderate deficit
2=Severely disturbed/absent
Scoring from 0 to 2
0=Normal
1=Mild/moderate deficit
2=Severely disturbed/absent

**Reference**


**Diabetes and CV risk**

Annexure 6: Statin treatment in patients with diabetes

<table>
<thead>
<tr>
<th>Risk</th>
<th>Age (years)</th>
<th>Statins</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASCVD risk factors*</td>
<td>&lt;40</td>
<td>Moderate**/high intensity statins</td>
</tr>
<tr>
<td></td>
<td>40-75</td>
<td>High intensity statins</td>
</tr>
<tr>
<td></td>
<td>&gt;75</td>
<td>Moderate/high intensity statins</td>
</tr>
<tr>
<td>ASCVD</td>
<td>&lt;40</td>
<td>High intensity statins</td>
</tr>
<tr>
<td></td>
<td>40-75</td>
<td>High intensity statins</td>
</tr>
<tr>
<td></td>
<td>&gt;75</td>
<td>High intensity statins</td>
</tr>
</tbody>
</table>

*ASCVD risk factors include LDL-C ≥100 mg/dL (2.6 mmol/L), high BP, smoking, overweight and obesity, and family history of premature ASCVD. **Moderate intensity statins (OD): Atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg, pravastatin 40-80 mg, lovastatin 40 mg, fluvastatin XL 80 mg, pitavastatin 2-4 mg. *High intensity statins (once daily): Atorvastatin 40-80 mg, rosuvastatin 20-40 mg. ASCVD: Atherosclerotic cardiovascular disease, BP: Blood pressure, LDL-C: Low-density lipoprotein-cholesterol, OD: Once daily.
### Infections and Vaccinations

**Annexure 7: Recommended vaccines for diabetic patients**[1]

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumococcal (polysaccharide)</td>
<td>1 or 2 doses</td>
</tr>
<tr>
<td>Influenza</td>
<td>1 dose TIV annually</td>
</tr>
<tr>
<td>Tetanus diphtheria pertussis (Td/Tdap)</td>
<td>Substitute one time dose of Td; then boost with Tdap every 10 years</td>
</tr>
<tr>
<td>MMR</td>
<td>1 or 2 doses, 4 weeks interval</td>
</tr>
<tr>
<td>Varicella</td>
<td>2 doses, at least 4 weeks apart</td>
</tr>
<tr>
<td>Zoster</td>
<td>1 dose, 60 years</td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>2 doses at least 6 months apart</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>3 doses</td>
</tr>
<tr>
<td>HPV</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>3 doses through age 26 years</td>
</tr>
<tr>
<td></td>
<td>The second dose should be administered 1-2 months after the first dose</td>
</tr>
<tr>
<td></td>
<td>Third dose should be administered 6 months after the first dose</td>
</tr>
<tr>
<td>Male</td>
<td>3 doses through age 21 years</td>
</tr>
</tbody>
</table>

**MMR: Measles mumps rubella, HPV: Human papillomavirus**

### Reference


### Fasting and Diabetes

**Annexure 8: Categories of risk in patients with T1DM or T2DM who fast during Ramadan**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Personal characteristics</td>
<td>Life stage</td>
<td>Childhood/adolescence/pregnancy/lactation/elderly</td>
<td>Late mid age</td>
<td>Healthy adulthood</td>
</tr>
<tr>
<td></td>
<td>Life style</td>
<td>Intense physical labour; potential public health impact of hypoglycaemia, e.g., in commercial drivers</td>
<td>Variable duties, e.g., shiftworkers</td>
<td>Routine life style</td>
</tr>
<tr>
<td></td>
<td>Overall health</td>
<td>Infirm; cognitive dysfunction; severe acute illness</td>
<td>Risk of dehydration; on concomitant steroid therapy</td>
<td>Stable</td>
</tr>
<tr>
<td>Diabetes related characteristics</td>
<td>Type of diabetes</td>
<td>Brittle diabetes; T1DM, poorly controlled</td>
<td>T2DM, poorly controlled</td>
<td>T2DM, well controlled</td>
</tr>
<tr>
<td></td>
<td>Acute complications</td>
<td>History of severe hypoglycaemia/ DKA/HHNKC within 3 months prior to Ramadan; history of recurrent hypoglycaemia</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Chronic complications</td>
<td>History of hypoglycaemia unawareness; CKD stage 4/5; advanced macrovascular</td>
<td>CKD stage 3, stable macrovascular complications</td>
<td>No complication</td>
</tr>
<tr>
<td>Therapeutic characteristics</td>
<td>Noninsulin therapy</td>
<td>Conventional sulfonylurea</td>
<td>TID regimes</td>
<td>All other therapy</td>
</tr>
<tr>
<td></td>
<td>Insulin therapy</td>
<td>Basal bolus regimes</td>
<td>TID regimes: Basal-plus; premixed TDS; rapid-rapid-premix; premix-rapid-premix</td>
<td>Once or BID regimes: Basal; premixed analogues</td>
</tr>
<tr>
<td>Medico-religious advice</td>
<td>Religious suggestion</td>
<td>Listen to medical advice. Do not fast in health is endangered. Be prepared to break the fast if ill health occurs</td>
<td>Structured education; SMBG; Dose titration. Watch for complications, and manage appropriately</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medical management</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

T1DM: Type 1 diabetes, T2DM: Type 2 diabetes, DKA: diabetes ketoacidosis, HHNKC: Hyperosmolar hyperglycaemic nonketotic coma, CKD: Chronic kidney disease, TID: Thrice daily
**Annexure 9: Dose adjustment/modifications for the management of T2DM during Ramadan fast[1-4]**

<table>
<thead>
<tr>
<th>Anti-diabetic agents</th>
<th>Current regimen</th>
<th>Recommended dose modification during Ramadan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metformin</td>
<td>OD</td>
<td>Take at iftar</td>
</tr>
<tr>
<td></td>
<td>BID</td>
<td>Take at iftar and suhur</td>
</tr>
<tr>
<td></td>
<td>TID</td>
<td>Take 2/3 of the total daily dose at the iftar and the other 1/3 at the suhur</td>
</tr>
<tr>
<td>Sulfonylureas*</td>
<td>OD</td>
<td>Take at iftar</td>
</tr>
<tr>
<td></td>
<td>BID</td>
<td>Take 1/2 of usual evening dose with the suhur and the usual morning dose with the iftar</td>
</tr>
<tr>
<td>Glinides</td>
<td></td>
<td>The daily dose may be ↓ or divided to 2 doses according to meal size and should be taken at iftar and suhur</td>
</tr>
<tr>
<td>TZD</td>
<td></td>
<td>No dose adjustments is required</td>
</tr>
<tr>
<td>DPP-4 inhibitors</td>
<td></td>
<td>No dose adjustments required</td>
</tr>
<tr>
<td>Acarbose</td>
<td></td>
<td>No dose adjustments is required</td>
</tr>
<tr>
<td>SGLT-2 inhibitors†</td>
<td></td>
<td>No dose adjustment is required and the dose be taken with iftar</td>
</tr>
<tr>
<td>GLP-1 receptor agonists</td>
<td></td>
<td>The dose should be titrated 6 weeks prior to Ramadan and no dose adjustment is required</td>
</tr>
<tr>
<td>AGIs</td>
<td></td>
<td>No dose modification is required</td>
</tr>
<tr>
<td>Long acting insulin</td>
<td>OD</td>
<td>↓ Dose by 15%-30% and take at iftar</td>
</tr>
<tr>
<td></td>
<td>BID</td>
<td>Take usual morning dose at iftar↓Evening dose by 50% and take at suhur</td>
</tr>
<tr>
<td>Short acting insulin</td>
<td></td>
<td>Take normal dose at iftar and lunch-time dose at dinner</td>
</tr>
<tr>
<td></td>
<td></td>
<td>↓Suhur dose by 50%</td>
</tr>
<tr>
<td>Premixed insulin</td>
<td>OD</td>
<td>Take normal dose at iftar</td>
</tr>
<tr>
<td></td>
<td>BID</td>
<td>Take 1/2 of usual evening dose with the suhur and the usual morning dose with the iftar</td>
</tr>
<tr>
<td></td>
<td>TID</td>
<td>Omit afternoon dose and adjust iftar and suhur doses</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Carry out dose titration every 3 days</td>
</tr>
<tr>
<td>Insulin pump</td>
<td>Basal rate</td>
<td>↓ Dose by 20%-40% in the last 3-4 h of fasting</td>
</tr>
<tr>
<td></td>
<td>Bolus rate</td>
<td>↑ Dose by 0%-30% early after iftar</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Normal carbohydrate counting and insulin sensitivity principles apply</td>
</tr>
</tbody>
</table>

*Gliclazide and glimepiride should be preferred among all other sulphonylureas. †Elderly patients, patients with renal impairment, hypotensive individuals, those at risk of dehydration or those taking diuretics should not be treated with SGLT2 inhibitors. BID: Twice daily, TID: Thrice daily, OD: Once daily, AGIs: Alpha glucosidase inhibitors, DPP-4: Dipeptidyl peptidase-4, SGLT-2: Sodium-glucose co-transporter-2, TZD: Thiazolidinedione, GLP-1: Glucagon-like peptide 1

**REFERENCES**